0001564590-22-018257.txt : 20220506 0001564590-22-018257.hdr.sgml : 20220506 20220505161627 ACCESSION NUMBER: 0001564590-22-018257 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220505 DATE AS OF CHANGE: 20220505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TransMedics Group, Inc. CENTRAL INDEX KEY: 0001756262 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38891 FILM NUMBER: 22896494 BUSINESS ADDRESS: STREET 1: 200 MINUTEMAN ROAD CITY: ANDOVER STATE: MA ZIP: 01810 BUSINESS PHONE: 9785520900 MAIL ADDRESS: STREET 1: 200 MINUTEMAN ROAD CITY: ANDOVER STATE: MA ZIP: 01810 10-Q 1 tmdx-10q_20220331.htm 10-Q tmdx-10q_20220331.htm
false Q1 0001756262 --12-31 1 1 0001756262 2022-01-01 2022-03-31 xbrli:shares 0001756262 2022-04-29 iso4217:USD 0001756262 2022-03-31 0001756262 2021-12-31 iso4217:USD xbrli:shares 0001756262 2021-01-01 2021-03-31 0001756262 us-gaap:CommonStockMember 2021-12-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001756262 us-gaap:RetainedEarningsMember 2021-12-31 0001756262 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001756262 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001756262 us-gaap:CommonStockMember 2022-03-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001756262 us-gaap:RetainedEarningsMember 2022-03-31 0001756262 us-gaap:CommonStockMember 2020-12-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001756262 us-gaap:RetainedEarningsMember 2020-12-31 0001756262 2020-12-31 0001756262 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001756262 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001756262 us-gaap:CommonStockMember 2021-03-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001756262 us-gaap:RetainedEarningsMember 2021-03-31 0001756262 2021-03-31 0001756262 2021-01-01 2021-12-31 xbrli:pure 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember tmdx:SignificantCustomersBenchmarkMember srt:MinimumMember 2022-01-01 2022-03-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember tmdx:SignificantCustomersBenchmarkMember srt:MinimumMember 2022-01-01 2022-03-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember tmdx:CustomerOneMember 2022-01-01 2022-03-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember tmdx:CustomerOneMember 2021-01-01 2021-03-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember tmdx:CustomerTwoMember 2022-01-01 2022-03-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember tmdx:CustomerTwoMember 2021-01-01 2021-03-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember tmdx:CustomerThreeMember 2022-01-01 2022-03-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember tmdx:CustomerOneMember 2022-01-01 2022-03-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember tmdx:CustomerOneMember 2021-01-01 2021-12-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember tmdx:CustomerTwoMember 2022-01-01 2022-03-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember tmdx:CustomerTwoMember 2021-01-01 2021-12-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember tmdx:CustomerThreeMember 2022-01-01 2022-03-31 0001756262 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember tmdx:CustomerFourMember 2022-01-01 2022-03-31 tmdx:Segment 0001756262 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001756262 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001756262 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001756262 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001756262 us-gaap:EmployeeStockMember 2022-01-01 2022-03-31 0001756262 us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0001756262 us-gaap:USTreasurySecuritiesMember 2022-03-31 0001756262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-03-31 0001756262 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001756262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001756262 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-03-31 0001756262 us-gaap:MoneyMarketFundsMember 2022-03-31 0001756262 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2022-03-31 0001756262 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-03-31 0001756262 us-gaap:FairValueInputsLevel1Member 2022-03-31 0001756262 us-gaap:FairValueInputsLevel2Member 2022-03-31 0001756262 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-12-31 0001756262 us-gaap:MoneyMarketFundsMember 2021-12-31 0001756262 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2021-12-31 0001756262 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001756262 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001756262 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001756262 tmdx:OrbiMedMember 2018-06-29 0001756262 tmdx:OrbiMedMember 2022-01-01 2022-03-31 0001756262 tmdx:OrbiMedMember srt:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-03-31 0001756262 tmdx:OrbiMedMember srt:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-03-31 0001756262 tmdx:OrbiMedMember srt:MaximumMember 2022-03-31 0001756262 tmdx:OrbiMedMember srt:MinimumMember 2022-01-01 2022-03-31 0001756262 tmdx:OrbiMedMember srt:MaximumMember 2022-01-01 2022-03-31 0001756262 tmdx:OrbiMedMember tmdx:CreditAgreementMember 2022-01-01 2022-03-31 0001756262 tmdx:OrbiMedMember 2022-03-31 0001756262 tmdx:InEventOfDefaultMember tmdx:OrbiMedMember 2022-01-01 2022-03-31 0001756262 tmdx:TwoThousandNineteenStockPlanMember 2019-04-15 0001756262 tmdx:TwoThousandNineteenStockPlanMember tmdx:FromTwoThousandFourteenPlanMember 2019-04-15 0001756262 tmdx:TwoThousandNineteenStockPlanMember 2022-03-31 0001756262 tmdx:TwoThousandNineteenEmployeeStockPurchasePlanMember 2019-04-14 2019-04-15 0001756262 tmdx:TwoThousandNineteenEmployeeStockPurchasePlanMember 2022-03-31 0001756262 tmdx:TwoThousandNineteenEmployeeStockPurchasePlanMember 2022-01-01 2022-03-31 0001756262 tmdx:TwoThousandTwentyOneInducementPlanMember us-gaap:CommonStockMember 2021-08-31 0001756262 tmdx:TwoThousandTwentyOneInducementPlanMember us-gaap:CommonStockMember 2022-03-31 0001756262 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001756262 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001756262 tmdx:ResearchDevelopmentAndClinicalTrialsExpensesMember 2022-01-01 2022-03-31 0001756262 tmdx:ResearchDevelopmentAndClinicalTrialsExpensesMember 2021-01-01 2021-03-31 0001756262 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001756262 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001756262 tmdx:EmployeesAndDirectorMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001756262 srt:MaximumMember 2022-01-01 2022-03-31 0001756262 2021-01-31 0001756262 2021-01-01 2021-01-31 0001756262 country:US 2022-03-31 0001756262 country:US 2021-12-31 0001756262 tmdx:OtherCountriesMember 2022-03-31 0001756262 tmdx:OtherCountriesMember 2021-12-31 0001756262 tmdx:OcsLungProductMember 2022-01-01 2022-03-31 0001756262 tmdx:OcsLungProductMember 2021-01-01 2021-03-31 0001756262 tmdx:OcsHeartProductMember 2022-01-01 2022-03-31 0001756262 tmdx:OcsHeartProductMember 2021-01-01 2021-03-31 0001756262 tmdx:OcsLiverProductMember 2022-01-01 2022-03-31 0001756262 tmdx:OcsLiverProductMember 2021-01-01 2021-03-31 0001756262 country:US 2022-01-01 2022-03-31 0001756262 country:US 2021-01-01 2021-03-31 0001756262 tmdx:NonUsAndUkMember 2022-01-01 2022-03-31 0001756262 tmdx:NonUsAndUkMember 2021-01-01 2021-03-31 0001756262 srt:DirectorMember 2022-01-01 2022-03-31 0001756262 srt:DirectorMember 2021-01-01 2021-03-31

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                  to                 

Commission File Number: 001-38891

 

TransMedics Group, Inc.

(Exact name of registrant as specified in its charter)

 

 

Massachusetts

83-2181531

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

 

200 Minuteman Road

Andover, Massachusetts

01810

(Address of principal executive offices)

(Zip code)

 

(978) 552-0900

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class 

 

Trading Symbol(s) 

 

Name of each exchange on which registered 

Common Stock, No Par Value

 

TMDX

 

The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of April 29, 2022, the registrant had 27,980,839 shares of common stock, no par value per share, outstanding.

 

 

 

 


 

 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements with respect to, among other things, our operations and financial performance. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy and plans and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “could,” “target,” “predict,” “seek” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those referenced in the section titled “Risk Factors,” which could cause actual results to differ materially. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date of this report. You should not rely upon forward-looking statements as predictions of future events. We cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or reflect interim developments.

Some of the key factors that could cause actual results to differ include:

 

that we continue to incur losses;

 

our need to raise additional funding;

 

our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity, and our ability to obtain additional financing on favorable terms or at all;

 

our ability to attract and retain key personnel;

 

the fluctuation of our financial results from quarter to quarter;

 

our ability to use net operating losses and research and development credit carryforwards;

 

our dependence on the success of the Organ Care System, or OCS;

 

our ability to expand access to the OCS through our National OCS Program;

 

the rate and degree of market acceptance of the OCS;

 

our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS;

 

our ability to improve the OCS platform;

 

our dependence on a limited number of customers for a significant portion of our net revenue;

 

our ability to maintain regulatory approvals or clearances for our OCS products;

 

our ability to adequately respond to the Food and Drug Administration, or FDA, follow-up inquiries in a timely manner;

 

the timing and our ability to commercialize and market our OCS products;

 

the performance of our third-party suppliers and manufacturers;

 

price increases of the components of our products;

 

the timing or results of post-approval studies and any clinical trials for the OCS;

i


 

 

 

our manufacturing, sales, marketing and clinical support capabilities and strategy;

 

attacks against our information technology infrastructure;

 

the economic, political and other risks associated with our foreign operations;

 

the impact of the outbreak of the novel strain of coronavirus, or COVID-19, including variants of the virus and associated containment, remediation and vaccination efforts;

 

our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties;

 

the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally;

 

regulatory developments in the United States, European Union and other jurisdictions;

 

the extent and success of competing products that are or may become available;

 

the impact of any product recalls or improper use of our products; and

 

our estimates regarding revenue, expenses and needs for additional financing.

ii


 

 

TransMedics Group, Inc.

Table of Contents

 

 

 

 

Page

 

PART I—FINANCIAL INFORMATION

 

 

 

 

 

 

Item 1.

Financial Statements (Unaudited)

 

1

 

Consolidated Balance Sheets

 

1

 

Consolidated Statements of Operations

 

2

 

Consolidated Statements of Comprehensive Loss

 

3

 

Consolidated Statements of Stockholders’ Equity

 

4

 

Consolidated Statements of Cash Flows

 

5

 

Notes to Unaudited Consolidated Financial Statements

 

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

16

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

24

Item 4.

Controls and Procedures

 

25

 

 

 

 

 

PART II—OTHER INFORMATION

 

 

 

 

 

 

Item 1.

Legal Proceedings

 

26

Item 1A.

Risk Factors

 

26

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

26

Item 6.

Exhibits

 

27

Signatures

 

28

 

 

 

iii


 

 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

TRANSMEDICS GROUP, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

(Unaudited)

 

 

 

March 31,

 

 

December 31,

 

 

 

2022

 

 

2021

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

17,897

 

 

$

25,580

 

Marketable securities

 

 

54,104

 

 

 

66,872

 

Accounts receivable

 

 

11,724

 

 

 

5,934

 

Inventory

 

 

16,714

 

 

 

14,859

 

Prepaid expenses and other current assets

 

 

5,356

 

 

 

5,460

 

Total current assets

 

 

105,795

 

 

 

118,705

 

Property and equipment, net

 

 

12,044

 

 

 

9,841

 

Restricted cash

 

 

500

 

 

 

500

 

Operating lease right-of-use assets

 

 

5,669

 

 

 

5,847

 

Total assets

 

$

124,008

 

 

$

134,893

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,934

 

 

$

6,651

 

Accrued expenses and other current liabilities

 

 

15,738

 

 

 

16,337

 

Deferred revenue

 

 

247

 

 

 

250

 

Operating lease liabilities

 

 

1,337

 

 

 

 

Total current liabilities

 

 

20,256

 

 

 

23,238

 

Long-term debt, net of discount and current portion

 

 

35,334

 

 

 

35,197

 

Operating lease liabilities, net of current portion

 

 

8,508

 

 

 

8,604

 

Total liabilities

 

 

64,098

 

 

 

67,039

 

Commitments and contingencies (Note 9)

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Preferred stock, no par value; 25,000,000 shares authorized; no shares

   issued or outstanding

 

 

 

 

 

 

Common stock, no par value; 150,000,000 shares authorized; 27,968,583

   shares and 27,791,615 shares issued and outstanding at March 31, 2022

   and December 31, 2021, respectively

 

 

513,203

 

 

 

510,488

 

Accumulated other comprehensive loss

 

 

(285

)

 

 

(188

)

Accumulated deficit

 

 

(453,008

)

 

 

(442,446

)

Total stockholders' equity

 

 

59,910

 

 

 

67,854

 

Total liabilities and stockholders' equity

 

$

124,008

 

 

$

134,893

 

 

The accompanying notes are an integral part of these consolidated financial statements.

1


 

TRANSMEDICS GROUP, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Net revenue

 

$

15,880

 

 

$

7,053

 

Cost of revenue

 

 

3,776

 

 

 

2,242

 

Gross profit

 

 

12,104

 

 

 

4,811

 

Operating expenses:

 

 

 

 

 

 

 

 

Research, development and clinical trials

 

 

7,534

 

 

 

4,532

 

Selling, general and administrative

 

 

13,939

 

 

 

6,786

 

Total operating expenses

 

 

21,473

 

 

 

11,318

 

Loss from operations

 

 

(9,369

)

 

 

(6,507

)

Other income (expense):

 

 

 

 

 

 

 

 

Interest expense

 

 

(960

)

 

 

(952

)

Other expense, net

 

 

(227

)

 

 

(454

)

Total other expense, net

 

 

(1,187

)

 

 

(1,406

)

Loss before income taxes

 

 

(10,556

)

 

 

(7,913

)

Provision for income taxes

 

 

(6

)

 

 

(4

)

Net loss

 

$

(10,562

)

 

$

(7,917

)

Net loss per share attributable to common stockholders,

   basic and diluted

 

$

(0.38

)

 

$

(0.29

)

Weighted average common shares outstanding,

   basic and diluted

 

 

27,950,330

 

 

 

27,368,090

 

 

The accompanying notes are an integral part of these consolidated financial statements.

2


 

TRANSMEDICS GROUP, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Net loss

 

$

(10,562

)

 

$

(7,917

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

 

(24

)

 

 

(2

)

Unrealized gains (losses) on marketable securities,

   net of tax of $0

 

 

(73

)

 

 

8

 

Total other comprehensive income (loss)

 

 

(97

)

 

 

6

 

Comprehensive loss

 

$

(10,659

)

 

$

(7,911

)

 

The accompanying notes are an integral part of these consolidated financial statements.

3


 

TRANSMEDICS GROUP, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Comprehen-

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

sive Loss

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2021

 

 

27,791,615

 

 

$

510,488

 

 

$

(188

)

 

$

(442,446

)

 

$

67,854

 

Issuance of common stock upon the

   exercise of common stock options

 

 

164,503

 

 

 

202

 

 

 

 

 

 

 

 

 

202

 

Issuance of common stock in

   connection with employee stock

   purchase plan

 

 

12,465

 

 

 

203

 

 

 

 

 

 

 

 

 

203

 

Stock-based compensation expense

 

 

 

 

 

2,310

 

 

 

 

 

 

 

 

 

2,310

 

Foreign currency translation

   adjustment

 

 

 

 

 

 

 

 

(24

)

 

 

 

 

 

(24

)

Unrealized losses on marketable

   securities

 

 

 

 

 

 

 

 

(73

)

 

 

 

 

 

(73

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(10,562

)

 

 

(10,562

)

Balances at March 31, 2022

 

 

27,968,583

 

 

$

513,203

 

 

$

(285

)

 

$

(453,008

)

 

$

59,910

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Comprehen-

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

sive Loss

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2020

 

 

27,175,305

 

 

$

502,217

 

 

$

(95

)

 

$

(398,231

)

 

$

103,891

 

Issuance of common stock upon the

   exercise of common stock options

 

 

287,705

 

 

 

372

 

 

 

 

 

 

 

 

 

372

 

Issuance of common stock in

   connection with employee stock

   purchase plan

 

 

14,951

 

 

 

211

 

 

 

 

 

 

 

 

 

211

 

Stock-based compensation expense

 

 

 

 

 

1,112

 

 

 

 

 

 

 

 

 

1,112

 

Foreign currency translation

   adjustment

 

 

 

 

 

 

 

 

(2

)

 

 

 

 

 

(2

)

Unrealized gains on marketable

   securities

 

 

 

 

 

 

 

 

8

 

 

 

 

 

 

8

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(7,917

)

 

 

(7,917

)

Balances at March 31, 2021

 

 

27,477,961

 

 

$

503,912

 

 

$

(89

)

 

$

(406,148

)

 

$

97,675

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4


 

 

TRANSMEDICS GROUP, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(10,562

)

 

$

(7,917

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization expense

 

 

507

 

 

 

445

 

Stock-based compensation expense

 

 

2,310

 

 

 

1,112

 

Non-cash interest expense and end of term accretion expense

 

 

137

 

 

 

130

 

Non-cash lease expense

 

 

178

 

 

 

 

Net amortization of premiums on marketable securities

 

 

228

 

 

 

391

 

Unrealized foreign currency transaction losses

 

 

214

 

 

 

484

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(5,804

)

 

 

(583

)

Inventory

 

 

(2,926

)

 

 

(381

)

Prepaid expenses and other current assets

 

 

88

 

 

 

(908

)

Accounts payable

 

 

(4,013

)

 

 

(82

)

Accrued expenses and other current liabilities

 

 

(4

)

 

 

(180

)

Deferred revenue

 

 

 

 

 

182

 

Operating lease liabilities

 

 

1,241

 

 

 

 

Deferred rent

 

 

 

 

 

(23

)

Net cash used in operating activities

 

 

(18,406

)

 

 

(7,330

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(1,953

)

 

 

(20

)

Purchases of marketable securities

 

 

(2,033

)

 

 

(11,708

)

Proceeds from sales and maturities of marketable securities

 

 

14,500

 

 

 

21,000

 

Net cash provided by investing activities

 

 

10,514

 

 

 

9,272

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock upon exercise of stock options

 

 

202

 

 

 

372

 

Proceeds from issuance of common stock in connection with employee stock

   purchase plan

 

 

203

 

 

 

211

 

Net cash provided by financing activities

 

 

405

 

 

 

583

 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

 

(196

)

 

 

(379

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

(7,683

)

 

 

2,146

 

Cash, cash equivalents and restricted cash, beginning of period

 

 

26,080

 

 

 

25,081

 

Cash, cash equivalents and restricted cash, end of period

 

$

18,397

 

 

$

27,227

 

Supplemental disclosure of non-cash investing and financing activities:

 

 

 

 

 

 

 

 

Transfers of inventory to property and equipment

 

$

1,030

 

 

$

429

 

Purchases of property and equipment included in accounts payable and accrued expenses

 

$

939

 

 

$

7

 

Reconciliation of cash, cash equivalents and restricted cash:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

17,897

 

 

$

26,727

 

Restricted cash

 

 

500

 

 

 

500

 

Total cash, cash equivalents and restricted cash shown in the statement of cash flows

 

$

18,397

 

 

$

27,227

 

 

The accompanying notes are an integral part of these consolidated financial statements.

5


 

TRANSMEDICS GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of the Business and Basis of Presentation

TransMedics Group, Inc. (“TransMedics Group” and, together with its consolidated subsidiaries, the “Company”) was incorporated in the Commonwealth of Massachusetts in October 2018. TransMedics, Inc. (“TransMedics”), an operating company and wholly owned subsidiary of TransMedics Group, was incorporated in the State of Delaware in August 1998. The Company is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company developed the Organ Care System (“OCS”) to replace a decades-old standard of care. The OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. The Company’s OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body.

The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since inception, including net losses of $10.6 million for the three months ended March 31, 2022 and $44.2 million for the year ended December 31, 2021. As of March 31, 2022, the Company had an accumulated deficit of $453.0 million. The Company expects to continue to generate operating losses in the foreseeable future.

The Company believes that its existing cash, cash equivalents, and marketable securities of $72.0 million as of March 31, 2022 will be sufficient to fund its operations, capital expenditures, and debt service payments for at least the next 12 months following the filing of this Quarterly Report on Form 10-Q. The Company may need to seek additional funding through equity financings, debt financings or strategic alliances. The Company may not be able to obtain financing on acceptable terms, or at all, and the terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders. If the Company is unable to obtain funding, the Company will be required to delay, reduce or eliminate some or all of its research and development programs, product expansion or commercialization efforts, or the Company may be unable to continue operations.

The Company is subject to risks and uncertainties common to companies in the medical device industry and of similar size, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, and the need to obtain additional financing to fund operations. Potential risks and uncertainties also include, without limitation, uncertainties regarding the duration and magnitude of the impact of the COVID-19 pandemic on the Company’s business and the economy generally. Products currently under development will require additional research and development efforts, including additional clinical testing and regulatory approval, prior to commercialization. These efforts require additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. The Company’s research and development may not be successfully completed, adequate protection for the Company’s technology may not be obtained, the Company may not obtain necessary government regulatory approval on its expected timeline or at all, and approved products may not prove commercially viable. The Company operates in an environment of rapid change in technology and competition.

The impact of the COVID-19 pandemic has been and may continue to be extensive in many aspects of society, which has resulted in and may continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Impacts to the Company’s business as a result of COVID-19 have included the temporary disruption of transplant procedures at many of the organ transplant centers that purchase OCS products; customer delays or reductions in customer capital expenditures and operating budgets and the related impact on its product sales; disruptions to the Company’s manufacturing operations and supply chain caused by facility closures, reductions in operating hours, staggered shifts and other social distancing efforts; labor shortages; decreased productivity and unavailability of materials or components; delays of reviews and approvals by the Food and Drug Administration (“FDA”) and other health authorities; delays in the Company’s clinical trial enrollment; limitations on its employees’ and customers’ ability to travel, and delays in product installations, trainings or shipments to and from other affected countries and within the United States.

6


 

In response to the pandemic, healthcare providers have, and may need to further, reallocate resources, such as physicians, staff, hospital beds and intensive care unit facilities, and these actions significantly delay the provision of other medical care such as organ transplantation and reduce the number of transplant procedures that are performed, which negatively impacts the Company’s revenue and cash flows. While the Company maintains an inventory of finished products and raw materials used in its OCS products, a prolonged pandemic could lead to shortages in the raw materials necessary to manufacture its products. The COVID-19 pandemic also has impacted operations at the FDA and other health authorities, resulting in delays of reviews and approvals, and may affect other potential Pre-Market Approval (“PMA”) applications. 

The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

2. Summary of Significant Accounting Policies

Unaudited Interim Financial Information

The accompanying unaudited interim financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2022 and results of operations for the three months ended March 31, 2022 and 2021 and cash flows for the three months ended March 31, 2022 and 2021 have been made. The Company’s results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the valuation of inventory and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these unaudited consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.

Risk of Concentrations of Credit, Significant Customers and Significant Suppliers

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. As of March 31, 2022 and December 31, 2021, the Company had no allowance for credit losses.

Significant customers are those that accounted for 10% or more of the Company’s net revenue or accounts receivable. For the three months ended March 31, 2022, three customers accounted for 16%, 15% and 12% of net revenue, respectively.

7


 

For the three months ended March 31, 2021, two customers each accounted for 12% of net revenue. As of March 31, 2022, four customers accounted for 14%, 12%, 12% and 10% of accounts receivable, respectively. As of December 31, 2021, two customers accounted for 21% and 15% of accounts receivable, respectively.

Certain of the components and subassemblies included in the Company’s products are obtained from a sole source, a single source or a limited group of suppliers. Although the Company seeks to reduce dependence on those limited sources of suppliers and manufacturers, the partial or complete loss of certain of these sources could have a material adverse effect on the Company’s operating results, financial condition and cash flows and damage its customer relationships.

Fair Value Measurements

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

 

Level 1—Quoted prices in active markets for identical assets or liabilities.

 

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

 

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The Company’s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company’s accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The carrying value of the Company’s long-term debt approximates its fair value (a level 2 measurement) at each balance sheet date due to its variable interest rate, which approximates a market interest rate.

Segment Information

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is developing and commercializing a proprietary system to preserve human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the Company’s chief operating decision maker, or decision-making group, in deciding how to allocate resources and assess performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer. The Company’s chief operating decision maker reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and assessing financial performance.

Net Income (Loss) per Share

Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the three months ended March 31, 2022 and 2021.

8


 

The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated above because including them would have had an anti-dilutive effect:

 

 

 

As of March 31,

 

 

 

2022

 

 

2021

 

Warrants to purchase common stock

 

 

64,440

 

 

 

64,440

 

Options to purchase common stock

 

 

3,484,914

 

 

 

2,764,876

 

Employee stock purchase plan

 

 

5,794

 

 

 

5,882

 

 

 

 

3,555,148

 

 

 

2,835,198

 

 

3. Marketable Securities

Marketable securities by security type consisted of the following (in thousands):

 

 

 

March 31, 2022

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

U.S. Treasury securities (due within one year)

 

$

51,212

 

 

$

 

 

$

(102

)

 

$

51,110

 

U.S. government agency bonds (due within one year)

 

 

3,001

 

 

 

 

 

 

(7

)

 

 

2,994

 

 

 

$

54,213

 

 

$

 

 

$

(109

)

 

$

54,104

 

 

 

 

December 31, 2021

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

U.S. Treasury securities (due within one year)

 

$

63,907

 

 

$

 

 

$

(33

)

 

$

63,874

 

U.S. government agency bonds (due within one year)

 

 

3,001

 

 

 

 

 

 

(3

)

 

 

2,998

 

 

 

$

66,908

 

 

$

 

 

$

(36

)

 

$

66,872

 

 

 

4. Fair Value of Financial Assets and Liabilities

The following tables present the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis (in thousands):

 

 

 

Fair Value Measurements at March 31, 2022 Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

2,847

 

 

$

 

 

$

 

 

$

2,847

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

 

 

 

51,110

 

 

 

 

 

 

51,110

 

U.S. government agency bonds

 

 

 

 

 

2,994

 

 

 

 

 

 

2,994

 

 

 

$

2,847

 

 

$

54,104

 

 

$

 

 

$

56,951

 

9


 

 

 

 

 

Fair Value Measurements at December 31, 2021 Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

11,169

 

 

$

 

 

$

 

 

$

11,169

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

 

 

 

63,874

 

 

 

 

 

 

63,874

 

U.S. government agency bonds

 

 

 

 

 

2,998

 

 

 

 

 

 

2,998

 

 

 

$

11,169

 

 

$

66,872

 

 

$

 

 

$

78,041

 

 

Money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. U.S. Treasury securities and U.S. government agency bonds were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy.

5. Inventory

Inventory consisted of the following (in thousands):

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Raw materials

 

$

8,322

 

 

$

7,274

 

Work-in-process

 

 

2,501

 

 

 

1,932

 

Finished goods

 

 

5,891

 

 

 

5,653

 

 

 

$

16,714

 

 

$

14,859

 

 

During the three months ended March 31, 2022 and 2021, the Company made non-cash transfers of OCS Consoles from inventory to property and equipment (OCS Consoles loaned to customers) of $1.0 million and $0.4 million, respectively.

6. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Accrued research, development and clinical trials expenses

 

 

$

4,532

 

 

$

4,567

 

Accrued payroll and related expenses

 

 

 

5,819

 

 

 

5,173

 

Accrued professional fees

 

 

 

857

 

 

 

1,973

 

Accrued other

 

 

 

4,530

 

 

 

4,624

 

 

 

 

$

15,738

 

 

$

16,337

 

 

10


 

 

7. Long-Term Debt

TransMedics has a credit agreement (the “Credit Agreement”) with OrbiMed Royalty Opportunities II, LP (“OrbiMed”), entered into in June 2018, pursuant to which TransMedics borrowed $35.0 million. Long-term debt consisted of the following (in thousands):

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Principal amount of long-term debt

 

$

35,000

 

 

$

35,000

 

Less: Current portion of long-term debt

 

 

 

 

 

 

Long-term debt, net of current portion

 

 

35,000

 

 

 

35,000

 

Debt discount, net of accretion

 

 

(428

)

 

 

(511

)

Accrued end-of-term payment

 

 

762

 

 

 

708

 

Long-term debt, net of discount and current portion

 

$

35,334

 

 

$

35,197

 

 

Borrowings under the Credit Agreement bear interest at an annual rate equal to the London Interbank Offered Rate (“LIBOR”), subject to a minimum of 1.0% and a maximum of 4.0%, plus 8.5% (the “Applicable Margin”), subject in the aggregate to a maximum interest rate of 11.5%. In addition, borrowings under the Credit Agreement bear paid-in-kind (“PIK”) interest at an annual rate equal to the amount by which LIBOR plus the Applicable Margin exceeds 11.5%, but not to exceed 12.5%. The PIK interest is added to the principal amount of the borrowings outstanding at the end of each quarter until the maturity date of the Credit Agreement in June 2023. Borrowings under the Credit Agreement are repayable in quarterly interest-only payments until the maturity date, at which time all principal and accrued interest is due and payable. At its option, the company may prepay outstanding borrowings under the Credit Agreement. The Company is required to make a final payment in an amount equal to 3.0% of the principal amount of any prepayment or repayment. The final payment and debt discount amounts are being accreted to interest expense over the term of the Credit Agreement using the effective interest method.

All obligations under the Credit Agreement are guaranteed by the Company and each of its material subsidiaries. All obligations of the Company and each guarantor are secured by substantially all of the Company’s and each guarantor’s assets, including their intellectual property, subject to certain exceptions, including a perfected security interest in substantially all tangible and intangible assets of the Company and each guarantor. Under the Credit Agreement, the Company has agreed to certain affirmative and negative covenants to which it will remain subject until maturity. The financial covenants include maintaining a minimum liquidity amount of $3.0 million; the requirement, on an annual basis, to deliver to OrbiMed annual audited financial statements with an unqualified audit opinion from the Company’s independent registered public accounting firm; and restrictions on the Company’s activities, including limitations on dispositions, mergers or acquisitions; encumbering its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and engaging in certain other business transactions. As of March 31, 2022, the Company was in compliance with the financial covenants under the Credit Agreement.

The obligations under the Credit Agreement are subject to acceleration upon the occurrence of specified events of default, including payment default, change in control, bankruptcy, insolvency, certain defaults under other material debt, certain events with respect to governmental approvals (if such events could cause a material adverse change in the Company’s business), failure to comply with certain covenants, including the minimum liquidity and unqualified audit opinion covenants, and a material adverse change in the Company’s business, operations or other financial condition.

Upon the occurrence of an event of default and until such event of default is no longer continuing, the Applicable Margin will increase by 4.0% per annum. If an event of default (other than certain events of bankruptcy or insolvency) occurs and is continuing, OrbiMed may declare all or any portion of the outstanding principal amount of the borrowings plus accrued and unpaid interest to be due and payable. Upon the occurrence of certain events of bankruptcy or insolvency, all of the outstanding principal amount of the borrowings plus accrued and unpaid interest will automatically become due and payable. In addition, the Company may be required to prepay outstanding borrowings, subject to certain exceptions, with portions of net cash proceeds of certain asset sales and certain casualty and condemnation events.

As of March 31, 2022, the interest rate applicable to borrowings under the Credit Agreement was 9.5%. During the three months ended March 31, 2022, the weighted average effective interest rate on outstanding borrowings under the Credit Agreement was approximately 11.2%.

11


 

8. Stock-Based Compensation

2019 Stock Incentive Plan

The Company’s 2019 Stock Incentive Plan (the “2019 Plan”) provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, unrestricted stock units, and other stock-based awards to employees, directors, and consultants of the Company and its subsidiaries. The number of shares of common stock of TransMedics Group initially available for issuance under the 2019 Plan was 3,428,571 shares, plus the number of shares underlying awards under the previously outstanding 2014 Stock Incentive Plan (the “2014 Plan”), not to exceed 1,595,189 shares, that expire or are terminated, surrendered, or cancelled without the delivery of shares, are forfeited to or repurchased by TransMedics Group or otherwise become available again for grant. Since the effectiveness of the Company’s 2019 Plan in April 2019, no future awards will be made under the 2014 Plan.

Shares withheld in payment of the exercise or purchase price of an award or in satisfaction of tax withholding requirements, and the shares covered by a stock appreciation right for which any portion is settled in stock, will reduce the number of shares available for issuance under the 2019 Plan. In addition, the number of shares available for issuance under the 2019 Plan (i) will not be increased by any shares delivered under the 2019 Plan that are subsequently repurchased using proceeds directly attributable to stock option exercises and (ii) will not be reduced by any awards that are settled in cash or that expire, become unexercisable, terminate or are forfeited to or repurchased by TransMedics Group without the issuance of stock under the 2019 Plan. As of March 31, 2022, 890,558 shares of common stock were available for issuance under the 2019 Plan.

2019 Employee Stock Purchase Plan

Pursuant to the Company’s 2019 Employee Stock Purchase Plan (the “2019 ESPP”), certain employees of the Company are eligible to purchase common stock of the Company at a reduced price during offering periods. The 2019 ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to the limitations set forth in the Internal Revenue Code, at a purchase price of 85% of the lower of the closing price of the Company’s common stock on the first trading day of the offering period or the closing price on the applicable purchase date, which is the final trading day of the applicable offering period. A total of 371,142 shares of the Company’s common stock are reserved for issuance under the 2019 ESPP. During the three months ended March 31, 2022, 12,465 shares of common stock were issued under the 2019 ESPP and as of March 31, 2022, 308,131 shares of common stock remained available for issuance.

2021 Inducement Plan

In August 2021, the Company’s board of directors approved the TransMedics Group, Inc. Inducement Plan (the “Inducement Plan”). Pursuant to the terms of the Inducement Plan, the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock unit awards and performance awards to individuals who were not previously employees or directors of the Company or individuals returning to employment after a bona fide period of non-employment with the Company.  A total of 1,000,000 shares of the Company’s common stock were initially available for issuance under the Inducement Plan. As of March 31, 2022, 580,200 shares of common stock were available for issuance under the Inducement Plan.

Stock-Based Compensation

The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Cost of revenue

 

$

25

 

 

$

13

 

Research, development and clinical trials expenses

 

 

321

 

 

 

197

 

Selling, general and administrative expenses

 

 

1,964

 

 

 

902

 

 

 

$

2,310

 

 

$

1,112

 

 

12


 

 

During the three months ended March 31, 2022, the Company granted options to its employees and directors with service-based vesting for the purchase of an aggregate of 880,910 shares of common stock with a weighted average grant-date fair value of $7.11 per share. As of March 31, 2022, total unrecognized compensation cost related to unvested share-based awards was $24.6 million, which is expected to be recognized over a weighted average period of 3.1 years.

9. Commitments and Contingencies

Operating Leases

The Company leases office, laboratory and manufacturing space under two non-cancelable operating leases. There have been no material changes to the Company’s leases during the three months ended March 31, 2022. For additional information, please read Note 12 Leases, to the consolidated financial statements in the Company’s Form 10-K for the year ended December 31, 2021.

License Agreement with the Department of Veterans Affairs

In 2002, the Company entered into a license agreement with the Department of Veterans Affairs (the “VA”), under which the Company was granted an exclusive, worldwide license under specified patents to make, use, sell and import certain technology used in the Company’s products and a non-exclusive, worldwide license to make, use, sell and import solutions for use in or with those products. The rights under the license agreement continue until the expiration of the last to expire of the licensed patents. The majority of the licensed U.S. patents expired in 2017, and the foreign patents expired in September 2018. However, the Company has requested a patent term extension for one U.S. patent covered by the VA license agreement, U.S. Patent No. 6100082. The Company was granted an interim patent term extension for this patent until November 6, 2021. The Company has not received final approval of the patent extension beyond the interim patent term extension already granted. The maximum extension requested would be through May 2022; however, the length of the patent term extension will be determined by the United States Patent and Trademark Office (“USPTO”) based on input from the FDA.  On February 8, 2021, the FDA provided to the USPTO a determined regulatory review period for the OCS Lung. Under the FDA’s analysis, the patent term extension of the ’082 patent would be until November 6, 2021. The Company has not yet received communication from the USPTO but expects that the USPTO’s determination of patent term extension for the ’082 patent will maintain the November 6, 2021 expiration date. The final determination of the length of the patent extension is not expected to have a material impact on the Company’s financial results. The license includes the right to grant sublicenses, subject to approval by the VA and other restrictions, and is subject to the U.S. government’s right to practice the licensed patents on its own behalf without payment of a royalty and obligation to grant certain sublicenses as necessary to fulfill public health, welfare and safety needs. The license agreement also requires the Company to make its products covered by the licensed patents available to the public on reasonable terms and to provide the U.S. government such products at the lowest price.

As consideration for the licenses granted by the VA, the Company is obligated to pay tiered royalties ranging from a low single-digit to a mid single-digit percentage on net sales of each product covered by a licensed patent (subject to a minimum aggregate royalty payment of less than $0.1 million per year during each of the first five years after the first commercial sale, after which no minimum is required). Royalties will be paid by the Company on a licensed product-by-licensed product and country-by-country basis, beginning on the first commercial sale of such licensed product in such country until expiration of the last valid patent claim covering such licensed product in such country. The Company is also responsible for all costs related to the amendment, prosecution and maintenance of the licensed patent rights.

The VA license agreement can be terminated by the Company or the VA only if the other party fails to cure its material breach within a specified period after receiving notice of such breach.

401(k) Savings Plan

The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the plan may be made at the discretion of the board of directors. As of March 31, 2022 and December 31, 2021, the Company had not made any contributions to the plan.

Indemnification Agreements

In the ordinary course of business, the Company has agreed to defend and indemnify its customers against third-party claims asserting infringement of certain intellectual property rights, which may include patents, copyrights, trademarks, or trade secrets. The Company’s exposure under these indemnification provisions is generally limited to the total amount paid

13


 

by the end-customer under the agreement. However, certain agreements include indemnification provisions that could potentially expose the Company to losses in excess of the amount received under the agreement. In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or services as directors or officers.

The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and had not accrued any liabilities related to such obligations in its consolidated financial statements as of March 31, 2022 and December 31, 2021.

 

 

Unconditional Purchase Commitment

In January 2021, the Company entered into an unconditional $9.5 million purchase commitment, in the ordinary course of business, for goods with specified annual minimum quantities to be purchased through December 2029. The contract is not cancellable without penalty. The remaining purchase commitment as of March 31, 2022 was $8.0 million.

Legal Proceedings

The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.

 

10. Segment Reporting and Geographic Data

The Company has determined that it operates in one segment (see Note 2).

See Note 11 for revenue by country. Long-lived assets by geography are summarized as follows (in thousands):

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Long-lived assets by country(1):

 

 

 

 

 

 

 

 

United States

 

$

11,317

 

 

$

9,085

 

All other countries

 

 

727

 

 

 

756

 

Total long-lived assets

 

$

12,044

 

 

$

9,841

 

 

 

(1)

The Company’s only long-lived assets consist of property and equipment, net of depreciation, which are categorized based on their location of domicile.

 

11. Revenue

The Company has determined that the payments made to the customer for reimbursement of clinical trial materials and customer’s costs incurred to execute specific clinical trial protocols related to the Company’s OCS products do not provide the Company with a distinct good or service transferred by the customer, and therefore such payments are recorded as a reduction of revenue from the customer in the Company’s consolidated statements of operations. Reductions of revenue related to such payments made to customers for reimbursements are recognized when the Company recognizes the revenue for the sale of its OCS disposable sets.

The reconciliation of gross revenue to net revenue for these certain payments is shown below (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Gross revenue from sales to customers

 

$

15,880

 

 

$

7,637

 

Less: clinical trial payments reducing

   revenue

 

 

 

 

 

584

 

Total net revenue

 

$

15,880

 

 

$

7,053

 

14


 

 

The Company determined that payments made to customers to obtain information related to post-approval studies or existing standard-of-care protocols (i.e., unrelated to the Company’s OCS products) meet the criteria to be classified as a cost because the Company receives a distinct good or service transferred by the customer separate from the customer’s purchase of the Company’s OCS products and the consideration paid to the customer represents the fair value of the distinct good or service received. As a result, such payments made to the customers are recorded as operating expenses. The Company recorded payments made to customers related to post-approval studies and for documentation related to existing standard-of-care protocols of $0.5 million for each of the three months ended March 31, 2022 and 2021, as operating expenses.

Disaggregated Revenue

The Company disaggregates revenue from contracts with customers by product type and geographical area as it believes this presentation best depicts how the nature, amount, timing and uncertainty of the Company’s revenue and cash flows are affected by economic factors, as shown below (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Net revenue by OCS product:

 

 

 

 

 

 

 

 

OCS Lung net revenue

 

$

2,298

 

 

$

2,430

 

OCS Heart net revenue

 

 

5,713

 

 

 

4,181

 

OCS Liver net revenue

 

 

7,869

 

 

 

442

 

Total net revenue

 

$

15,880

 

 

$

7,053

 

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Net revenue by country(1):

 

 

 

 

 

 

 

 

United States

 

$

13,561

 

 

$

5,757

 

All other countries

 

 

2,319

 

 

 

1,296

 

Total net revenue

 

$

15,880

 

 

$

7,053

 

 

 

(1)

Net revenue by country is categorized based on the location of the end customer.

 

Contract Assets and Liabilities

The Company recognizes a receivable at the point in time at which it has an unconditional right to payment. Such receivables are not contract assets. Contract assets arise from unbilled amounts in customer arrangements when revenue recognized exceeds the amount billed to the customer and the Company’s right to payment is not just subject to the passage of time. The Company had no contract assets as of March 31, 2022 and December 31, 2021.

Contract liabilities represent the Company’s obligation to transfer goods or services to a customer for which it has received consideration (or the amount is due) from the customer. The Company has determined that its only contract liabilities are deferred revenue, which consists of amounts that have been invoiced but that have not been recognized as revenue.

The Company generally satisfies performance obligations within one year of the contract inception date. As of March 31, 2022, the Company’s wholly- or partially unsatisfied performance obligations totaled $2.1 million and are expected to be completed within the next year.

12. Related Party Transactions

Employment of Dr. Amira Hassanein

Dr. Amira Hassanein, who serves as Product Director for the Company’s OCS Lung program, is the sister of Dr. Waleed Hassanein, the Company’s President and Chief Executive Officer and a member of the Company’s board of directors.  The Company paid Dr. Amira Hassanein approximately $0.1 million in total compensation for each of the three months ended March 31, 2022 and 2021 for her services as an employee.

 

 

15


 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 1, 2022 (“2021 Form 10-K”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Item 1A. Risk Factors” section of this Quarterly Report on Form 10-Q and the “Item 1A. Risk Factors” section of our 2021 Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. Our innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body. As such, the OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. We believe the use of the OCS has the potential to significantly increase the number of organ transplants and improve post-transplant outcomes. We have developed our National OCS Program, a turnkey solution to provide outsourced organ retrieval and OCS organ management, to provide transplant programs with a more efficient process to procure donor organs with the OCS.  

We designed the OCS to be a platform that allows us to leverage core technologies across products for multiple organs. To date, we have developed three OCS products, one for each of lung, heart and liver transplantations, making the OCS the only multi-organ technology platform. We have commercialized the OCS Lung and OCS Heart outside of the United States. All three of our products, OCS Lung, OCS Heart, and OCS Liver have received Pre-Market Approval, or PMA, from the Food and Drug Administration, or FDA, as follows:  

 

OCS Lung for the preservation of standard criteria donor lungs for double-lung transplantation;

 

OCS Lung for the preservation of donor lungs initially deemed unsuitable due to limitations of cold storage for double-lung transplantation;

 

OCS Heart for the preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage (e.g. >4 hours of cross-clamp time);

 

OCS Heart for the ex vivo reanimation, functional monitoring, and beating-heart preservation of DCD hearts (FDA approval received on April 28, 2022), and

 

OCS Liver for the preservation of DBD and DCD donor livers < 55 years old, macrosteatosis <15% and with < 30 mins of warm ischemia time.

Since our inception, we have focused substantially all of our resources on designing, developing and building our proprietary OCS technology platform and organ-specific OCS products; obtaining clinical evidence for the safety and effectiveness of our OCS products through clinical trials; securing regulatory approval; organizing and staffing our company; planning our business; raising capital; commercializing our products; developing our market and distribution chain and providing general and administrative support for these operations. To date, we have funded our operations primarily with proceeds from sales of preferred stock, borrowings under loan agreements, proceeds from the sale of common stock in our public offerings, and revenue from clinical trials and commercial sales of our OCS products.

Since our inception, we have incurred significant operating losses. Our ability to generate net revenue sufficient to achieve profitability will depend on the successful further development and commercialization of our products. We generated net revenue of $15.9 million and incurred a net loss of $10.6 million for the three months ended March 31, 2022. We generated net revenue of $30.3 million and incurred a net loss of $44.2 million for the year ended December 31, 2021. As of March 31, 2022, we had an accumulated deficit of $453.0 million. We expect to continue to incur net losses for the foreseeable future as we focus on growing commercial sales of our products in both the United States and select non-U.S. markets, including growing our commercial team, which will pursue increasing commercial sales of our OCS products; scaling our manufacturing operations; building our commercial operations; continuing research, development and clinical trial efforts; seeking regulatory clearance for new products and product enhancements, including new indications, in both the

16


 

United States and select non-U.S. markets; and operating as a public company. As a result, we will need substantial additional funding for expenses related to our operating activities, including selling, general and administrative expenses and research, development and clinical trials expenses.

Because of the numerous risks and uncertainties associated with product development and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Until such time, if ever, as we can generate substantial net revenue sufficient to achieve profitability, we expect to finance our operations through a combination of equity offerings, debt financings and strategic alliances. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms or at all. If we are unable to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the further development and commercialization efforts of one or more of our products, or may be forced to reduce or terminate our operations.

As of March 31, 2022, we had cash, cash equivalents and marketable securities of $72.0 million.  Our credit facility of $35.0 million with OrbiMed matures on June 22, 2023.  We believe that our cash, cash equivalents and marketable securities will be sufficient for us to fund our operating expenses, capital expenditure requirements and debt service payments for at least 12 months following the filing of our Quarterly Report on Form 10-Q. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “—Liquidity and Capital Resources”.

COVID-19

The COVID-19 pandemic, including efforts to contain the spread of the coronavirus, has impacted, and may continue to impact, our business, financial condition, operating results and cash flows, including as a result of the impact of new variants. Impacts to our business as a result of COVID-19 have included the temporary disruption of transplant procedures at many of the organ transplant centers who purchase OCS products; customer delays or reductions in customer capital expenditures and operating budgets and the related impact on our product sales; disruptions to our manufacturing operations and supply chain caused by facility closures, reductions in operating hours, staggered shifts and other social distancing efforts; labor shortages; decreased productivity and unavailability of materials or components; delays of reviews and approvals by the FDA and other health authorities; delays in our clinical trial enrollment; limitations on our employees’ and customers’ ability to travel, and delays in product installations, trainings or shipments to and from other affected countries and within the United States.

In response to the pandemic, healthcare providers have, and may need to further, reallocate resources, such as physicians, staff, hospital beds and intensive care unit facilities, as they prioritize limited resources and personnel capacity to focus on the treatment of patients with COVID-19. These actions significantly delay the provision of other medical care such as organ transplantation and reduce the number of transplant procedures that are performed, which negatively impacts our revenue and cash flows. These measures and challenges may continue for the duration of the COVID-19 pandemic.

The COVID-19 pandemic has also impacted, and may continue to impact, our third party suppliers, including through the effects of facility closures, reductions in operating hours, staggered shifts and other social distancing efforts, labor shortages, decreased productivity and unavailability of materials or components. In addition, inflation, changes in trade policies, and the imposition of duties and tariffs could adversely impact the price or availability of raw materials, the components of our products as well as shipping and transportation costs. While we maintain an inventory of finished products and raw materials used in our OCS products, a further prolonged pandemic could lead to shortages in the raw materials necessary to manufacture our products. The extent to which COVID-19 impacts operations of our third-party partners will depend on future developments, which are highly uncertain and cannot be predicted with confidence. If we experience a prolonged disruption in our manufacturing, supply chains, or commercial operations, we would expect to experience a material adverse impact on our business, financial condition, results of operations and prospects.

Recent Developments

On April 28, 2022, we received a PMA from the FDA for the use in the United States of the OCS Heart for use with organs from donors after circulatory death. The PMA for the OCS Heart was based on the results of the OCS DCD Heart Trial.

Components of Our Results of Operations

17


 

Net Revenue

We generate revenue primarily from sales of our single-use, organ-specific disposable sets used on our organ-specific OCS Consoles. To a lesser extent, we also generate revenue from the sale of OCS Consoles to customers and from the implied rental of OCS Consoles loaned to customers at no charge. For each new transplant procedure, customers purchase an additional OCS disposable set for use on the customer’s existing organ-specific OCS Console.

All of our revenue has been generated by sales to transplant centers and Organ Procurement Organizations, not-for-profit organizations responsible for recovering organs from deceased donors for transplantation, in the United States, Europe and Asia-Pacific, or, in some cases, to distributors selling to transplant centers in select countries. Substantially all of our customer contracts have multiple-performance obligations that contain promises consisting of OCS Perfusion Sets and OCS Solutions. In some of those contracts, the promises also include an OCS Console, whether sold or loaned to the customer.

We have customer agreements under which we loan our OCS Consoles to the customer for the duration of the agreement. In such cases, we place an organ-specific OCS Console at the customer site for its use free of charge, and the customer separately purchases from us the OCS disposable sets used in each transplant procedure. When we loan the OCS Console to the customer, we retain title to the console at all times and do not require minimum purchase commitments from the customer related to any OCS products. In such cases, we invoice the customer for OCS disposable sets based on customer orders received for each new transplant procedure and the prices set forth in the customer agreement. Over time, we typically recover the cost of the loaned OCS Console through the customer’s continued purchasing and use of additional OCS disposable sets. For these reasons, we have determined that part of the selling price for the disposable set is an implied rental payment for use of the OCS Console.

Because all promises of a customer contract are delivered and recognized as revenue at the same time and because revenue allocated to promises other than OCS disposable sets, such as implied rental income and service revenue, is insignificant, all performance obligations from customer contracts are classified as a single category of revenue in our consolidated statements of operations.

Under some of our customer clinical trial agreements, we made payments to our customers for reimbursements of clinical trial materials and for specified clinical documentation related to their use of our OCS products. Because some of these payments did not provide us with a separately identifiable benefit, we recorded such payments as a reduction of revenue from the customer, resulting in our net revenue presentation. We did not record any reimbursable clinical trial costs as a reduction of revenue for the three months ended March 31, 2022. We recorded reimbursable clinical trial costs as a reduction of revenue of $0.6 million for the three months ended March 31, 2021.

Through March 31, 2022, all of our sales outside of the United States have been commercial sales (unrelated to any clinical trials). We expect that our net revenue will increase over the long term as a result of receiving PMAs for the OCS Lung, OCS Heart and OCS Liver in the United States. Additionally, commercial sales of OCS disposable sets generally have a higher average selling price than clinical trial sales of OCS disposable sets. We also expect that our net revenue will increase over the long term as a result of anticipated growth in non-U.S. sales if national healthcare systems begin to reimburse transplant centers for the use of the OCS, if transplant centers utilize the OCS in more transplant cases, and if more transplant centers adopt the OCS in their programs.

Cost of Revenue, Gross Profit and Gross Margin

Cost of revenue consists primarily of costs of components of our OCS Consoles and disposable sets, costs of direct materials, labor and the manufacturing overhead that directly supports production, and costs related to the depreciation of OCS Consoles loaned to customers. When we loan an OCS Console to a customer for its use free of charge, we capitalize as property and equipment the cost of our OCS Console and depreciate these assets over the five-year estimated useful life of the console. Included in the cost of OCS disposable sets are the costs of our OCS Lung, OCS Heart and OCS Liver Solutions. We expect that cost of revenue will increase or decrease in absolute dollars primarily as, and to the extent that, our net revenue increases or decreases.

Gross profit is the amount by which our net revenue exceeds our cost of revenue in each reporting period. We calculate gross margin as gross profit divided by net revenue. Our gross margin has been and will continue to be affected by a variety of factors, primarily production volumes, the cost of components and direct materials, manufacturing overhead costs, direct labor, the selling price of our OCS products and fluctuations in amounts paid by us to customers related to reimbursements of their clinical trial expenses during clinical trials.

18


 

We expect that cost of revenue as a percentage of net revenue will moderately decrease and gross margin and gross profit will moderately increase over the long term as our sales and production volumes increase and our cost per unit of our OCS disposable sets decreases due to economies of scale. We intend to use our design, engineering and manufacturing capabilities to further advance and improve the efficiency of our manufacturing processes, which we believe will reduce costs and increase our gross margin. While we expect gross margin to increase over the long term, it will likely fluctuate from quarter to quarter.

Operating Expenses

Research, Development and Clinical Trials Expenses

Research, development and clinical trials expenses consist primarily of costs incurred for our research activities, product development, hardware and software engineering, clinical trials to continue to develop clinical evidence of our products’ safety and effectiveness, regulatory expenses, testing, consultant services and other costs associated with our OCS technology platform and OCS products, which include:

 

employee-related expenses, including salaries, related benefits and stock-based compensation expense for employees engaged in research, hardware and software development, regulatory and clinical trial functions;

 

expenses incurred in connection with the clinical trials of our products, including under agreements with third parties, such as consultants, contractors and data management organizations;

 

the cost of maintaining and improving our product designs, including the testing of materials and parts used in our products;

 

laboratory supplies and research materials; and

 

facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance.

We expense research, development and clinical trials costs as incurred. In the future, we expect that research, development and clinical trials expenses will increase over the long term due to ongoing product development and approval efforts. We expect to continue to perform activities related to obtaining additional regulatory approvals for expanded indications in the United States and other served geographies, as well as developing the next generation of our OCS technology platform.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in our commercial team and personnel in executive, marketing, finance and administrative functions. Selling, general and administrative expenses also include direct and allocated facility-related costs, promotional activities, marketing, conferences and trade show costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. We expect to continue to increase headcount in our commercial team and increase marketing efforts as we continue to grow commercial sales of our OCS products in both U.S. and select non-U.S. markets.

We expect that our selling, general and administrative expenses will increase over the long term as we increase our headcount to support the expected continued sales growth of our OCS products.

Other Income (Expense)

Interest Expense

Interest expense consists of interest expense associated with outstanding borrowings under our loan agreement as well as the amortization of debt discount associated with such agreement.

Other Income (Expense), Net

Other income (expense), net includes interest income, realized and unrealized foreign currency transaction gains and losses and other non-operating income and expense items unrelated to our core operations. Interest income consists of interest earned on our invested cash balances. Foreign currency transaction gains and losses result from intercompany transactions as well as transactions with customers or vendors denominated in currencies other than the functional currency of the legal entity in which the transaction is recorded.

19


 

Results of Operations

Comparison of the Three Months Ended March 31, 2022 and 2021

The following table summarizes our results of operations for the three months ended March 31, 2022 and 2021:

 

 

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2022

 

 

2021

 

 

Change

 

 

 

(in thousands)

 

Net revenue

 

$

15,880

 

 

$

7,053

 

 

$

8,827

 

Cost of revenue

 

 

3,776

 

 

 

2,242

 

 

 

1,534

 

Gross profit

 

 

12,104

 

 

 

4,811

 

 

 

7,293

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research, development and clinical trials

 

 

7,534

 

 

 

4,532

 

 

 

3,002

 

Selling, general and administrative

 

 

13,939

 

 

 

6,786

 

 

 

7,153

 

Total operating expenses

 

 

21,473

 

 

 

11,318

 

 

 

10,155

 

Loss from operations

 

 

(9,369

)

 

 

(6,507

)

 

 

(2,862

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(960

)

 

 

(952

)

 

 

(8

)

Other expense, net

 

 

(227

)

 

 

(454

)

 

 

227

 

Total other expense, net

 

 

(1,187

)

 

 

(1,406

)

 

 

219

 

Loss before income taxes

 

 

(10,556

)

 

 

(7,913

)

 

 

(2,643

)

Provision for income taxes

 

 

(6

)

 

 

(4

)

 

 

(2

)

Net loss

 

$

(10,562

)

 

$

(7,917

)

 

$

(2,645

)

 

Net Revenue

 

 

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2022

 

 

2021

 

 

Change

 

 

 

(in thousands)

 

Net revenue by geography:

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

$

13,561

 

 

$

5,757

 

 

$

7,804

 

Outside the U.S.

 

 

2,319

 

 

 

1,296

 

 

 

1,023

 

Total net revenue

 

$

15,880

 

 

$

7,053

 

 

$

8,827

 

Net revenue by OCS product:

 

 

 

 

 

 

 

 

 

 

 

 

OCS Lung net revenue

 

$

2,298

 

 

$

2,430

 

 

$

(132

)

OCS Heart net revenue

 

 

5,713

 

 

 

4,181

 

 

 

1,532

 

OCS Liver net revenue

 

 

7,869

 

 

 

442

 

 

 

7,427

 

Total net revenue

 

$

15,880

 

 

$

7,053

 

 

$

8,827

 

 

Net revenue from customers in the United States was $13.6 million in the three months ended March 31, 2022 and increased by $7.8 million compared to the three months ended March 31, 2021, primarily due to higher sales volumes of our OCS Liver and OCS Heart disposable sets as a result of the FDA approval for these two products in the third quarter of 2021. This increase was partially offset by lower sales volumes of our OCS Lung disposable sets. Net revenue from sales of OCS Liver disposable sets in the United States increased by $7.4 million due primarily to higher sales volumes of OCS Liver disposable sets resulting from the recent FDA approval of the OCS Liver product along with the expansion of our National OCS Program to provide a streamlined solution for transplant centers to use the OCS Liver. Net revenue from sales of OCS Heart disposable sets in the United States increased by $0.7 million also primarily as a result of the FDA approval of the OCS Heart in the third quarter of 2021. Both the OCS Heart and the OCS Liver were approved for commercial sale in September 2021, which has provided the opportunity for increased sales volumes and pricing. Net revenue from sales of OCS Lung disposable sets in the United States decreased by $0.4 million due to lower sales volumes of OCS Lung disposable sets, which were negatively impacted by the Omicron variant of COVID-19 in the early part of the first quarter of 2022.

Net revenue from customers outside the United States was $2.3 million in the three months ended March 31, 2022 compared to $1.3 million in the three months ended March 31, 2021. The increase in net revenue from customers outside the United States was primarily due to a progressive return to pre-COVID-19 volumes of transplant procedures in the European

20


 

market. Net revenue from sales of OCS Heart disposable sets outside the United States increased by $0.8 million due to increased sales volume of OCS Heart disposable sets. Net revenue from OCS Lung disposable sets increased by $0.2 million from the three months ended March 31, 2021 to the three months ended March 31, 2022 due to higher sales volumes of OCS Lung disposable sets.

Cost of Revenue, Gross Profit and Gross Margin

Cost of revenue increased by $1.5 million in the three months ended March 31, 2022 compared to the three months ended March 31, 2021. Gross profit increased by $7.3 million in the three months ended March 31, 2022 compared to the three months ended March 31, 2021. Gross margin was 76% and 68% for the three months ended March 31, 2022 and 2021, respectively. Gross margin increased primarily as a result economies of scale from higher sales volumes and an increase in pricing.

Operating Expenses

Research, Development and Clinical Trials Expenses

 

 

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2022

 

 

2021

 

 

Change

 

 

 

(in thousands)

 

Personnel related (including stock-based compensation

   expense)

 

$

2,252

 

 

$

2,130

 

 

$

122

 

Clinical trials costs

 

 

563

 

 

 

977

 

 

 

(414

)

Consulting and third-party testing

 

 

2,479

 

 

 

312

 

 

 

2,167

 

Laboratory supplies and research materials

 

 

1,137

 

 

 

410

 

 

 

727

 

Other

 

 

1,103

 

 

 

703

 

 

 

400

 

Total research, development and clinical trials expenses

 

$

7,534

 

 

$

4,532

 

 

$

3,002

 

Total research, development and clinical trials expenses increased by $3.0 million from $4.5 million in the three months ended March 31, 2021 to $7.5 million in the three months ended March 31, 2022. Consulting and third-party testing, laboratory supplies and research materials and other costs increased by $2.2 million, $0.7 million and $0.4 million, respectively, due to increased activity in our next generation program and ongoing existing research activities. Clinical trial costs decreased by $0.4 million due to the completion of pre-market approval clinical trial enrollment activity following the approval of the OCS Heart and OCS Liver by the FDA in September 2021.

Selling, General and Administrative Expenses

 

 

 

Three Months Ended March 31,

 

 

 

 

 

 

 

2022

 

 

2021

 

 

Change

 

 

 

(in thousands)

 

Personnel related (including stock-based compensation

   expense)

 

$

8,387

 

 

$

3,838

 

 

$

4,549

 

Professional and consultant fees

 

 

2,088

 

 

 

1,402

 

 

 

686

 

Tradeshows and conferences

 

 

453

 

 

 

188

 

 

 

265

 

Other

 

 

3,011

 

 

 

1,358

 

 

 

1,653

 

Total selling, general and administrative expenses

 

$

13,939

 

 

$

6,786

 

 

$

7,153

 

Total selling, general and administrative expenses increased by $7.2 million from $6.8 million in the three months ended March 31, 2021 to $13.9 million in the three months ended March 31, 2022 due to increases in personnel related costs, professional and consultant fees, tradeshows and conferences and other costs. Personnel related costs increased by $4.5 million primarily due to the continued expansion of our team to support the National OCS Program and commercial growth of our OCS Lung, OCS Heart and OCS Liver products in the United States, as well as an increase in stock-based compensation expense of $1.1 million due primarily to additional grants to new and existing employees. Professional and consultant fees increased by $0.7 million due to additional sales and administration costs related to the expansion of our National OCS Program. Tradeshows and conferences costs increased by $0.3 million as a result of an increase in activities as restrictions implemented in response to the COVID-19 pandemic were eased. Other costs increased by $1.7 million due to increased logistics costs related to the expansion of our National OCS Program.

21


 

Other Income (Expense)

Interest Expense

Interest expense was $1.0 million for each of the three months ended March 31, 2022 and 2021.

Other Expense, Net

Other expense, net for the three months ended March 31, 2022 and 2021 included interest income of less than $0.1 million in each period resulting from interest earned on invested cash balances, and $0.2 million and $0.5 million of realized and unrealized foreign currency transactions losses, respectively.  

Liquidity and Capital Resources

Since our inception, we have incurred significant operating losses. To date, we have funded our operations primarily with proceeds from sales of preferred stock and borrowings under loan agreements, proceeds from the sale of common stock in our public offerings and revenue from clinical trials and commercial sales of our OCS products.

As of March 31, 2022, we had cash, cash equivalents, and marketable securities of $72.0 million.

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

 

 

(in thousands)

 

Net cash used in operating activities

 

$

(18,406

)

 

$

(7,330

)

Net cash provided by investing activities

 

 

10,514

 

 

 

9,272

 

Net cash provided by financing activities

 

 

405

 

 

 

583

 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

 

(196

)

 

 

(379

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

$

(7,683

)

 

$

2,146

 

 

Operating Activities

During the three months ended March 31, 2022, operating activities used $18.4 million of cash, primarily resulting from our net loss of $10.6 million and net cash used by changes in our operating assets and liabilities of $11.4 million, partially offset by net non-cash charges of $3.6 million. Net cash used by changes in our operating assets and liabilities for the three months ended March 31, 2022 consisted primarily of an increase in accounts receivable of $5.8 million, an increase in inventory of $2.9 million and a decrease in accounts payable and accrued expenses and other current liabilities of $4.0 million, partially offset by an increase in operating lease liabilities of $1.2 million related to the reimbursement of tenant improvement costs.

During the three months ended March 31, 2021, operating activities used $7.3 million of cash, primarily resulting from our net loss of $7.9 million and net cash used by changes in our operating assets and liabilities of $2.0 million, partially offset by net non-cash charges of $2.6 million. Net cash used by changes in our operating assets and liabilities for the three months ended March 31, 2021 consisted primarily of a $0.9 million increase in prepaid expenses and other current assets, a $0.6 million increase in accounts receivable, a $0.4 million increase in inventory and a $0.3 million decrease in accounts payable and accrued expenses and other current liabilities, partially offset by a $0.2 million increase in deferred revenue.

Changes in accounts receivable, inventory, accounts payable, and accrued expenses and other current liabilities in each reporting period are generally due to growth in our business and timing of invoices and payments.

Investing Activities

During the three months ended March 31, 2022, net cash provided by investing activities of $10.5 million consisted of proceeds from sales and maturities of marketable securities of $14.5 million, partially offset by purchases of marketable securities of $2.0 million and purchases of property and equipment of $2.0 million.

22


 

During the three months ended March 31, 2021, net cash provided by investing activities of $9.3 million consisted of proceeds from sales and maturities of marketable securities of $21.0 million, partially offset by $11.7 million in purchases of marketable securities.

Financing Activities

During the three months ended March 31, 2022, net cash provided by financing activities of $0.4 million consisted of proceeds from the issuance of common stock upon exercise of stock options of $0.2 million and proceeds from the issuance of common stock in connection with the 2019 Employee Stock Purchase Plan of $0.2 million.

During the three months ended March 31, 2021, net cash provided by financing activities of $0.6 million consisted of proceeds from the issuance of common stock in connection with the 2019 Employee Stock Purchase Plan of $0.2 million and proceeds from the issuance of common stock upon exercise of stock options of $0.4 million.

Long-Term Debt

We have a Credit Agreement with OrbiMed, pursuant to which we borrowed $35.0 million.

Borrowings under the Credit Agreement bear interest at an annual rate equal to the LIBOR subject to a minimum of 1.0% and a maximum of 4.0%, plus 8.5%, or the Applicable Margin, subject in the aggregate to a maximum interest rate of 11.5%. In addition, borrowings under the Credit Agreement bear paid-in-kind, or PIK interest, at an annual rate equal to the amount by which LIBOR plus the Applicable Margin exceeds 11.5%, but not to exceed 12.5%. The PIK interest is added to the principal amount of the borrowings outstanding at the end of each quarter until the maturity date of the Credit Agreement in June 2023. Borrowings under the Credit Agreement are repayable in quarterly interest-only payments until the maturity date, at which time all principal and accrued interest is due and payable. At our option, we may prepay outstanding borrowings under the Credit Agreement. We are required to make a final payment in an amount equal to 3.0% of the principal amount of any prepayment or repayment, which we are accreting to interest expense over the term of the Credit Agreement using the effective interest method.

All obligations under the Credit Agreement are guaranteed by us and each of our material subsidiaries. All obligations of us and each guarantor are secured by substantially all of our and each guarantor’s assets, including their intellectual property, subject to certain exceptions, including a perfected security interest in substantially all tangible and intangible assets of us and each guarantor. Under the Credit Agreement, we have agreed to certain affirmative and negative covenants to which we will remain subject until maturity. The financial covenants include maintaining a minimum liquidity amount of $3.0 million; the requirement, on an annual basis, to deliver to OrbiMed annual audited financial statements with an unqualified audit opinion from our independent registered public accounting firm; and restrictions on our activities, including limitations on dispositions, mergers or acquisitions; encumbering our intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and engaging in certain other business transactions. The obligations under the Credit Agreement are subject to acceleration upon the occurrence of specified events of default, including payment default, change in control, bankruptcy, insolvency, certain defaults under other material debt, certain events with respect to governmental approvals (if such events could cause a material adverse change in our business), failure to comply with certain covenants, including the minimum liquidity and unqualified audit opinion covenants, and a material adverse change in our business, operations or other financial condition. As of March 31, 2022, we were in compliance with all of the covenants under the Credit Agreement.

Upon the occurrence of an event of default and until such event of default is no longer continuing, the Applicable Margin will increase by 4.0% per annum. If an event of default (other than certain events of bankruptcy or insolvency) occurs and is continuing, OrbiMed may declare all or any portion of the outstanding principal amount of the borrowings plus accrued and unpaid interest to be due and payable. Upon the occurrence of certain events of bankruptcy or insolvency, all of the outstanding principal amount of the borrowings plus accrued and unpaid interest will automatically become due and payable. In addition, we may be required to prepay outstanding borrowings, subject to certain exceptions, with portions of net cash proceeds of certain asset sales and certain casualty and condemnation events. While we do not expect that the transition from LIBOR, including any legal or regulatory changes made in response to its future phase out, or the risks related to its discontinuance will have a material effect on our financing costs, the impact is uncertain at this time.

23


 

Funding Requirements

As we continue to pursue and increase commercial sales of our OCS products, we expect our costs and expenses to increase in the future, particularly as we expand our commercial team, grow our National OCS Program, scale our manufacturing operations, continue research, development and clinical trial efforts, and seek regulatory approval for new products and product enhancements, including new indications, both in the United States and in select non-U.S. markets. In addition, following the closing of our IPO, we have incurred and expect to continue to incur additional costs associated with operating as a public company. The timing and amount of our operating and capital expenditures will depend on many factors, including:

 

the amount of net revenue generated by sales of our OCS Consoles, OCS disposable sets and other products that may be approved in the United States and select non-U.S. markets;

 

the costs and expenses of expanding our U.S. and non-U.S. sales and marketing infrastructure and our manufacturing operations;

 

the extent to which our OCS products are adopted by the transplant community;

 

the ability of our customers to obtain adequate reimbursement from third-party payors for procedures performed using the OCS products;

 

the degree of success we experience in commercializing our OCS products for additional indications;

 

the costs, timing and outcomes of post-approval studies or any future clinical studies and regulatory reviews, including to seek and obtain approvals for new indications for our OCS products;

 

the emergence of competing or complementary technologies;

 

the number and types of future products we develop and commercialize;

 

the costs associated with building our commercial operations;

 

the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and

 

the level of our selling, general and administrative expenses.

We believe that our existing cash, cash equivalents, and marketable securities will enable us to fund our operating expenses, capital expenditure requirements, and debt service payments for at least 12 months following the filing of this Quarterly Report on Form 10-Q.

We may need to raise additional funding, which might not be available on favorable terms or at all. See “Item 1A. Risk Factors—Risks Related to Our Financial Position and Need for Additional Capital” in our 2021 Form 10-K.

Critical Accounting Policies and Significant Judgments and Estimates

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. We evaluate our estimates on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes to our critical accounting policies and estimates from those disclosed in our consolidated financial statements and the related notes and other financial information included in our 2021 Form 10-K.

Recently Issued Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

We are exposed to changes in interest rates and foreign currency exchange rates because we finance certain operations through variable rate debt instruments, hold investments and denominate our transactions in a variety of foreign currencies. Changes in these rates may have an impact on future cash flow and earnings. We manage these risks through normal

24


 

operating and financing activities. There has been no material change in the foreign currency exchange risk or interest rate risk discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2021 Form 10-K.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial and accounting officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2022, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended March 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

25


 

PART II—OTHER INFORMATION

We are not currently subject to any material legal proceedings.

Item 1A. Risk Factors

Investing in our common stock involves a high degree of risk. For a detailed discussion of the risks that affect our business, please refer to the section titled “Item 1A. Risk Factors” in our 2021 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Use of Proceeds

We completed our IPO pursuant to a registration statement on Form S-1 (File No. 333-230736), which was declared effective by the SEC on May 1, 2019 and a registration statement on Form S-1MEF (File No. 333-231166), which was automatically effective upon filing with the SEC on May 1, 2019. The net offering proceeds to us, after deducting underwriting discounts and commissions and other offering expenses, were $91.4 million. None of the net proceeds were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10.0% or more of any class of our equity securities or to any other affiliates, other than payments in the ordinary course of business to officers for salaries and to non-employee directors as compensation for board or board committee service. As of March 31, 2022, we estimate that we used all of the net proceeds from our IPO for commercialization of our OCS products, research and development, and general corporate purposes. There has been no material change in our planned use of the net proceeds from the IPO as described in the final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act, with the SEC, on May 2, 2019.

26


 

Item 6. Exhibits.

 

Exhibit

Number

 

Description

 

 

 

  31.1*

 

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

  31.2*

 

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

  32.1†

 

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

  32.2†

 

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

101.INS

 

XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document.

 

 

 

101.CAL

 

Inline XBRL Taxonomy Calculation Linkbase Document.

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

 

 

101.LAB

 

Inline XBRL Taxonomy Label Linkbase Document.

 

 

 

101.PRE

 

Inline XBRL Taxonomy Presentation Linkbase Document.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*

Filed herewith

This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

27


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: May 5, 2022

TRANSMEDICS GROUP, INC.

 

 

 

By:

/s/ Waleed H. Hassanein, M.D.

 

 

Waleed H. Hassanein, M.D.

 

 

President and Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

Date: May 5, 2022

By:

/s/ Stephen Gordon

 

 

Stephen Gordon

 

 

Chief Financial Officer, Treasurer and Secretary

 

 

(Principal Financial and Accounting Officer)

 

28

EX-31.1 2 tmdx-ex311_9.htm EX-31.1 tmdx-ex311_9.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT

OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Waleed Hassanein, M.D., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of TransMedics Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 5, 2022

 

/s/ Waleed H. Hassanein, M.D.

 

Waleed H. Hassanein, M.D.

President and Chief Executive Officer

(Principal Executive Officer)

 

EX-31.2 3 tmdx-ex312_6.htm EX-31.2 tmdx-ex312_6.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT

OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen Gordon, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of TransMedics Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 5, 2022

 

/s/ Stephen Gordon

 

Stephen Gordon

Chief Financial Officer, Treasurer and Secretary

(Principal Financial and Accounting Officer)

 

EX-32.1 4 tmdx-ex321_8.htm EX-32.1 tmdx-ex321_8.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of TransMedics Group, Inc. (the “Company”) for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Waleed Hassanein, M.D., President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 5, 2022

By:

/s/ Waleed H. Hassanein, M.D.

 

 

Waleed H. Hassanein, M.D.

 

 

President and Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

EX-32.2 5 tmdx-ex322_7.htm EX-32.2 tmdx-ex322_7.htm

 

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of TransMedics Group, Inc. (the “Company”) for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Stephen Gordon, Chief Financial Officer, Treasurer and Secretary of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 5, 2022

By:

/s/ Stephen Gordon

 

 

Stephen Gordon

 

 

Chief Financial Officer, Treasurer and Secretary

 

 

(Principal Financial and Accounting Officer)

 

 

EX-101.SCH 6 tmdx-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Nature of the Business and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Marketable Securities link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Fair Value of Financial Assets and Liabilities link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Inventory link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Accrued Expenses and Other Current Liabilities link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Segment Reporting and Geographic Data link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Revenue link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Marketable Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Inventory (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Long-term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Segment Reporting and Geographic Data (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Revenue (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Marketable Securities - Components of Marketable Securities by Security Type (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Inventory - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Long-term Debt - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Long-term Debt - Schedule of Long-term Debt Instruments (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Segment Reporting and Geographic Data - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Segment Reporting and Geographic Data - Geographic Areas Long Lived Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Revenue - Schedule of Recognized Revenue Net of Payments (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Revenue - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Revenue - Schedule of Net Revenue by OCS Product and Country (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 tmdx-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 tmdx-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 tmdx-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Shell Company Entity Shell Company Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Marketable securities Marketable Securities Current Accounts receivable Accounts Receivable Net Current Inventory Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Restricted cash Restricted Cash Noncurrent Operating lease right-of-use assets Operating Lease Right Of Use Asset Total assets Assets Liabilities and Stockholders' Equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses and other current liabilities Accrued Liabilities And Other Liabilities Deferred revenue Contract With Customer Liability Current Operating lease liabilities Operating Lease Liability Current Total current liabilities Liabilities Current Long-term debt, net of discount and current portion Long Term Debt Noncurrent Operating lease liabilities, net of current portion Operating Lease Liability Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 9) Commitments And Contingencies Stockholders' equity: Stockholders Equity [Abstract] Preferred stock, no par value; 25,000,000 shares authorized; no shares issued or outstanding Preferred Stock Value Common stock, no par value; 150,000,000 shares authorized; 27,968,583 shares and 27,791,615 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively Common Stock Value Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders' equity Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity Preferred Stock, No Par Value Preferred Stock No Par Value Preferred Stock, Shares Authorized Preferred Stock Shares Authorized Preferred Stock, Shares Issued Preferred Stock Shares Issued Preferred Stock, Shares Outstanding Preferred Stock Shares Outstanding Common Stock, No Par Value Common Stock No Par Value Common Stock, Shares Authorized Common Stock Shares Authorized Common Stock, Shares, Issued Common Stock Shares Issued Common Stock, Shares, Outstanding Common Stock Shares Outstanding Income Statement [Abstract] Net revenue Revenues Cost of revenue Cost Of Revenue Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Research, development and clinical trials Research And Development Expense Selling, general and administrative Selling General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income (expense): Other Nonoperating Income Expense [Abstract] Interest expense Interest Expense Other expense, net Other Nonoperating Income Expense Total other expense, net Nonoperating Income Expense Loss before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Provision for income taxes Current Income Tax Expense Benefit Net loss Net Income Loss Net loss per share attributable to common stockholders, basic Earnings Per Share Basic Net loss per share attributable to common stockholders, diluted Earnings Per Share Diluted Weighted average common shares outstanding, basic Weighted Average Number Of Shares Outstanding Basic Weighted average common shares outstanding, diluted Weighted Average Number Of Diluted Shares Outstanding Statement Of Income And Comprehensive Income [Abstract] Net loss Other comprehensive income (loss): Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Foreign currency translation adjustment Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Unrealized gains (losses) on marketable securities, net of tax of $0 Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Total other comprehensive income (loss) Other Comprehensive Income Loss Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax Amount of increase to common stock for recognition of cost for option under share-based payment arrangement. The change in value for stock issued as a result of a change in estimated offering costs during the period. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Accumulated Other Comprehensive Loss Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Balance Balance, Shares Shares Outstanding Issuance of common stock upon the exercise of common stock options Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon the exercise of common stock options, Shares Stock Issued During Period Shares Stock Options Exercised Issuance of common stock in connection with employee stock purchase plan Stock Issued During Period Value Employee Stock Purchase Plan Issuance of common stock in connection with employee stock purchase plan , Shares Stock Issued During Period Shares Employee Stock Purchase Plans Issuance of common stock in public offering,net of discounts and issuance costs Stock Issued During Period Value New Issues Issuance of common stock in public offering,net of discounts and issuance costs, Shares Stock Issued During Period Shares New Issues Reversal of estimated offering costs Reversal Of Estimated Offering Costs Stock-based compensation expense Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition Unrealized gains (losses) on marketable securities Balance Balance, Shares Amount of noncash expense for interest and accretion on long-term debt. Amount of noncash expense related to leasing arrangements. Value of inventory transferred to the entity's property plant and equipment in noncash transactions. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization expense Depreciation Depletion And Amortization Stock-based compensation expense Share Based Compensation Non-cash interest expense and end of term accretion expense Non Cash Interest And End Of Term Accretion Expense Non-cash lease expense Non Cash Lease Expense Net amortization of premiums on marketable securities Amortization Of Debt Discount Premium Unrealized foreign currency transaction losses Foreign Currency Transaction Gain Loss Unrealized Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Inventory Increase Decrease In Inventories Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses and other current liabilities Increase Decrease In Accrued Liabilities And Other Operating Liabilities Deferred revenue Increase Decrease In Contract With Customer Liability Operating lease liabilities Increase Decrease In Operating Lease Liability Deferred rent Increase Decrease In Deferred Charges Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Purchases of marketable securities Payments To Acquire Marketable Securities Proceeds from sales and maturities of marketable securities Proceeds From Sale And Maturity Of Marketable Securities Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of common stock upon exercise of stock options Proceeds From Stock Options Exercised Proceeds from issuance of common stock in connection with employee stock purchase plan Proceeds From Stock Plans Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Net increase (decrease) in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash, beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents and restricted cash, end of period Supplemental disclosure of non-cash investing and financing activities: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Transfers of inventory to property and equipment Inventory Transfer To Property Plant And Equipment Purchases of property and equipment included in accounts payable and accrued expenses Capital Expenditures Incurred But Not Yet Paid Reconciliation of cash, cash equivalents and restricted cash: Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract] Restricted cash Restricted Cash And Cash Equivalents Total cash, cash equivalents and restricted cash shown in the statement of cash flows Accounting Policies [Abstract] Nature of the Business and Basis of Presentation Business Description And Basis Of Presentation [Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Investments Debt And Equity Securities [Abstract] Marketable Securities Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value of Financial Assets and Liabilities Fair Value Disclosures [Text Block] Inventory Disclosure [Abstract] Inventory Inventory Disclosure [Text Block] Accrued Expenses and Other Current Liabilities [Abstract] Accrued Expenses And Other Current Liabilities [Abstract] Accrued Expenses and Other Current Liabilities Accounts Payable And Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Long-Term Debt Long Term Debt [Text Block] Stockholders Equity Note [Abstract] Stock-Based Compensation Shareholders Equity And Share Based Payments [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Segment Reporting [Abstract] Segment Reporting and Geographic Data Segment Reporting Disclosure [Text Block] Revenue From Contract With Customer [Abstract] Revenue Revenue From Contract With Customer [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Unaudited Interim Financial Information Basis Of Accounting Policy Policy [Text Block] Use of Estimates Use Of Estimates Risk of Concentrations of Credit, Significant Customers and Significant Suppliers Concentration Risk Credit Risk Fair Value Measurements Fair Value Measurement Policy Policy [Text Block] Segment Information Segment Reporting Policy Policy [Text Block] Net Income (Loss) per Share Earnings Per Share Policy [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Components of Marketable Securities by Security Type Marketable Securities [Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Schedule of Inventory, Current Schedule Of Inventory Current Table [Text Block] Schedule of Accrued Expenses and Other Current Liabilities Schedule Of Accrued Liabilities Table [Text Block] Schedule of Long-term Debt Instruments Schedule Of Debt Instruments [Text Block] Schedule of Stock-Based Compensation Expense Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block] Long-lived assets by geographical area Long Lived Assets By Geographic Areas Table [Text Block] Tabular disclosure of revenue from sales to customers, including detail for clinical trial payments that are not distinct which are removed from revenue recognized. Schedule of Recognized Revenue Net of Payments Schedule Of Sources Health Care Organization Table [Text Block] Schedule of Net Revenue by OCS Product and Country Disaggregation Of Revenue Table [Text Block] Net loss Accumulated deficit Cash equivalents and marketable securities Cash Cash Equivalents And Short Term Investments Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Revenue Benchmark Sales Revenue Net [Member] Accounts Receivable Accounts Receivable [Member] Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Significant Customers Benchmark. Significant Customer Benchmark [Member] Significant Customers Benchmark [Member] Customer One Customer One [Member] Customer One [Member] Customer Two Customer Two [Member] Customer Two [Member] Customer three. Customer Three [Member] Customer Three [Member] Customer four. Customer Four [Member] Customer Four [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Allowance for credit losses Allowance For Doubtful Accounts Receivable Concentration risk percentage Concentration Risk Percentage1 Number of operating segments Number Of Operating Segments Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Warrants to purchase common stock [Member] Warrant [Member] Options to purchase common stock [Member] Employee Stock Option [Member] Employee stock purchase plan [Member] Employee Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share Amount Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Marketable Securities [Table] Marketable Securities [Table] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] U.S. Treasury Securities (due within one year) [Member] U S Treasury Securities [Member] U.S. Government Agency Bonds (due within one year) [Member] U S Government Agencies Debt Securities [Member] Schedule Of Available For Sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Marketable Securities, Amortized Cost Available For Sale Debt Securities Amortized Cost Basis Marketable Securities, Gross Unrealized Gains Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Marketable Securities, Gross Unrealized Losses Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Marketable Securities, Fair Value Available For Sale Securities Debt Securities Level 2 [Member] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 [Member] Fair Value Inputs Level1 [Member] Level 2 [Member] Fair Value Inputs Level2 [Member] Level 3 [Member] Fair Value Inputs Level3 [Member] Cash and Cash Equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Money Market Funds [Member] Money Market Funds [Member] U.S. Treasury Securities [Member] U.S. Government Agency Bonds [Member] Cash equivalents: Cash Equivalents At Carrying Value [Abstract] Cash equivalents Cash And Cash Equivalents Fair Value Disclosure Marketable securities: Available For Sale Securities [Abstract] Marketable securities Cash equivalents and marketable securities Assets Fair Value Disclosure Raw materials Inventory Raw Materials Net Of Reserves Work-in-process Inventory Work In Process Net Of Reserves Finished goods Inventory Finished Goods Net Of Reserves Inventory, net Inventory transfer to property plant and equipment Carrying value as of the balance sheet date of obligations incurred and payable for research, development and clinical trials expenses. Accrued research, development and clinical trials expenses Accrued Research Development And Clinical Trials Expenses Current Accrued payroll and related expenses Employee Related Liabilities Current Accrued professional fees Accrued Professional Fees Current Accrued other Other Accrued Liabilities Current Accrued expenses and other liabilities current Lender Name Line Of Credit Facility [Axis] Line of Credit Facility, Lender Line Of Credit Facility Lender [Domain] Orbi Med [Member] Orbi Med [Member] Orbi Med [Member] Variable Rate Variable Rate [Axis] Variable Rate Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate L I B O R [Member] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Credit agreement. Credit Agreement [Member] Credit Agreement [Member] Scenario Statement Scenario [Axis] Scenario Scenario Unspecified [Domain] In Event Of Default [Member] In Event Of Default [Member] Long-term Debt, Gross Debt Instrument Carrying Amount Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, excluding current portion. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. Principal amount of long-term debt Less: Current portion of long-term debt Long Term Debt Current Long-term debt, net of current portion Long Term Debt Noncurrent Before Debt Discount And Accrued Payments Debt discount, net of accretion Debt Instrument Unamortized Discount Accrued end-of-term payment Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid Long-term debt, net of discount and current portion The threshold interest rate over/under which paid-in-kind interest is due. Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt, as a percentage of the principal amount of any prepayment or repayment. Debt instrument, maturity month and year. Description of variable rate basis Debt Instrument Description Of Variable Rate Basis LIBOR rate Debt Instrument Interest Rate Stated Percentage Basis spread on variable rate Debt Instrument Basis Spread On Variable Rate1 Interest rate effective percentage Debt Instrument Interest Rate Effective Percentage Paid in kind interest threshold Paid In Kind Interest Rate Threshold Debt instrument, maturity month and year Debt Instrument Maturity Month And Year Final payment Balloon Payment To Be Paid Percentage Minimum liquidity covenant amount. Description of covenants Debt Instrument Covenant Description Minimum liquidity covenant amount Minimum Liquidity Covenant Amount Increasing applicable margin Debt Instrument Interest Rate Increase Decrease Average effective interest rate Debt Weighted Average Interest Rate Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] 2019 Stock Plan [Member] 2019 Stock Plan [Member] Two Thousand Nineteen Stock Plan [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] From 2014 Plan. From 2014 Plan [Member] From Two Thousand Fourteen Plan [Member] 2019 Employee Stock Purchase Plan [Member] 2019 Employee Stock Purchase Plan [Member] Two Thousand Nineteen Employee Stock Purchase Plan [Member] Two thousand twenty one inducement plan. 2021 Inducement Plan [Member] Two Thousand Twenty One Inducement Plan [Member] Title of Individual Title Of Individual [Axis] Title of Individual Title Of Individual With Relationship To Entity [Domain] Employees and director. Employees and Directors [Member] Employees And Director [Member] Share-based compensation arrangement by share-based payment award, number of shares authorized Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Share based compensation arrangement by share based payment award number of shares available for grant Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Purchase price of common stock, percent Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent Number of shares issued Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Cost of revenue [Member] Cost Of Sales [Member] Research, development and clinical trials expenses [Member] Research, development and clinical trials expenses [Member] Research Development And Clinical Trials Expenses [Member] Selling, general and administrative expenses [Member] Selling General And Administrative Expenses [Member] Allocated Share-based Compensation Expense Allocated Share Based Compensation Expense Options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Unrecognized compensation cost related to unvested employee and director stock-based awards Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Weighted average period for unrecognized compensation cost Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 The minimum annual aggregate royalty payment due for the first five years after the first commercial sale. Guaranteed minimum annual royalty payment Guaranteed Minimum Annual Royalty Payment Defined contribution plan, contribution amount Defined Contribution Plan Employer Discretionary Contribution Amount Maturity year and month of recorded unconditional purchase commitment. The amount remaining on an unconditional purchase commitment. Recorded unconditional purchase commitment, minimum quantity required Recorded Unconditional Purchase Obligation Recorded unconditional purchase commitment, maturity year and month Recorded Unconditional Purchase Commitment Maturity Year And Month Remaining purchase commitment Unconditional Purchase Obligation Remaining Amount Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] United States [Member] UNITED STATES All Other Countries [Member] Other Countries [Member] Geographic Areas, Long-Lived Assets [Abstract] Geographic Areas Long Lived Assets [Abstract] Long-lived assets Noncurrent Assets Amount of reimbursable clinical costs recorded as a reduction to revenue. Gross revenue from sales to customers Revenue From Contract With Customer Excluding Assessed Tax Less: clinical trial payments reducing revenue Clinical Trial Expense Total net revenue The amount of payments made to customers related to post-approval studies or existing standard-of-care protocols that are recorded as operating expenses.. Research development and clinical trials expenses Customer Payments Recorded As Operating Expenses Net revenue product and country [Abstract]. Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] OCS Lung net revenue [Member] Ocs Lung Product [Member] OCS Heart net revenue [Member] Ocs Heart Product [Member] OCS Liver net revenue [Member] Ocs Liver Product [Member] Non US and UK member. All Other Countries [Member] Non Us And Uk [Member] Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Net revenue by OCS product and country Net Revenue Product And Country [Abstract] Contract assets Contract With Customer Asset Net Performance obligations totaled Revenue Remaining Performance Obligation Revenue performance obligation description of timing Revenue Performance Obligation Description Of Timing Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Director [Member] Director [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Compensation expense Compensation Expense Excluding Cost Of Good And Service Sold EX-101.PRE 10 tmdx-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2022
Apr. 29, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Entity Registrant Name TransMedics Group, Inc.  
Entity Central Index Key 0001756262  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Shell Company false  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Common Stock, Shares Outstanding   27,980,839
Entity File Number 001-38891  
Entity Incorporation, State or Country Code MA  
Entity Tax Identification Number 83-2181531  
Entity Address, Address Line One 200 Minuteman Road  
Entity Address, City or Town Andover  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 01810  
City Area Code 978  
Local Phone Number 552-0900  
Document Quarterly Report true  
Document Transition Report false  
Title of 12(b) Security Common Stock, No Par Value  
Trading Symbol TMDX  
Security Exchange Name NASDAQ  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 17,897 $ 25,580
Marketable securities 54,104 66,872
Accounts receivable 11,724 5,934
Inventory 16,714 14,859
Prepaid expenses and other current assets 5,356 5,460
Total current assets 105,795 118,705
Property and equipment, net 12,044 9,841
Restricted cash 500 500
Operating lease right-of-use assets 5,669 5,847
Total assets 124,008 134,893
Current liabilities:    
Accounts payable 2,934 6,651
Accrued expenses and other current liabilities 15,738 16,337
Deferred revenue 247 250
Operating lease liabilities 1,337  
Total current liabilities 20,256 23,238
Long-term debt, net of discount and current portion 35,334 35,197
Operating lease liabilities, net of current portion 8,508 8,604
Total liabilities 64,098 67,039
Commitments and contingencies (Note 9)  
Stockholders' equity:    
Preferred stock, no par value; 25,000,000 shares authorized; no shares issued or outstanding
Common stock, no par value; 150,000,000 shares authorized; 27,968,583 shares and 27,791,615 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively 513,203 510,488
Accumulated other comprehensive loss (285) (188)
Accumulated deficit (453,008) (442,446)
Total stockholders' equity 59,910 67,854
Total liabilities and stockholders' equity $ 124,008 $ 134,893
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Statement Of Financial Position [Abstract]    
Preferred Stock, No Par Value
Preferred Stock, Shares Authorized 25,000,000 25,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Common Stock, No Par Value
Common Stock, Shares Authorized 150,000,000 150,000,000
Common Stock, Shares, Issued 27,968,583 27,791,615
Common Stock, Shares, Outstanding 27,968,583 27,791,615
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Net revenue [1] $ 15,880 $ 7,053
Cost of revenue 3,776 2,242
Gross profit 12,104 4,811
Operating expenses:    
Research, development and clinical trials 7,534 4,532
Selling, general and administrative 13,939 6,786
Total operating expenses 21,473 11,318
Loss from operations (9,369) (6,507)
Other income (expense):    
Interest expense (960) (952)
Other expense, net (227) (454)
Total other expense, net (1,187) (1,406)
Loss before income taxes (10,556) (7,913)
Provision for income taxes (6) (4)
Net loss $ (10,562) $ (7,917)
Net loss per share attributable to common stockholders, basic $ (0.38) $ (0.29)
Net loss per share attributable to common stockholders, diluted $ (0.38) $ (0.29)
Weighted average common shares outstanding, basic 27,950,330 27,368,090
Weighted average common shares outstanding, diluted 27,950,330 27,368,090
[1]

Net revenue by country is categorized based on the location of the end customer.

XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement Of Income And Comprehensive Income [Abstract]    
Net loss $ (10,562) $ (7,917)
Other comprehensive income (loss):    
Foreign currency translation adjustment (24) (2)
Unrealized gains (losses) on marketable securities, net of tax of $0 (73) 8
Total other comprehensive income (loss) (97) 6
Comprehensive loss $ (10,659) $ (7,911)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement Of Income And Comprehensive Income [Abstract]    
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax $ 0 $ 0
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Accumulated Other Comprehensive Loss
Accumulated Deficit
Balance at Dec. 31, 2020 $ 103,891 $ 502,217 $ (95) $ (398,231)
Balance, Shares at Dec. 31, 2020   27,175,305    
Issuance of common stock upon the exercise of common stock options 372 $ 372    
Issuance of common stock upon the exercise of common stock options, Shares   287,705    
Issuance of common stock in connection with employee stock purchase plan 211 $ 211    
Issuance of common stock in connection with employee stock purchase plan , Shares   14,951    
Stock-based compensation expense 1,112 $ 1,112    
Foreign currency translation adjustment (2)   (2)  
Unrealized gains (losses) on marketable securities 8   8  
Net loss (7,917)     (7,917)
Balance at Mar. 31, 2021 97,675 $ 503,912 (89) (406,148)
Balance, Shares at Mar. 31, 2021   27,477,961    
Balance at Dec. 31, 2020 103,891 $ 502,217 (95) (398,231)
Balance, Shares at Dec. 31, 2020   27,175,305    
Net loss (44,200)      
Balance at Dec. 31, 2021 67,854 $ 510,488 (188) (442,446)
Balance, Shares at Dec. 31, 2021   27,791,615    
Issuance of common stock upon the exercise of common stock options 202 $ 202    
Issuance of common stock upon the exercise of common stock options, Shares   164,503    
Issuance of common stock in connection with employee stock purchase plan 203 $ 203    
Issuance of common stock in connection with employee stock purchase plan , Shares   12,465    
Stock-based compensation expense 2,310 $ 2,310    
Foreign currency translation adjustment (24)   (24)  
Unrealized gains (losses) on marketable securities (73)   (73)  
Net loss (10,562)     (10,562)
Balance at Mar. 31, 2022 $ 59,910 $ 513,203 $ (285) $ (453,008)
Balance, Shares at Mar. 31, 2022   27,968,583    
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net loss $ (10,562) $ (7,917)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 507 445
Stock-based compensation expense 2,310 1,112
Non-cash interest expense and end of term accretion expense 137 130
Non-cash lease expense 178  
Net amortization of premiums on marketable securities 228 391
Unrealized foreign currency transaction losses 214 484
Changes in operating assets and liabilities:    
Accounts receivable (5,804) (583)
Inventory (2,926) (381)
Prepaid expenses and other current assets 88 (908)
Accounts payable (4,013) (82)
Accrued expenses and other current liabilities (4) (180)
Deferred revenue   182
Operating lease liabilities 1,241  
Deferred rent   (23)
Net cash used in operating activities (18,406) (7,330)
Cash flows from investing activities:    
Purchases of property and equipment (1,953) (20)
Purchases of marketable securities (2,033) (11,708)
Proceeds from sales and maturities of marketable securities 14,500 21,000
Net cash provided by investing activities 10,514 9,272
Cash flows from financing activities:    
Proceeds from issuance of common stock upon exercise of stock options 202 372
Proceeds from issuance of common stock in connection with employee stock purchase plan 203 211
Net cash provided by financing activities 405 583
Effect of exchange rate changes on cash, cash equivalents and restricted cash (196) (379)
Net increase (decrease) in cash, cash equivalents and restricted cash (7,683) 2,146
Cash, cash equivalents and restricted cash, beginning of period 26,080 25,081
Cash, cash equivalents and restricted cash, end of period 18,397 27,227
Supplemental disclosure of non-cash investing and financing activities:    
Transfers of inventory to property and equipment 1,030 429
Purchases of property and equipment included in accounts payable and accrued expenses 939 7
Reconciliation of cash, cash equivalents and restricted cash:    
Cash and cash equivalents 17,897 26,727
Restricted cash 500 500
Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 18,397 $ 27,227
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of the Business and Basis of Presentation
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Nature of the Business and Basis of Presentation

1. Nature of the Business and Basis of Presentation

TransMedics Group, Inc. (“TransMedics Group” and, together with its consolidated subsidiaries, the “Company”) was incorporated in the Commonwealth of Massachusetts in October 2018. TransMedics, Inc. (“TransMedics”), an operating company and wholly owned subsidiary of TransMedics Group, was incorporated in the State of Delaware in August 1998. The Company is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company developed the Organ Care System (“OCS”) to replace a decades-old standard of care. The OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. The Company’s OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body.

The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since inception, including net losses of $10.6 million for the three months ended March 31, 2022 and $44.2 million for the year ended December 31, 2021. As of March 31, 2022, the Company had an accumulated deficit of $453.0 million. The Company expects to continue to generate operating losses in the foreseeable future.

The Company believes that its existing cash, cash equivalents, and marketable securities of $72.0 million as of March 31, 2022 will be sufficient to fund its operations, capital expenditures, and debt service payments for at least the next 12 months following the filing of this Quarterly Report on Form 10-Q. The Company may need to seek additional funding through equity financings, debt financings or strategic alliances. The Company may not be able to obtain financing on acceptable terms, or at all, and the terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders. If the Company is unable to obtain funding, the Company will be required to delay, reduce or eliminate some or all of its research and development programs, product expansion or commercialization efforts, or the Company may be unable to continue operations.

The Company is subject to risks and uncertainties common to companies in the medical device industry and of similar size, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, and the need to obtain additional financing to fund operations. Potential risks and uncertainties also include, without limitation, uncertainties regarding the duration and magnitude of the impact of the COVID-19 pandemic on the Company’s business and the economy generally. Products currently under development will require additional research and development efforts, including additional clinical testing and regulatory approval, prior to commercialization. These efforts require additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. The Company’s research and development may not be successfully completed, adequate protection for the Company’s technology may not be obtained, the Company may not obtain necessary government regulatory approval on its expected timeline or at all, and approved products may not prove commercially viable. The Company operates in an environment of rapid change in technology and competition.

The impact of the COVID-19 pandemic has been and may continue to be extensive in many aspects of society, which has resulted in and may continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Impacts to the Company’s business as a result of COVID-19 have included the temporary disruption of transplant procedures at many of the organ transplant centers that purchase OCS products; customer delays or reductions in customer capital expenditures and operating budgets and the related impact on its product sales; disruptions to the Company’s manufacturing operations and supply chain caused by facility closures, reductions in operating hours, staggered shifts and other social distancing efforts; labor shortages; decreased productivity and unavailability of materials or components; delays of reviews and approvals by the Food and Drug Administration (“FDA”) and other health authorities; delays in the Company’s clinical trial enrollment; limitations on its employees’ and customers’ ability to travel, and delays in product installations, trainings or shipments to and from other affected countries and within the United States.

In response to the pandemic, healthcare providers have, and may need to further, reallocate resources, such as physicians, staff, hospital beds and intensive care unit facilities, and these actions significantly delay the provision of other medical care such as organ transplantation and reduce the number of transplant procedures that are performed, which negatively impacts the Company’s revenue and cash flows. While the Company maintains an inventory of finished products and raw materials used in its OCS products, a prolonged pandemic could lead to shortages in the raw materials necessary to manufacture its products. The COVID-19 pandemic also has impacted operations at the FDA and other health authorities, resulting in delays of reviews and approvals, and may affect other potential Pre-Market Approval (“PMA”) applications. 

The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Unaudited Interim Financial Information

The accompanying unaudited interim financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2022 and results of operations for the three months ended March 31, 2022 and 2021 and cash flows for the three months ended March 31, 2022 and 2021 have been made. The Company’s results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the valuation of inventory and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these unaudited consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.

Risk of Concentrations of Credit, Significant Customers and Significant Suppliers

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. As of March 31, 2022 and December 31, 2021, the Company had no allowance for credit losses.

Significant customers are those that accounted for 10% or more of the Company’s net revenue or accounts receivable. For the three months ended March 31, 2022, three customers accounted for 16%, 15% and 12% of net revenue, respectively.

For the three months ended March 31, 2021, two customers each accounted for 12% of net revenue. As of March 31, 2022, four customers accounted for 14%, 12%, 12% and 10% of accounts receivable, respectively. As of December 31, 2021, two customers accounted for 21% and 15% of accounts receivable, respectively.

Certain of the components and subassemblies included in the Company’s products are obtained from a sole source, a single source or a limited group of suppliers. Although the Company seeks to reduce dependence on those limited sources of suppliers and manufacturers, the partial or complete loss of certain of these sources could have a material adverse effect on the Company’s operating results, financial condition and cash flows and damage its customer relationships.

Fair Value Measurements

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

 

Level 1—Quoted prices in active markets for identical assets or liabilities.

 

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

 

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The Company’s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company’s accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The carrying value of the Company’s long-term debt approximates its fair value (a level 2 measurement) at each balance sheet date due to its variable interest rate, which approximates a market interest rate.

Segment Information

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is developing and commercializing a proprietary system to preserve human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the Company’s chief operating decision maker, or decision-making group, in deciding how to allocate resources and assess performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer. The Company’s chief operating decision maker reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and assessing financial performance.

Net Income (Loss) per Share

Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the three months ended March 31, 2022 and 2021.

The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated above because including them would have had an anti-dilutive effect:

 

 

 

As of March 31,

 

 

 

2022

 

 

2021

 

Warrants to purchase common stock

 

 

64,440

 

 

 

64,440

 

Options to purchase common stock

 

 

3,484,914

 

 

 

2,764,876

 

Employee stock purchase plan

 

 

5,794

 

 

 

5,882

 

 

 

 

3,555,148

 

 

 

2,835,198

 

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Marketable Securities
3 Months Ended
Mar. 31, 2022
Investments Debt And Equity Securities [Abstract]  
Marketable Securities

3. Marketable Securities

Marketable securities by security type consisted of the following (in thousands):

 

 

 

March 31, 2022

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

U.S. Treasury securities (due within one year)

 

$

51,212

 

 

$

 

 

$

(102

)

 

$

51,110

 

U.S. government agency bonds (due within one year)

 

 

3,001

 

 

 

 

 

 

(7

)

 

 

2,994

 

 

 

$

54,213

 

 

$

 

 

$

(109

)

 

$

54,104

 

 

 

 

December 31, 2021

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

U.S. Treasury securities (due within one year)

 

$

63,907

 

 

$

 

 

$

(33

)

 

$

63,874

 

U.S. government agency bonds (due within one year)

 

 

3,001

 

 

 

 

 

 

(3

)

 

 

2,998

 

 

 

$

66,908

 

 

$

 

 

$

(36

)

 

$

66,872

 

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Assets and Liabilities
3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value of Financial Assets and Liabilities

4. Fair Value of Financial Assets and Liabilities

The following tables present the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis (in thousands):

 

 

 

Fair Value Measurements at March 31, 2022 Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

2,847

 

 

$

 

 

$

 

 

$

2,847

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

 

 

 

51,110

 

 

 

 

 

 

51,110

 

U.S. government agency bonds

 

 

 

 

 

2,994

 

 

 

 

 

 

2,994

 

 

 

$

2,847

 

 

$

54,104

 

 

$

 

 

$

56,951

 

 

 

 

 

Fair Value Measurements at December 31, 2021 Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

11,169

 

 

$

 

 

$

 

 

$

11,169

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

 

 

 

63,874

 

 

 

 

 

 

63,874

 

U.S. government agency bonds

 

 

 

 

 

2,998

 

 

 

 

 

 

2,998

 

 

 

$

11,169

 

 

$

66,872

 

 

$

 

 

$

78,041

 

 

Money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. U.S. Treasury securities and U.S. government agency bonds were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Inventory
3 Months Ended
Mar. 31, 2022
Inventory Disclosure [Abstract]  
Inventory

5. Inventory

Inventory consisted of the following (in thousands):

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Raw materials

 

$

8,322

 

 

$

7,274

 

Work-in-process

 

 

2,501

 

 

 

1,932

 

Finished goods

 

 

5,891

 

 

 

5,653

 

 

 

$

16,714

 

 

$

14,859

 

 

During the three months ended March 31, 2022 and 2021, the Company made non-cash transfers of OCS Consoles from inventory to property and equipment (OCS Consoles loaned to customers) of $1.0 million and $0.4 million, respectively.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses and Other Current Liabilities
3 Months Ended
Mar. 31, 2022
Accrued Expenses And Other Current Liabilities [Abstract]  
Accrued Expenses and Other Current Liabilities

6. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Accrued research, development and clinical trials expenses

 

 

$

4,532

 

 

$

4,567

 

Accrued payroll and related expenses

 

 

 

5,819

 

 

 

5,173

 

Accrued professional fees

 

 

 

857

 

 

 

1,973

 

Accrued other

 

 

 

4,530

 

 

 

4,624

 

 

 

 

$

15,738

 

 

$

16,337

 

 

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Long-Term Debt
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Long-Term Debt

7. Long-Term Debt

TransMedics has a credit agreement (the “Credit Agreement”) with OrbiMed Royalty Opportunities II, LP (“OrbiMed”), entered into in June 2018, pursuant to which TransMedics borrowed $35.0 million. Long-term debt consisted of the following (in thousands):

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Principal amount of long-term debt

 

$

35,000

 

 

$

35,000

 

Less: Current portion of long-term debt

 

 

 

 

 

 

Long-term debt, net of current portion

 

 

35,000

 

 

 

35,000

 

Debt discount, net of accretion

 

 

(428

)

 

 

(511

)

Accrued end-of-term payment

 

 

762

 

 

 

708

 

Long-term debt, net of discount and current portion

 

$

35,334

 

 

$

35,197

 

 

Borrowings under the Credit Agreement bear interest at an annual rate equal to the London Interbank Offered Rate (“LIBOR”), subject to a minimum of 1.0% and a maximum of 4.0%, plus 8.5% (the “Applicable Margin”), subject in the aggregate to a maximum interest rate of 11.5%. In addition, borrowings under the Credit Agreement bear paid-in-kind (“PIK”) interest at an annual rate equal to the amount by which LIBOR plus the Applicable Margin exceeds 11.5%, but not to exceed 12.5%. The PIK interest is added to the principal amount of the borrowings outstanding at the end of each quarter until the maturity date of the Credit Agreement in June 2023. Borrowings under the Credit Agreement are repayable in quarterly interest-only payments until the maturity date, at which time all principal and accrued interest is due and payable. At its option, the company may prepay outstanding borrowings under the Credit Agreement. The Company is required to make a final payment in an amount equal to 3.0% of the principal amount of any prepayment or repayment. The final payment and debt discount amounts are being accreted to interest expense over the term of the Credit Agreement using the effective interest method.

All obligations under the Credit Agreement are guaranteed by the Company and each of its material subsidiaries. All obligations of the Company and each guarantor are secured by substantially all of the Company’s and each guarantor’s assets, including their intellectual property, subject to certain exceptions, including a perfected security interest in substantially all tangible and intangible assets of the Company and each guarantor. Under the Credit Agreement, the Company has agreed to certain affirmative and negative covenants to which it will remain subject until maturity. The financial covenants include maintaining a minimum liquidity amount of $3.0 million; the requirement, on an annual basis, to deliver to OrbiMed annual audited financial statements with an unqualified audit opinion from the Company’s independent registered public accounting firm; and restrictions on the Company’s activities, including limitations on dispositions, mergers or acquisitions; encumbering its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and engaging in certain other business transactions. As of March 31, 2022, the Company was in compliance with the financial covenants under the Credit Agreement.

The obligations under the Credit Agreement are subject to acceleration upon the occurrence of specified events of default, including payment default, change in control, bankruptcy, insolvency, certain defaults under other material debt, certain events with respect to governmental approvals (if such events could cause a material adverse change in the Company’s business), failure to comply with certain covenants, including the minimum liquidity and unqualified audit opinion covenants, and a material adverse change in the Company’s business, operations or other financial condition.

Upon the occurrence of an event of default and until such event of default is no longer continuing, the Applicable Margin will increase by 4.0% per annum. If an event of default (other than certain events of bankruptcy or insolvency) occurs and is continuing, OrbiMed may declare all or any portion of the outstanding principal amount of the borrowings plus accrued and unpaid interest to be due and payable. Upon the occurrence of certain events of bankruptcy or insolvency, all of the outstanding principal amount of the borrowings plus accrued and unpaid interest will automatically become due and payable. In addition, the Company may be required to prepay outstanding borrowings, subject to certain exceptions, with portions of net cash proceeds of certain asset sales and certain casualty and condemnation events.

As of March 31, 2022, the interest rate applicable to borrowings under the Credit Agreement was 9.5%. During the three months ended March 31, 2022, the weighted average effective interest rate on outstanding borrowings under the Credit Agreement was approximately 11.2%.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2022
Stockholders Equity Note [Abstract]  
Stock-Based Compensation

8. Stock-Based Compensation

2019 Stock Incentive Plan

The Company’s 2019 Stock Incentive Plan (the “2019 Plan”) provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, unrestricted stock units, and other stock-based awards to employees, directors, and consultants of the Company and its subsidiaries. The number of shares of common stock of TransMedics Group initially available for issuance under the 2019 Plan was 3,428,571 shares, plus the number of shares underlying awards under the previously outstanding 2014 Stock Incentive Plan (the “2014 Plan”), not to exceed 1,595,189 shares, that expire or are terminated, surrendered, or cancelled without the delivery of shares, are forfeited to or repurchased by TransMedics Group or otherwise become available again for grant. Since the effectiveness of the Company’s 2019 Plan in April 2019, no future awards will be made under the 2014 Plan.

Shares withheld in payment of the exercise or purchase price of an award or in satisfaction of tax withholding requirements, and the shares covered by a stock appreciation right for which any portion is settled in stock, will reduce the number of shares available for issuance under the 2019 Plan. In addition, the number of shares available for issuance under the 2019 Plan (i) will not be increased by any shares delivered under the 2019 Plan that are subsequently repurchased using proceeds directly attributable to stock option exercises and (ii) will not be reduced by any awards that are settled in cash or that expire, become unexercisable, terminate or are forfeited to or repurchased by TransMedics Group without the issuance of stock under the 2019 Plan. As of March 31, 2022, 890,558 shares of common stock were available for issuance under the 2019 Plan.

2019 Employee Stock Purchase Plan

Pursuant to the Company’s 2019 Employee Stock Purchase Plan (the “2019 ESPP”), certain employees of the Company are eligible to purchase common stock of the Company at a reduced price during offering periods. The 2019 ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to the limitations set forth in the Internal Revenue Code, at a purchase price of 85% of the lower of the closing price of the Company’s common stock on the first trading day of the offering period or the closing price on the applicable purchase date, which is the final trading day of the applicable offering period. A total of 371,142 shares of the Company’s common stock are reserved for issuance under the 2019 ESPP. During the three months ended March 31, 2022, 12,465 shares of common stock were issued under the 2019 ESPP and as of March 31, 2022, 308,131 shares of common stock remained available for issuance.

2021 Inducement Plan

In August 2021, the Company’s board of directors approved the TransMedics Group, Inc. Inducement Plan (the “Inducement Plan”). Pursuant to the terms of the Inducement Plan, the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock unit awards and performance awards to individuals who were not previously employees or directors of the Company or individuals returning to employment after a bona fide period of non-employment with the Company.  A total of 1,000,000 shares of the Company’s common stock were initially available for issuance under the Inducement Plan. As of March 31, 2022, 580,200 shares of common stock were available for issuance under the Inducement Plan.

Stock-Based Compensation

The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Cost of revenue

 

$

25

 

 

$

13

 

Research, development and clinical trials expenses

 

 

321

 

 

 

197

 

Selling, general and administrative expenses

 

 

1,964

 

 

 

902

 

 

 

$

2,310

 

 

$

1,112

 

 

 

During the three months ended March 31, 2022, the Company granted options to its employees and directors with service-based vesting for the purchase of an aggregate of 880,910 shares of common stock with a weighted average grant-date fair value of $7.11 per share. As of March 31, 2022, total unrecognized compensation cost related to unvested share-based awards was $24.6 million, which is expected to be recognized over a weighted average period of 3.1 years.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

9. Commitments and Contingencies

Operating Leases

The Company leases office, laboratory and manufacturing space under two non-cancelable operating leases. There have been no material changes to the Company’s leases during the three months ended March 31, 2022. For additional information, please read Note 12 Leases, to the consolidated financial statements in the Company’s Form 10-K for the year ended December 31, 2021.

License Agreement with the Department of Veterans Affairs

In 2002, the Company entered into a license agreement with the Department of Veterans Affairs (the “VA”), under which the Company was granted an exclusive, worldwide license under specified patents to make, use, sell and import certain technology used in the Company’s products and a non-exclusive, worldwide license to make, use, sell and import solutions for use in or with those products. The rights under the license agreement continue until the expiration of the last to expire of the licensed patents. The majority of the licensed U.S. patents expired in 2017, and the foreign patents expired in September 2018. However, the Company has requested a patent term extension for one U.S. patent covered by the VA license agreement, U.S. Patent No. 6100082. The Company was granted an interim patent term extension for this patent until November 6, 2021. The Company has not received final approval of the patent extension beyond the interim patent term extension already granted. The maximum extension requested would be through May 2022; however, the length of the patent term extension will be determined by the United States Patent and Trademark Office (“USPTO”) based on input from the FDA.  On February 8, 2021, the FDA provided to the USPTO a determined regulatory review period for the OCS Lung. Under the FDA’s analysis, the patent term extension of the ’082 patent would be until November 6, 2021. The Company has not yet received communication from the USPTO but expects that the USPTO’s determination of patent term extension for the ’082 patent will maintain the November 6, 2021 expiration date. The final determination of the length of the patent extension is not expected to have a material impact on the Company’s financial results. The license includes the right to grant sublicenses, subject to approval by the VA and other restrictions, and is subject to the U.S. government’s right to practice the licensed patents on its own behalf without payment of a royalty and obligation to grant certain sublicenses as necessary to fulfill public health, welfare and safety needs. The license agreement also requires the Company to make its products covered by the licensed patents available to the public on reasonable terms and to provide the U.S. government such products at the lowest price.

As consideration for the licenses granted by the VA, the Company is obligated to pay tiered royalties ranging from a low single-digit to a mid single-digit percentage on net sales of each product covered by a licensed patent (subject to a minimum aggregate royalty payment of less than $0.1 million per year during each of the first five years after the first commercial sale, after which no minimum is required). Royalties will be paid by the Company on a licensed product-by-licensed product and country-by-country basis, beginning on the first commercial sale of such licensed product in such country until expiration of the last valid patent claim covering such licensed product in such country. The Company is also responsible for all costs related to the amendment, prosecution and maintenance of the licensed patent rights.

The VA license agreement can be terminated by the Company or the VA only if the other party fails to cure its material breach within a specified period after receiving notice of such breach.

401(k) Savings Plan

The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the plan may be made at the discretion of the board of directors. As of March 31, 2022 and December 31, 2021, the Company had not made any contributions to the plan.

Indemnification Agreements

In the ordinary course of business, the Company has agreed to defend and indemnify its customers against third-party claims asserting infringement of certain intellectual property rights, which may include patents, copyrights, trademarks, or trade secrets. The Company’s exposure under these indemnification provisions is generally limited to the total amount paid

by the end-customer under the agreement. However, certain agreements include indemnification provisions that could potentially expose the Company to losses in excess of the amount received under the agreement. In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or services as directors or officers.

The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and had not accrued any liabilities related to such obligations in its consolidated financial statements as of March 31, 2022 and December 31, 2021.

 

 

Unconditional Purchase Commitment

In January 2021, the Company entered into an unconditional $9.5 million purchase commitment, in the ordinary course of business, for goods with specified annual minimum quantities to be purchased through December 2029. The contract is not cancellable without penalty. The remaining purchase commitment as of March 31, 2022 was $8.0 million.

Legal Proceedings

The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Reporting and Geographic Data
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Segment Reporting and Geographic Data

10. Segment Reporting and Geographic Data

The Company has determined that it operates in one segment (see Note 2).

See Note 11 for revenue by country. Long-lived assets by geography are summarized as follows (in thousands):

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Long-lived assets by country(1):

 

 

 

 

 

 

 

 

United States

 

$

11,317

 

 

$

9,085

 

All other countries

 

 

727

 

 

 

756

 

Total long-lived assets

 

$

12,044

 

 

$

9,841

 

 

 

(1)

The Company’s only long-lived assets consist of property and equipment, net of depreciation, which are categorized based on their location of domicile.

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue
3 Months Ended
Mar. 31, 2022
Revenue From Contract With Customer [Abstract]  
Revenue

11. Revenue

The Company has determined that the payments made to the customer for reimbursement of clinical trial materials and customer’s costs incurred to execute specific clinical trial protocols related to the Company’s OCS products do not provide the Company with a distinct good or service transferred by the customer, and therefore such payments are recorded as a reduction of revenue from the customer in the Company’s consolidated statements of operations. Reductions of revenue related to such payments made to customers for reimbursements are recognized when the Company recognizes the revenue for the sale of its OCS disposable sets.

The reconciliation of gross revenue to net revenue for these certain payments is shown below (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Gross revenue from sales to customers

 

$

15,880

 

 

$

7,637

 

Less: clinical trial payments reducing

   revenue

 

 

 

 

 

584

 

Total net revenue

 

$

15,880

 

 

$

7,053

 

 

The Company determined that payments made to customers to obtain information related to post-approval studies or existing standard-of-care protocols (i.e., unrelated to the Company’s OCS products) meet the criteria to be classified as a cost because the Company receives a distinct good or service transferred by the customer separate from the customer’s purchase of the Company’s OCS products and the consideration paid to the customer represents the fair value of the distinct good or service received. As a result, such payments made to the customers are recorded as operating expenses. The Company recorded payments made to customers related to post-approval studies and for documentation related to existing standard-of-care protocols of $0.5 million for each of the three months ended March 31, 2022 and 2021, as operating expenses.

Disaggregated Revenue

The Company disaggregates revenue from contracts with customers by product type and geographical area as it believes this presentation best depicts how the nature, amount, timing and uncertainty of the Company’s revenue and cash flows are affected by economic factors, as shown below (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Net revenue by OCS product:

 

 

 

 

 

 

 

 

OCS Lung net revenue

 

$

2,298

 

 

$

2,430

 

OCS Heart net revenue

 

 

5,713

 

 

 

4,181

 

OCS Liver net revenue

 

 

7,869

 

 

 

442

 

Total net revenue

 

$

15,880

 

 

$

7,053

 

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Net revenue by country(1):

 

 

 

 

 

 

 

 

United States

 

$

13,561

 

 

$

5,757

 

All other countries

 

 

2,319

 

 

 

1,296

 

Total net revenue

 

$

15,880

 

 

$

7,053

 

 

 

(1)

Net revenue by country is categorized based on the location of the end customer.

 

Contract Assets and Liabilities

The Company recognizes a receivable at the point in time at which it has an unconditional right to payment. Such receivables are not contract assets. Contract assets arise from unbilled amounts in customer arrangements when revenue recognized exceeds the amount billed to the customer and the Company’s right to payment is not just subject to the passage of time. The Company had no contract assets as of March 31, 2022 and December 31, 2021.

Contract liabilities represent the Company’s obligation to transfer goods or services to a customer for which it has received consideration (or the amount is due) from the customer. The Company has determined that its only contract liabilities are deferred revenue, which consists of amounts that have been invoiced but that have not been recognized as revenue.

The Company generally satisfies performance obligations within one year of the contract inception date. As of March 31, 2022, the Company’s wholly- or partially unsatisfied performance obligations totaled $2.1 million and are expected to be completed within the next year.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
Related Party Transactions

12. Related Party Transactions

Employment of Dr. Amira Hassanein

Dr. Amira Hassanein, who serves as Product Director for the Company’s OCS Lung program, is the sister of Dr. Waleed Hassanein, the Company’s President and Chief Executive Officer and a member of the Company’s board of directors.  The Company paid Dr. Amira Hassanein approximately $0.1 million in total compensation for each of the three months ended March 31, 2022 and 2021 for her services as an employee.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Unaudited Interim Financial Information

Unaudited Interim Financial Information

The accompanying unaudited interim financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2022 and results of operations for the three months ended March 31, 2022 and 2021 and cash flows for the three months ended March 31, 2022 and 2021 have been made. The Company’s results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the valuation of inventory and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these unaudited consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.

Risk of Concentrations of Credit, Significant Customers and Significant Suppliers

Risk of Concentrations of Credit, Significant Customers and Significant Suppliers

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. As of March 31, 2022 and December 31, 2021, the Company had no allowance for credit losses.

Significant customers are those that accounted for 10% or more of the Company’s net revenue or accounts receivable. For the three months ended March 31, 2022, three customers accounted for 16%, 15% and 12% of net revenue, respectively.

For the three months ended March 31, 2021, two customers each accounted for 12% of net revenue. As of March 31, 2022, four customers accounted for 14%, 12%, 12% and 10% of accounts receivable, respectively. As of December 31, 2021, two customers accounted for 21% and 15% of accounts receivable, respectively.

Certain of the components and subassemblies included in the Company’s products are obtained from a sole source, a single source or a limited group of suppliers. Although the Company seeks to reduce dependence on those limited sources of suppliers and manufacturers, the partial or complete loss of certain of these sources could have a material adverse effect on the Company’s operating results, financial condition and cash flows and damage its customer relationships.

Fair Value Measurements

Fair Value Measurements

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

 

Level 1—Quoted prices in active markets for identical assets or liabilities.

 

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

 

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The Company’s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company’s accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The carrying value of the Company’s long-term debt approximates its fair value (a level 2 measurement) at each balance sheet date due to its variable interest rate, which approximates a market interest rate.

Segment Information

Segment Information

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is developing and commercializing a proprietary system to preserve human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the Company’s chief operating decision maker, or decision-making group, in deciding how to allocate resources and assess performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer. The Company’s chief operating decision maker reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and assessing financial performance.

Net Income (Loss) per Share

Net Income (Loss) per Share

Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the three months ended March 31, 2022 and 2021.

The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated above because including them would have had an anti-dilutive effect:

 

 

 

As of March 31,

 

 

 

2022

 

 

2021

 

Warrants to purchase common stock

 

 

64,440

 

 

 

64,440

 

Options to purchase common stock

 

 

3,484,914

 

 

 

2,764,876

 

Employee stock purchase plan

 

 

5,794

 

 

 

5,882

 

 

 

 

3,555,148

 

 

 

2,835,198

 

 

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated above because including them would have had an anti-dilutive effect:

 

 

 

As of March 31,

 

 

 

2022

 

 

2021

 

Warrants to purchase common stock

 

 

64,440

 

 

 

64,440

 

Options to purchase common stock

 

 

3,484,914

 

 

 

2,764,876

 

Employee stock purchase plan

 

 

5,794

 

 

 

5,882

 

 

 

 

3,555,148

 

 

 

2,835,198

 

 

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Marketable Securities (Tables)
3 Months Ended
Mar. 31, 2022
Investments Debt And Equity Securities [Abstract]  
Components of Marketable Securities by Security Type

Marketable securities by security type consisted of the following (in thousands):

 

 

 

March 31, 2022

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

U.S. Treasury securities (due within one year)

 

$

51,212

 

 

$

 

 

$

(102

)

 

$

51,110

 

U.S. government agency bonds (due within one year)

 

 

3,001

 

 

 

 

 

 

(7

)

 

 

2,994

 

 

 

$

54,213

 

 

$

 

 

$

(109

)

 

$

54,104

 

 

 

 

December 31, 2021

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

U.S. Treasury securities (due within one year)

 

$

63,907

 

 

$

 

 

$

(33

)

 

$

63,874

 

U.S. government agency bonds (due within one year)

 

 

3,001

 

 

 

 

 

 

(3

)

 

 

2,998

 

 

 

$

66,908

 

 

$

 

 

$

(36

)

 

$

66,872

 

 

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Assets and Liabilities (Tables)
3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following tables present the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis (in thousands):

 

 

 

Fair Value Measurements at March 31, 2022 Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

2,847

 

 

$

 

 

$

 

 

$

2,847

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

 

 

 

51,110

 

 

 

 

 

 

51,110

 

U.S. government agency bonds

 

 

 

 

 

2,994

 

 

 

 

 

 

2,994

 

 

 

$

2,847

 

 

$

54,104

 

 

$

 

 

$

56,951

 

 

 

 

 

Fair Value Measurements at December 31, 2021 Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

11,169

 

 

$

 

 

$

 

 

$

11,169

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

 

 

 

 

63,874

 

 

 

 

 

 

63,874

 

U.S. government agency bonds

 

 

 

 

 

2,998

 

 

 

 

 

 

2,998

 

 

 

$

11,169

 

 

$

66,872

 

 

$

 

 

$

78,041

 

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Inventory (Tables)
3 Months Ended
Mar. 31, 2022
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current

Inventory consisted of the following (in thousands):

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Raw materials

 

$

8,322

 

 

$

7,274

 

Work-in-process

 

 

2,501

 

 

 

1,932

 

Finished goods

 

 

5,891

 

 

 

5,653

 

 

 

$

16,714

 

 

$

14,859

 

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses and Other Current Liabilities (Tables)
3 Months Ended
Mar. 31, 2022
Accrued Expenses And Other Current Liabilities [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Accrued research, development and clinical trials expenses

 

 

$

4,532

 

 

$

4,567

 

Accrued payroll and related expenses

 

 

 

5,819

 

 

 

5,173

 

Accrued professional fees

 

 

 

857

 

 

 

1,973

 

Accrued other

 

 

 

4,530

 

 

 

4,624

 

 

 

 

$

15,738

 

 

$

16,337

 

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Long-term Debt (Tables)
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments Long-term debt consisted of the following (in thousands):

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Principal amount of long-term debt

 

$

35,000

 

 

$

35,000

 

Less: Current portion of long-term debt

 

 

 

 

 

 

Long-term debt, net of current portion

 

 

35,000

 

 

 

35,000

 

Debt discount, net of accretion

 

 

(428

)

 

 

(511

)

Accrued end-of-term payment

 

 

762

 

 

 

708

 

Long-term debt, net of discount and current portion

 

$

35,334

 

 

$

35,197

 

 

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2022
Stockholders Equity Note [Abstract]  
Schedule of Stock-Based Compensation Expense

The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Cost of revenue

 

$

25

 

 

$

13

 

Research, development and clinical trials expenses

 

 

321

 

 

 

197

 

Selling, general and administrative expenses

 

 

1,964

 

 

 

902

 

 

 

$

2,310

 

 

$

1,112

 

 

 

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Reporting and Geographic Data (Tables)
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Long-lived assets by geographical area See Note 11 for revenue by country. Long-lived assets by geography are summarized as follows (in thousands):

 

 

 

March 31, 2022

 

 

December 31, 2021

 

Long-lived assets by country(1):

 

 

 

 

 

 

 

 

United States

 

$

11,317

 

 

$

9,085

 

All other countries

 

 

727

 

 

 

756

 

Total long-lived assets

 

$

12,044

 

 

$

9,841

 

 

 

(1)

The Company’s only long-lived assets consist of property and equipment, net of depreciation, which are categorized based on their location of domicile.

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2022
Revenue From Contract With Customer [Abstract]  
Schedule of Recognized Revenue Net of Payments

The reconciliation of gross revenue to net revenue for these certain payments is shown below (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Gross revenue from sales to customers

 

$

15,880

 

 

$

7,637

 

Less: clinical trial payments reducing

   revenue

 

 

 

 

 

584

 

Total net revenue

 

$

15,880

 

 

$

7,053

 

Schedule of Net Revenue by OCS Product and Country

The Company disaggregates revenue from contracts with customers by product type and geographical area as it believes this presentation best depicts how the nature, amount, timing and uncertainty of the Company’s revenue and cash flows are affected by economic factors, as shown below (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Net revenue by OCS product:

 

 

 

 

 

 

 

 

OCS Lung net revenue

 

$

2,298

 

 

$

2,430

 

OCS Heart net revenue

 

 

5,713

 

 

 

4,181

 

OCS Liver net revenue

 

 

7,869

 

 

 

442

 

Total net revenue

 

$

15,880

 

 

$

7,053

 

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Net revenue by country(1):

 

 

 

 

 

 

 

 

United States

 

$

13,561

 

 

$

5,757

 

All other countries

 

 

2,319

 

 

 

1,296

 

Total net revenue

 

$

15,880

 

 

$

7,053

 

 

 

(1)

Net revenue by country is categorized based on the location of the end customer.

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Nature of the Business and Basis of Presentation - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Accounting Policies [Abstract]      
Net loss $ 10,562 $ 7,917 $ 44,200
Accumulated deficit 453,008   $ 442,446
Cash equivalents and marketable securities $ 72,000    
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies - Additional Information (Detail)
3 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
Segment
Mar. 31, 2021
Dec. 31, 2021
USD ($)
Allowance for credit losses | $ $ 0   $ 0
Number of operating segments | Segment 1    
Customer Concentration Risk | Revenue Benchmark | Significant Customer Benchmark [Member] | Minimum [Member]      
Concentration risk percentage 10.00%    
Customer Concentration Risk | Revenue Benchmark | Customer One [Member]      
Concentration risk percentage 16.00% 12.00%  
Customer Concentration Risk | Revenue Benchmark | Customer Two [Member]      
Concentration risk percentage 15.00% 12.00%  
Customer Concentration Risk | Revenue Benchmark | Customer Three [Member]      
Concentration risk percentage 12.00%    
Customer Concentration Risk | Accounts Receivable | Significant Customer Benchmark [Member] | Minimum [Member]      
Concentration risk percentage 10.00%    
Customer Concentration Risk | Accounts Receivable | Customer One [Member]      
Concentration risk percentage 14.00%   21.00%
Customer Concentration Risk | Accounts Receivable | Customer Two [Member]      
Concentration risk percentage 12.00%   15.00%
Customer Concentration Risk | Accounts Receivable | Customer Three [Member]      
Concentration risk percentage 12.00%    
Customer Concentration Risk | Accounts Receivable | Customer Four [Member]      
Concentration risk percentage 10.00%    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share Amount 3,555,148 2,835,198
Warrants to purchase common stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share Amount 64,440 64,440
Options to purchase common stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share Amount 3,484,914 2,764,876
Employee stock purchase plan [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share Amount 5,794 5,882
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Marketable Securities - Components of Marketable Securities by Security Type (Detail) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]    
Marketable Securities, Amortized Cost $ 54,213 $ 66,908
Marketable Securities, Gross Unrealized Losses (109) (36)
Marketable Securities, Fair Value 54,104 66,872
U.S. Treasury Securities (due within one year) [Member]    
Schedule Of Available For Sale Securities [Line Items]    
Marketable Securities, Amortized Cost 51,212 63,907
Marketable Securities, Gross Unrealized Losses (102) (33)
Marketable Securities, Fair Value 51,110 63,874
U.S. Government Agency Bonds (due within one year) [Member]    
Schedule Of Available For Sale Securities [Line Items]    
Marketable Securities, Amortized Cost 3,001 3,001
Marketable Securities, Gross Unrealized Losses (7) (3)
Marketable Securities, Fair Value $ 2,994 $ 2,998
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Assets and Liabilities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Marketable securities:    
Marketable securities $ 54,104 $ 66,872
Cash equivalents and marketable securities 56,951 78,041
U.S. Treasury Securities [Member]    
Marketable securities:    
Marketable securities 51,110 63,874
U.S. Government Agency Bonds [Member]    
Marketable securities:    
Marketable securities 2,994 2,998
Money Market Funds [Member]    
Cash equivalents:    
Cash equivalents 2,847 11,169
Level 1 [Member]    
Marketable securities:    
Cash equivalents and marketable securities 2,847 11,169
Level 1 [Member] | Money Market Funds [Member]    
Cash equivalents:    
Cash equivalents 2,847 11,169
Level 2 [Member]    
Marketable securities:    
Cash equivalents and marketable securities 54,104 66,872
Level 2 [Member] | U.S. Treasury Securities [Member]    
Marketable securities:    
Marketable securities 51,110 63,874
Level 2 [Member] | U.S. Government Agency Bonds [Member]    
Marketable securities:    
Marketable securities $ 2,994 $ 2,998
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Inventory - Schedule of Inventory, Current (Detail) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 8,322 $ 7,274
Work-in-process 2,501 1,932
Finished goods 5,891 5,653
Inventory, net $ 16,714 $ 14,859
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Inventory - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Inventory Disclosure [Abstract]    
Inventory transfer to property plant and equipment $ 1,030 $ 429
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Accrued Expenses And Other Current Liabilities [Abstract]    
Accrued research, development and clinical trials expenses $ 4,532 $ 4,567
Accrued payroll and related expenses 5,819 5,173
Accrued professional fees 857 1,973
Accrued other 4,530 4,624
Accrued expenses and other liabilities current $ 15,738 $ 16,337
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Long-term Debt - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Jun. 29, 2018
Long-term Debt, Gross $ 35,000 $ 35,000  
Orbi Med [Member]      
Long-term Debt, Gross     $ 35,000
Description of variable rate basis London Interbank Offered Rate (“LIBOR”), subject to a minimum of 1.0% and a maximum of 4.0%    
Basis spread on variable rate 8.50%    
Interest rate effective percentage 9.50%    
Final payment 3.00%    
Description of covenants The financial covenants include maintaining a minimum liquidity amount of $3.0 million; the requirement, on an annual basis, to deliver to OrbiMed annual audited financial statements with an unqualified audit opinion from the Company’s independent registered public accounting firm; and restrictions on the Company’s activities, including limitations on dispositions, mergers or acquisitions; encumbering its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and engaging in certain other business transactions.    
Minimum liquidity covenant amount $ 3,000    
Average effective interest rate 11.20%    
Orbi Med [Member] | In Event Of Default [Member]      
Increasing applicable margin 4.00%    
Orbi Med [Member] | Credit Agreement [Member]      
Debt instrument, maturity month and year 2023-06    
Orbi Med [Member] | Minimum [Member]      
Paid in kind interest threshold 11.50%    
Orbi Med [Member] | Maximum [Member]      
Interest rate effective percentage 11.50%    
Paid in kind interest threshold 12.50%    
Orbi Med [Member] | London Interbank Offered Rate (LIBOR) | Minimum [Member]      
LIBOR rate 1.00%    
Orbi Med [Member] | London Interbank Offered Rate (LIBOR) | Maximum [Member]      
LIBOR rate 4.00%    
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Long-term Debt - Schedule of Long-term Debt Instruments (Detail) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]    
Principal amount of long-term debt $ 35,000 $ 35,000
Long-term debt, net of current portion 35,000 35,000
Debt discount, net of accretion (428) (511)
Accrued end-of-term payment 762 708
Long-term debt, net of discount and current portion $ 35,334 $ 35,197
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended
Apr. 15, 2019
Mar. 31, 2022
Aug. 31, 2021
Unrecognized compensation cost related to unvested employee and director stock-based awards   $ 24.6  
Weighted average period for unrecognized compensation cost   3 years 1 month 6 days  
Common Stock | Employees and Directors [Member]      
Options granted   880,910  
Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value   $ 7.11  
2019 Stock Plan [Member]      
Share-based compensation arrangement by share-based payment award, number of shares authorized 3,428,571    
Share based compensation arrangement by share based payment award number of shares available for grant   890,558  
2019 Stock Plan [Member] | From 2014 Plan [Member]      
Share-based compensation arrangement by share-based payment award, number of shares authorized 1,595,189    
2019 Employee Stock Purchase Plan [Member]      
Share-based compensation arrangement by share-based payment award, number of shares authorized   371,142  
Share based compensation arrangement by share based payment award number of shares available for grant   308,131  
Purchase price of common stock, percent 85.00%    
Number of shares issued   12,465  
2021 Inducement Plan [Member] | Common Stock      
Share-based compensation arrangement by share-based payment award, number of shares authorized     1,000,000
Share based compensation arrangement by share based payment award number of shares available for grant   580,200  
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Allocated Share-based Compensation Expense $ 2,310 $ 1,112
Cost of revenue [Member]    
Allocated Share-based Compensation Expense 25 13
Research, development and clinical trials expenses [Member]    
Allocated Share-based Compensation Expense 321 197
Selling, general and administrative expenses [Member]    
Allocated Share-based Compensation Expense $ 1,964 $ 902
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2021
Mar. 31, 2022
Dec. 31, 2021
Defined contribution plan, contribution amount   $ 0.0 $ 0.0
Recorded unconditional purchase commitment, minimum quantity required $ 9.5    
Recorded unconditional purchase commitment, maturity year and month 2029-12    
Remaining purchase commitment   8.0  
Maximum [Member]      
Guaranteed minimum annual royalty payment   $ 0.1  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Reporting and Geographic Data - Additional Information (Detail)
3 Months Ended
Mar. 31, 2022
Segment
Segment Reporting [Abstract]  
Number of operating segments 1
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Reporting and Geographic Data - Geographic Areas Long Lived Assets (Detail) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Geographic Areas, Long-Lived Assets [Abstract]    
Long-lived assets [1] $ 12,044 $ 9,841
United States [Member]    
Geographic Areas, Long-Lived Assets [Abstract]    
Long-lived assets [1] 11,317 9,085
All Other Countries [Member]    
Geographic Areas, Long-Lived Assets [Abstract]    
Long-lived assets [1] $ 727 $ 756
[1] The Company’s only long-lived assets consist of property and equipment, net of depreciation, which are categorized based on their location of domicile
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue - Schedule of Recognized Revenue Net of Payments (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue From Contract With Customer [Abstract]    
Gross revenue from sales to customers $ 15,880 $ 7,637
Less: clinical trial payments reducing revenue   584
Total net revenue [1] $ 15,880 $ 7,053
[1]

Net revenue by country is categorized based on the location of the end customer.

XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue - Additional Information (Detail) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Revenue From Contract With Customer [Abstract]      
Research development and clinical trials expenses $ 500,000 $ 500,000  
Contract assets 0   $ 0
Performance obligations totaled $ 2,100,000    
Revenue performance obligation description of timing The Company generally satisfies performance obligations within one year of the contract inception date.    
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue - Schedule of Net Revenue by OCS Product and Country (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation Of Revenue [Line Items]    
Net revenue [1] $ 15,880 $ 7,053
United States [Member]    
Disaggregation Of Revenue [Line Items]    
Net revenue [1] 13,561 5,757
All Other Countries [Member]    
Disaggregation Of Revenue [Line Items]    
Net revenue [1] 2,319 1,296
OCS Lung net revenue [Member]    
Disaggregation Of Revenue [Line Items]    
Net revenue 2,298 2,430
OCS Heart net revenue [Member]    
Disaggregation Of Revenue [Line Items]    
Net revenue 5,713 4,181
OCS Liver net revenue [Member]    
Disaggregation Of Revenue [Line Items]    
Net revenue $ 7,869 $ 442
[1]

Net revenue by country is categorized based on the location of the end customer.

XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Director [Member]    
Related Party Transaction [Line Items]    
Compensation expense $ 0.1 $ 0.1
XML 60 tmdx-10q_20220331_htm.xml IDEA: XBRL DOCUMENT 0001756262 2022-01-01 2022-03-31 0001756262 2022-04-29 0001756262 2022-03-31 0001756262 2021-12-31 0001756262 2021-01-01 2021-03-31 0001756262 us-gaap:CommonStockMember 2021-12-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001756262 us-gaap:RetainedEarningsMember 2021-12-31 0001756262 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001756262 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001756262 us-gaap:CommonStockMember 2022-03-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001756262 us-gaap:RetainedEarningsMember 2022-03-31 0001756262 us-gaap:CommonStockMember 2020-12-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001756262 us-gaap:RetainedEarningsMember 2020-12-31 0001756262 2020-12-31 0001756262 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001756262 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001756262 us-gaap:CommonStockMember 2021-03-31 0001756262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001756262 us-gaap:RetainedEarningsMember 2021-03-31 0001756262 2021-03-31 0001756262 2021-01-01 2021-12-31 0001756262 tmdx:SignificantCustomersBenchmarkMember srt:MinimumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001756262 tmdx:SignificantCustomersBenchmarkMember srt:MinimumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001756262 tmdx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001756262 tmdx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001756262 tmdx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001756262 tmdx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001756262 tmdx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001756262 tmdx:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001756262 tmdx:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001756262 tmdx:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001756262 tmdx:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001756262 tmdx:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001756262 tmdx:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001756262 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001756262 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001756262 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001756262 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001756262 us-gaap:EmployeeStockMember 2022-01-01 2022-03-31 0001756262 us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0001756262 us-gaap:USTreasurySecuritiesMember 2022-03-31 0001756262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-03-31 0001756262 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001756262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001756262 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0001756262 us-gaap:MoneyMarketFundsMember 2022-03-31 0001756262 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2022-03-31 0001756262 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-03-31 0001756262 us-gaap:FairValueInputsLevel1Member 2022-03-31 0001756262 us-gaap:FairValueInputsLevel2Member 2022-03-31 0001756262 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001756262 us-gaap:MoneyMarketFundsMember 2021-12-31 0001756262 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2021-12-31 0001756262 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001756262 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001756262 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001756262 tmdx:OrbiMedMember 2018-06-29 0001756262 tmdx:OrbiMedMember 2022-01-01 2022-03-31 0001756262 srt:MinimumMember tmdx:OrbiMedMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-03-31 0001756262 srt:MaximumMember tmdx:OrbiMedMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-03-31 0001756262 srt:MaximumMember tmdx:OrbiMedMember 2022-03-31 0001756262 srt:MinimumMember tmdx:OrbiMedMember 2022-01-01 2022-03-31 0001756262 srt:MaximumMember tmdx:OrbiMedMember 2022-01-01 2022-03-31 0001756262 tmdx:CreditAgreementMember tmdx:OrbiMedMember 2022-01-01 2022-03-31 0001756262 tmdx:OrbiMedMember 2022-03-31 0001756262 tmdx:InEventOfDefaultMember tmdx:OrbiMedMember 2022-01-01 2022-03-31 0001756262 tmdx:TwoThousandNineteenStockPlanMember 2019-04-15 0001756262 tmdx:FromTwoThousandFourteenPlanMember tmdx:TwoThousandNineteenStockPlanMember 2019-04-15 0001756262 tmdx:TwoThousandNineteenStockPlanMember 2022-03-31 0001756262 tmdx:TwoThousandNineteenEmployeeStockPurchasePlanMember 2019-04-14 2019-04-15 0001756262 tmdx:TwoThousandNineteenEmployeeStockPurchasePlanMember 2022-03-31 0001756262 tmdx:TwoThousandNineteenEmployeeStockPurchasePlanMember 2022-01-01 2022-03-31 0001756262 tmdx:TwoThousandTwentyOneInducementPlanMember us-gaap:CommonStockMember 2021-08-31 0001756262 tmdx:TwoThousandTwentyOneInducementPlanMember us-gaap:CommonStockMember 2022-03-31 0001756262 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001756262 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001756262 tmdx:ResearchDevelopmentAndClinicalTrialsExpensesMember 2022-01-01 2022-03-31 0001756262 tmdx:ResearchDevelopmentAndClinicalTrialsExpensesMember 2021-01-01 2021-03-31 0001756262 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001756262 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001756262 tmdx:EmployeesAndDirectorMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001756262 srt:MaximumMember 2022-01-01 2022-03-31 0001756262 2021-01-31 0001756262 2021-01-01 2021-01-31 0001756262 country:US 2022-03-31 0001756262 country:US 2021-12-31 0001756262 tmdx:OtherCountriesMember 2022-03-31 0001756262 tmdx:OtherCountriesMember 2021-12-31 0001756262 tmdx:OcsLungProductMember 2022-01-01 2022-03-31 0001756262 tmdx:OcsLungProductMember 2021-01-01 2021-03-31 0001756262 tmdx:OcsHeartProductMember 2022-01-01 2022-03-31 0001756262 tmdx:OcsHeartProductMember 2021-01-01 2021-03-31 0001756262 tmdx:OcsLiverProductMember 2022-01-01 2022-03-31 0001756262 tmdx:OcsLiverProductMember 2021-01-01 2021-03-31 0001756262 country:US 2022-01-01 2022-03-31 0001756262 country:US 2021-01-01 2021-03-31 0001756262 tmdx:NonUsAndUkMember 2022-01-01 2022-03-31 0001756262 tmdx:NonUsAndUkMember 2021-01-01 2021-03-31 0001756262 srt:DirectorMember 2022-01-01 2022-03-31 0001756262 srt:DirectorMember 2021-01-01 2021-03-31 shares iso4217:USD iso4217:USD shares pure tmdx:Segment false Q1 0001756262 --12-31 1 1 10-Q true 2022-03-31 2022 false 001-38891 TransMedics Group, Inc. MA 83-2181531 200 Minuteman Road Andover MA 01810 978 552-0900 Common Stock, No Par Value TMDX NASDAQ Yes Yes Large Accelerated Filer false false false 27980839 17897000 25580000 54104000 66872000 11724000 5934000 16714000 14859000 5356000 5460000 105795000 118705000 12044000 9841000 500000 500000 5669000 5847000 124008000 134893000 2934000 6651000 15738000 16337000 247000 250000 1337000 20256000 23238000 35334000 35197000 8508000 8604000 64098000 67039000 25000000 25000000 0 0 0 0 150000000 150000000 27968583 27968583 27791615 27791615 513203000 510488000 -285000 -188000 -453008000 -442446000 59910000 67854000 124008000 134893000 15880000 7053000 3776000 2242000 12104000 4811000 7534000 4532000 13939000 6786000 21473000 11318000 -9369000 -6507000 960000 952000 -227000 -454000 -1187000 -1406000 -10556000 -7913000 6000 4000 -10562000 -7917000 -0.38 -0.38 -0.29 -0.29 27950330 27950330 27368090 27368090 -10562000 -7917000 -24000 -2000 0 0 -73000 8000 -97000 6000 -10659000 -7911000 27791615 510488000 -188000 -442446000 67854000 164503 202000 202000 12465 203000 203000 2310000 2310000 -24000 -24000 -73000 -73000 -10562000 -10562000 27968583 513203000 -285000 -453008000 59910000 27175305 502217000 -95000 -398231000 103891000 287705 372000 372000 14951 211000 211000 1112000 1112000 -2000 -2000 8000 8000 -7917000 -7917000 27477961 503912000 -89000 -406148000 97675000 -10562000 -7917000 507000 445000 2310000 1112000 137000 130000 178000 228000 391000 -214000 -484000 5804000 583000 2926000 381000 -88000 908000 -4013000 -82000 -4000 -180000 182000 1241000 23000 -18406000 -7330000 1953000 20000 2033000 11708000 14500000 21000000 10514000 9272000 202000 372000 203000 211000 405000 583000 -196000 -379000 -7683000 2146000 26080000 25081000 18397000 27227000 1030000 429000 939000 7000 17897000 26727000 500000 500000 18397000 27227000 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business and Basis of Presentation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TransMedics Group, Inc. (“TransMedics Group” and, together with its consolidated subsidiaries, the “Company”) was incorporated in the Commonwealth of Massachusetts in October 2018. TransMedics, Inc. (“TransMedics”), an operating company and wholly owned subsidiary of TransMedics Group, was incorporated in the State of Delaware in August 1998. The Company is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company developed the Organ Care System (“OCS”) to replace a decades-old standard of care. The OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. The Company’s OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since inception, including net losses of $10.6 million for the three months ended March 31, 2022 and $44.2 million for the year ended December 31, 2021. As of March 31, 2022, the Company had an accumulated deficit of $453.0 million. The Company expects to continue to generate operating losses in the foreseeable future. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its existing cash, cash equivalents, and marketable securities of $72.0 million as of March 31, 2022 will be sufficient to fund its operations, capital expenditures, and debt service payments for at least the next 12 months following the filing of this Quarterly Report on Form 10-Q. <span style="color:#000000;">The Company may need to seek additional funding through equity financings, debt financings or strategic alliances. The Company may not be able to obtain financing on acceptable terms, or at all, and the terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders. If the Company is unable to obtain funding, the Company will be required to delay, reduce or eliminate some or all of its research and development programs, product expansion or commercialization efforts, or the Company may be unable to continue operations.</span> </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.91%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to companies in the medical device industry and of similar size, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, and the need to obtain additional financing to fund operations. Potential risks and uncertainties also include, without limitation, uncertainties regarding the duration and magnitude of the impact of the COVID-19 pandemic on the Company’s business and the economy generally. Products currently under development will require additional research and development efforts, including additional clinical testing and regulatory approval, prior to commercialization. These efforts require additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. The Company’s research and development may not be successfully completed, adequate protection for the Company’s technology may not be obtained, the Company may not obtain necessary government regulatory approval on its expected timeline or at all, and approved products may not prove commercially viable. The Company operates in an environment of rapid change in technology and competition.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of the COVID-19 pandemic has been and may continue to be extensive in many aspects of society, which has resulted in and may continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. Impacts to the Company’s business as a result of COVID-19 have included the temporary disruption of transplant procedures at many of the organ transplant centers that purchase OCS products; customer delays or reductions in customer capital expenditures and operating budgets and the related impact on its product sales; disruptions to the Company’s manufacturing operations and supply chain caused by facility closures, reductions in operating hours, staggered shifts and other social distancing efforts; labor shortages; decreased productivity and unavailability of materials or components; delays of reviews and approvals by the Food and Drug Administration (“FDA”) and other health authorities; delays in the Company’s clinical trial enrollment; limitations on its employees’ and customers’ ability to travel, and delays in product installations, trainings or shipments to and from other affected countries and within the United States. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the pandemic, healthcare providers have, and may need to further, reallocate resources, such as physicians, staff, hospital beds and intensive care unit facilities, and these actions significantly delay the provision of other medical care such as organ transplantation and reduce the number of transplant procedures that are performed, which negatively impacts the Company’s revenue and cash flows. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the Company maintains an inventory of finished products and raw materials used in its OCS products, a prolonged pandemic could lead to shortages in the raw materials necessary to manufacture its products. The COVID-19 pandemic also has impacted operations at the FDA and other health authorities, resulting in delays of reviews and approvals, and may affect other potential Pre-Market Approval </span><span style="color:#000000;">(“PMA”)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> applications.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). <span style="color:#000000;">Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). </span>The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p> -10600000 -44200000 -453000000.0 72000000.0 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2022 and results of operations for the three months ended March 31, 2022 and 2021 and cash flows for the three months ended March 31, 2022 and 2021 have been made. The Company’s results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the valuation of inventory and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. <span style="Background-color:#FFFFFF;color:#212529;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. </span>As of the date of issuance of these unaudited consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities.<span style="Background-color:#FFFFFF;color:#212529;"> </span>Actual results may differ from those estimates or assumptions. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risk of Concentrations of Credit, Significant Customers and Significant Suppliers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. As of March 31, 2022 and December 31, 2021, the Company had no allowance for credit losses. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers are those that accounted for 10% or more of the Company’s net revenue or accounts receivable. <span style="Background-color:#FFFFFF;color:#000000;">For the three months ended March 31, 2022, three customers accounted for</span> 16<span style="Background-color:#FFFFFF;color:#000000;">%, 15% and 12% of net revenue, respectively. </span></p> <p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;">For the</span><span style="Background-color:#FFFFFF;color:#000000;"> three months ended </span><span style="Background-color:#FFFFFF;color:#000000;">March</span><span style="Background-color:#FFFFFF;color:#000000;"> 3</span><span style="Background-color:#FFFFFF;color:#000000;">1</span><span style="Background-color:#FFFFFF;color:#000000;">, 202</span><span style="Background-color:#FFFFFF;color:#000000;">1</span><span style="Background-color:#FFFFFF;color:#000000;">, </span><span style="Background-color:#FFFFFF;color:#000000;">two</span><span style="Background-color:#FFFFFF;color:#000000;"> customer</span><span style="Background-color:#FFFFFF;color:#000000;">s</span><span style="Background-color:#FFFFFF;color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">each </span><span style="Background-color:#FFFFFF;color:#000000;">accounted for </span>12<span style="Background-color:#FFFFFF;color:#000000;">%</span><span style="Background-color:#FFFFFF;color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">of net revenue. </span><span style="Background-color:#FFFFFF;color:#000000;">As of </span><span style="Background-color:#FFFFFF;color:#000000;">March 31, 2022</span><span style="Background-color:#FFFFFF;color:#000000;">, </span><span style="Background-color:#FFFFFF;color:#000000;">four</span><span style="Background-color:#FFFFFF;color:#000000;"> customer</span><span style="Background-color:#FFFFFF;color:#000000;">s</span><span style="Background-color:#FFFFFF;color:#000000;"> accounted for</span><span style="Background-color:#FFFFFF;color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">14</span><span style="Background-color:#FFFFFF;color:#000000;">%</span><span style="Background-color:#FFFFFF;color:#000000;">, </span><span style="Background-color:#FFFFFF;color:#000000;">12</span><span style="Background-color:#FFFFFF;color:#000000;">%, </span><span style="Background-color:#FFFFFF;color:#000000;">12</span><span style="Background-color:#FFFFFF;color:#000000;">% and </span><span style="Background-color:#FFFFFF;color:#000000;">10</span><span style="Background-color:#FFFFFF;color:#000000;">%</span><span style="Background-color:#FFFFFF;color:#000000;"> of accounts receivable</span><span style="Background-color:#FFFFFF;color:#000000;">, respectively</span><span style="Background-color:#FFFFFF;color:#000000;">. As of </span><span style="Background-color:#FFFFFF;color:#000000;">December </span><span style="Background-color:#FFFFFF;color:#000000;">31</span><span style="Background-color:#FFFFFF;color:#000000;">, 20</span><span style="Background-color:#FFFFFF;color:#000000;">2</span><span style="Background-color:#FFFFFF;color:#000000;">1</span><span style="Background-color:#FFFFFF;color:#000000;">, </span><span style="Background-color:#FFFFFF;color:#000000;">two</span><span style="Background-color:#FFFFFF;color:#000000;"> customer</span><span style="Background-color:#FFFFFF;color:#000000;">s</span><span style="Background-color:#FFFFFF;color:#000000;"> accounted for </span><span style="Background-color:#FFFFFF;color:#000000;">21</span><span style="Background-color:#FFFFFF;color:#000000;">%</span><span style="Background-color:#FFFFFF;color:#000000;"> and </span><span style="Background-color:#FFFFFF;color:#000000;">15</span><span style="Background-color:#FFFFFF;color:#000000;">%</span><span style="Background-color:#FFFFFF;color:#000000;"> of accounts receivable</span><span style="Background-color:#FFFFFF;color:#000000;">, respectively</span><span style="Background-color:#FFFFFF;color:#000000;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the components and subassemblies included in the Company’s products are obtained from a sole source, a single source or a limited group of suppliers. Although the Company seeks to reduce dependence on those limited sources of suppliers and manufacturers, the partial or complete loss of certain of these sources could have a material adverse effect on the Company’s operating results, financial condition and cash flows and damage its customer relationships. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.86%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:3.64%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 1—Quoted prices in active markets for identical assets or liabilities. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.86%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:3.64%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.86%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:3.64%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company’s accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The carrying value of the Company’s long-term debt approximates its fair value (a level 2 measurement) at each balance sheet date due to its variable interest rate, which approximates a market interest rate. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a <span style="-sec-ix-hidden:F_000294_2">single</span> segment for the purposes of assessing performance and making operating decisions. The Company is developing and commercializing a proprietary system to preserve human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the Company’s chief operating decision maker, or decision-making group, in deciding how to allocate resources and assess performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer. The Company’s chief operating decision maker reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and assessing financial performance. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Income (Loss) per Share </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the three months ended March 31, 2022 and 2021.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated above because including them would have had an anti-dilutive effect:</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.84%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.84%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,484,914</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,764,876</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,794</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,882</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,555,148</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,835,198</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2022 and results of operations for the three months ended March 31, 2022 and 2021 and cash flows for the three months ended March 31, 2022 and 2021 have been made. The Company’s results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the valuation of inventory and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. <span style="Background-color:#FFFFFF;color:#212529;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. </span>As of the date of issuance of these unaudited consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities.<span style="Background-color:#FFFFFF;color:#212529;"> </span>Actual results may differ from those estimates or assumptions. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risk of Concentrations of Credit, Significant Customers and Significant Suppliers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. As of March 31, 2022 and December 31, 2021, the Company had no allowance for credit losses. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers are those that accounted for 10% or more of the Company’s net revenue or accounts receivable. <span style="Background-color:#FFFFFF;color:#000000;">For the three months ended March 31, 2022, three customers accounted for</span> 16<span style="Background-color:#FFFFFF;color:#000000;">%, 15% and 12% of net revenue, respectively. </span></p> <p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;">For the</span><span style="Background-color:#FFFFFF;color:#000000;"> three months ended </span><span style="Background-color:#FFFFFF;color:#000000;">March</span><span style="Background-color:#FFFFFF;color:#000000;"> 3</span><span style="Background-color:#FFFFFF;color:#000000;">1</span><span style="Background-color:#FFFFFF;color:#000000;">, 202</span><span style="Background-color:#FFFFFF;color:#000000;">1</span><span style="Background-color:#FFFFFF;color:#000000;">, </span><span style="Background-color:#FFFFFF;color:#000000;">two</span><span style="Background-color:#FFFFFF;color:#000000;"> customer</span><span style="Background-color:#FFFFFF;color:#000000;">s</span><span style="Background-color:#FFFFFF;color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">each </span><span style="Background-color:#FFFFFF;color:#000000;">accounted for </span>12<span style="Background-color:#FFFFFF;color:#000000;">%</span><span style="Background-color:#FFFFFF;color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">of net revenue. </span><span style="Background-color:#FFFFFF;color:#000000;">As of </span><span style="Background-color:#FFFFFF;color:#000000;">March 31, 2022</span><span style="Background-color:#FFFFFF;color:#000000;">, </span><span style="Background-color:#FFFFFF;color:#000000;">four</span><span style="Background-color:#FFFFFF;color:#000000;"> customer</span><span style="Background-color:#FFFFFF;color:#000000;">s</span><span style="Background-color:#FFFFFF;color:#000000;"> accounted for</span><span style="Background-color:#FFFFFF;color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">14</span><span style="Background-color:#FFFFFF;color:#000000;">%</span><span style="Background-color:#FFFFFF;color:#000000;">, </span><span style="Background-color:#FFFFFF;color:#000000;">12</span><span style="Background-color:#FFFFFF;color:#000000;">%, </span><span style="Background-color:#FFFFFF;color:#000000;">12</span><span style="Background-color:#FFFFFF;color:#000000;">% and </span><span style="Background-color:#FFFFFF;color:#000000;">10</span><span style="Background-color:#FFFFFF;color:#000000;">%</span><span style="Background-color:#FFFFFF;color:#000000;"> of accounts receivable</span><span style="Background-color:#FFFFFF;color:#000000;">, respectively</span><span style="Background-color:#FFFFFF;color:#000000;">. As of </span><span style="Background-color:#FFFFFF;color:#000000;">December </span><span style="Background-color:#FFFFFF;color:#000000;">31</span><span style="Background-color:#FFFFFF;color:#000000;">, 20</span><span style="Background-color:#FFFFFF;color:#000000;">2</span><span style="Background-color:#FFFFFF;color:#000000;">1</span><span style="Background-color:#FFFFFF;color:#000000;">, </span><span style="Background-color:#FFFFFF;color:#000000;">two</span><span style="Background-color:#FFFFFF;color:#000000;"> customer</span><span style="Background-color:#FFFFFF;color:#000000;">s</span><span style="Background-color:#FFFFFF;color:#000000;"> accounted for </span><span style="Background-color:#FFFFFF;color:#000000;">21</span><span style="Background-color:#FFFFFF;color:#000000;">%</span><span style="Background-color:#FFFFFF;color:#000000;"> and </span><span style="Background-color:#FFFFFF;color:#000000;">15</span><span style="Background-color:#FFFFFF;color:#000000;">%</span><span style="Background-color:#FFFFFF;color:#000000;"> of accounts receivable</span><span style="Background-color:#FFFFFF;color:#000000;">, respectively</span><span style="Background-color:#FFFFFF;color:#000000;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the components and subassemblies included in the Company’s products are obtained from a sole source, a single source or a limited group of suppliers. Although the Company seeks to reduce dependence on those limited sources of suppliers and manufacturers, the partial or complete loss of certain of these sources could have a material adverse effect on the Company’s operating results, financial condition and cash flows and damage its customer relationships. </p> 0 0 0.10 0.10 0.16 0.15 0.12 0.12 0.12 0.14 0.12 0.12 0.10 0.21 0.15 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.86%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:3.64%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 1—Quoted prices in active markets for identical assets or liabilities. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.86%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:3.64%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.86%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:3.64%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company’s accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The carrying value of the Company’s long-term debt approximates its fair value (a level 2 measurement) at each balance sheet date due to its variable interest rate, which approximates a market interest rate. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a <span style="-sec-ix-hidden:F_000294_2">single</span> segment for the purposes of assessing performance and making operating decisions. The Company is developing and commercializing a proprietary system to preserve human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the Company’s chief operating decision maker, or decision-making group, in deciding how to allocate resources and assess performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer. The Company’s chief operating decision maker reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and assessing financial performance. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Income (Loss) per Share </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock awards. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for each of the three months ended March 31, 2022 and 2021.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated above because including them would have had an anti-dilutive effect:</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.84%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.84%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,484,914</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,764,876</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,794</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,882</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,555,148</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,835,198</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"> </p> The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated above because including them would have had an anti-dilutive effect: <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.84%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.84%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,484,914</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.26%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,764,876</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock purchase plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,794</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,882</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.84%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,555,148</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.26%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,835,198</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"> </p> 64440 64440 3484914 2764876 5794 5882 3555148 2835198 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Marketable Securities </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities by security type consisted of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities (due within one year)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,212</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency bonds (due within one year)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,001</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,994</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,213</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,104</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities (due within one year)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,907</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,874</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency bonds (due within one year)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,001</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,998</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,908</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,872</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities by security type consisted of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities (due within one year)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,212</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency bonds (due within one year)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,001</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,994</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,213</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,104</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities (due within one year)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,907</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,874</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency bonds (due within one year)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,001</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,998</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,908</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,872</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;"> </p> 51212000 102000 51110000 3001000 7000 2994000 54213000 109000 54104000 63907000 33000 63874000 3001000 3000 2998000 66908000 36000 66872000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Fair Value of Financial Assets and Liabilities </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at March 31, 2022 Using:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,994</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,994</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,104</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,951</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2021 Using:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,169</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,169</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,874</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,874</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,998</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,998</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,169</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,872</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,041</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. <span style="color:#000000;">U.S. Treasury securities and U.S. government agency bonds were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at March 31, 2022 Using:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,110</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,994</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,994</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,847</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,104</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,951</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2021 Using:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,169</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,169</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,874</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,874</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,998</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,998</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,169</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,872</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,041</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 2847000 2847000 51110000 51110000 2994000 2994000 2847000 54104000 56951000 11169000 11169000 63874000 63874000 2998000 2998000 11169000 66872000 78041000 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Inventory </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consisted of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,322</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,274</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-process</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,932</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,891</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,653</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,714</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,859</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2022 and 2021, the Company made non-cash transfers of OCS Consoles from inventory to property and equipment (OCS Consoles loaned to customers) of $1.0 million and $0.4 million, respectively. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory consisted of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,322</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,274</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in-process</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,932</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,891</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,653</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,714</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,859</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 8322000 7274000 2501000 1932000 5891000 5653000 16714000 14859000 1000000.0 400000 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Accrued Expenses and Other Current Liabilities </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research, development and clinical trials expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,532</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,567</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.38%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,819</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,173</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.38%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">857</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.38%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,530</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,624</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,738</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,337</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research, development and clinical trials expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,532</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,567</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.38%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,819</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,173</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.38%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">857</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,973</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.38%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,530</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,624</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,738</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,337</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 4532000 4567000 5819000 5173000 857000 1973000 4530000 4624000 15738000 16337000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Long-Term Debt </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TransMedics has a credit agreement (the “Credit Agreement”) with OrbiMed Royalty Opportunities II, LP (“OrbiMed”), entered into in June 2018, pursuant to which TransMedics borrowed $35.0 million. Long-term debt consisted of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.3%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal amount of long-term debt</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.3%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Current portion of long-term debt</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.3%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt, net of current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.3%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt discount, net of accretion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(428</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(511</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.3%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued end-of-term payment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">762</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">708</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.3%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt, net of discount and current portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,334</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,197</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings under the Credit Agreement bear interest at an annual rate equal to the London Interbank Offered Rate (“LIBOR”), subject to a minimum of 1.0% and a maximum of 4.0%, plus 8.5% (the “Applicable Margin”), subject in the aggregate to a maximum interest rate of 11.5%. In addition, borrowings under the Credit Agreement bear paid-in-kind (“PIK”) interest at an annual rate equal to the amount by which LIBOR plus the Applicable Margin exceeds 11.5%, but not to exceed 12.5%. The PIK interest is added to the principal amount of the borrowings outstanding at the end of each quarter until the maturity date of the Credit Agreement in June 2023. Borrowings under the Credit Agreement are repayable in quarterly interest-only payments until the maturity date, at which time all principal and accrued interest is due and payable. At its option, the company may prepay outstanding borrowings under the Credit Agreement. The Company is required to make a final payment in an amount equal to 3.0% of the principal amount of any prepayment or repayment. The final payment and debt discount amounts are being accreted to interest expense over the term of the Credit Agreement using the effective interest method. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All obligations under the Credit Agreement are guaranteed by the Company and each of its material subsidiaries. All obligations of the Company and each guarantor are secured by substantially all of the Company’s and each guarantor’s assets, including their intellectual property, subject to certain exceptions, including a perfected security interest in substantially all tangible and intangible assets of the Company and each guarantor. Under the Credit Agreement, the Company has agreed to certain affirmative and negative covenants to which it will remain subject until maturity. The financial covenants include maintaining a minimum liquidity amount of $3.0 million; the requirement, on an annual basis, to deliver to OrbiMed annual audited financial statements with an unqualified audit opinion from the Company’s independent registered public accounting firm; and restrictions on the Company’s activities, including limitations on dispositions, mergers or acquisitions; encumbering its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and engaging in certain other business transactions. As of March 31, 2022, the Company was in compliance with the financial covenants under the Credit Agreement. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The obligations under the Credit Agreement are subject to acceleration upon the occurrence of specified events of default, including payment default, change in control, bankruptcy, insolvency, certain defaults under other material debt, certain events with respect to governmental approvals (if such events could cause a material adverse change in the Company’s business), failure to comply with certain covenants, including the minimum liquidity and unqualified audit opinion covenants, and a material adverse change in the Company’s business, operations or other financial condition. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the occurrence of an event of default and until such event of default is no longer continuing, the Applicable Margin will increase by 4.0% per annum. If an event of default (other than certain events of bankruptcy or insolvency) occurs and is continuing, OrbiMed may declare all or any portion of the outstanding principal amount of the borrowings plus accrued and unpaid interest to be due and payable. Upon the occurrence of certain events of bankruptcy or insolvency, all of the outstanding principal amount of the borrowings plus accrued and unpaid interest will automatically become due and payable. In addition, the Company may be required to prepay outstanding borrowings, subject to certain exceptions, with portions of net cash proceeds of certain asset sales and certain casualty and condemnation events. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2022, the interest rate applicable to borrowings under the Credit Agreement was 9.5%. During the three months ended March 31, 2022, the weighted average effective interest rate on outstanding borrowings under the Credit Agreement was approximately 11.2%.<span style="font-size:12pt;"> </span></p> 35000000.0 Long-term debt consisted of the following (in thousands): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.3%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal amount of long-term debt</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.3%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Current portion of long-term debt</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.3%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt, net of current portion</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.3%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt discount, net of accretion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.18%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(428</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(511</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.3%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued end-of-term payment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">762</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">708</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.3%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt, net of discount and current portion</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.18%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,334</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,197</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"> </p> 35000000 35000000 35000000 35000000 428000 511000 762000 708000 35334000 35197000 London Interbank Offered Rate (“LIBOR”), subject to a minimum of 1.0% and a maximum of 4.0% 0.010 0.040 0.085 0.115 0.115 0.125 2023-06 0.030 The financial covenants include maintaining a minimum liquidity amount of $3.0 million; the requirement, on an annual basis, to deliver to OrbiMed annual audited financial statements with an unqualified audit opinion from the Company’s independent registered public accounting firm; and restrictions on the Company’s activities, including limitations on dispositions, mergers or acquisitions; encumbering its intellectual property; incurring indebtedness or liens; paying dividends; making certain investments; and engaging in certain other business transactions. 3000000.0 0.040 0.095 0.112 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Stock-Based Compensation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Stock Incentive Plan</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s 2019 Stock Incentive Plan (the “2019 Plan”) provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, unrestricted stock units, and other stock-based awards to employees, directors, and consultants of the Company and its subsidiaries. The number of shares of common stock of TransMedics Group initially available for issuance under the 2019 Plan was 3,428,571 shares, plus the number of shares underlying awards under the previously outstanding 2014 Stock Incentive Plan (the “2014 Plan”), not to exceed 1,595,189 shares, that expire or are terminated, surrendered, or cancelled without the delivery of shares, are forfeited to or repurchased by TransMedics Group or otherwise become available again for grant. Since the effectiveness of the Company’s 2019 Plan in April 2019, no future awards will be made under the 2014 Plan.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares withheld in payment of the exercise or purchase price of an award or in satisfaction of tax withholding requirements, and the shares covered by a stock appreciation right for which any portion is settled in stock, will reduce the number of shares available for issuance under the 2019 Plan. In addition, the number of shares available for issuance under the 2019 Plan (i) will not be increased by any shares delivered under the 2019 Plan that are subsequently repurchased using proceeds directly attributable to stock option exercises and (ii) will not be reduced by any awards that are settled in cash or that expire, become unexercisable, terminate or are forfeited to or repurchased by TransMedics Group without the issuance of stock under the 2019 Plan. As of March 31, 2022, 890,558 shares of common stock were available for issuance under the 2019 Plan.</p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2019 Employee Stock Purchase Plan </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Company’s 2019 Employee Stock Purchase Plan (the “2019 ESPP”), certain employees of the Company are eligible to purchase common stock of the Company at a reduced price during offering periods. The 2019 ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to the limitations set forth in the Internal Revenue Code, at a purchase price of 85% of the lower of the closing price of the Company’s common stock on the first trading day of the offering period or the closing price on the applicable purchase date, which is the final trading day of the applicable offering period. A total of 371,142 shares of the Company’s common stock are reserved for issuance under the 2019 ESPP. During the three months ended March 31, 2022, 12,465 shares of common stock were issued under the 2019 ESPP and as of March 31, 2022, 308,131 shares of common stock remained available for issuance.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2021 Inducement Plan </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2021, the Company’s board of directors approved the TransMedics Group, Inc. Inducement Plan (the “Inducement Plan”). Pursuant to the terms of the Inducement Plan, the Company may grant nonstatutory stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock unit awards and performance awards to individuals who were not previously employees or directors of the Company or individuals returning to employment after a bona fide period of non-employment with the Company.  A total of 1,000,000 shares of the Company’s common stock were initially available for issuance under the Inducement Plan. As of March 31, 2022, 580,200 shares of common stock were available for issuance under the Inducement Plan.</p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research, development and clinical trials expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,964</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">902</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,310</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,112</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2022, the Company granted options to its employees and directors with service-based vesting for the purchase of an aggregate of 880,910 shares of common stock with a weighted average grant-date fair value of $7.11 per share. As of March 31, 2022, total unrecognized compensation cost related to unvested share-based awards was $24.6 million, which is expected to be recognized over a weighted average period of 3.1 years.<span style="font-size:12pt;"> </span></p> 3428571 1595189 890558 0.85 371142 12465 308131 1000000 580200 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research, development and clinical trials expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,964</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">902</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,310</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,112</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> 25000 13000 321000 197000 1964000 902000 2310000 1112000 880910 7.11 24600000 P3Y1M6D <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. Commitments and Contingencies </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Leases </p> <p style="margin-bottom:6pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office, laboratory and manufacturing space under two non-cancelable<span style="font-size:12pt;color:#000000;"> </span>operating leases. There have been no material changes to the Company’s leases during the three months ended March 31, 2022. For additional information, please read Note 12 <span style="font-style:italic;">Leases,</span><span style="font-size:12pt;color:#000000;"> </span>to the consolidated financial statements in the Company’s Form 10-K<span style="font-size:12pt;color:#000000;"> </span>for the year ended December 31, 2021.</p> <p style="margin-bottom:0pt;margin-top:2pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement with the Department of Veterans Affairs </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2002, the Company entered into a license agreement with the Department of Veterans Affairs (the “VA”), under which the Company was granted an exclusive, worldwide license under specified patents to make, use, sell and import certain technology used in the Company’s products and a non-exclusive, worldwide license to make, use, sell and import solutions for use in or with those products. The rights under the license agreement continue until the expiration of the last to expire of the licensed patents. The majority of the licensed U.S. patents expired in 2017, and the foreign patents expired in September 2018. However, the Company has requested a patent term extension for one U.S. patent covered by the VA license agreement, U.S. Patent No. 6100082. The Company was granted an interim patent term extension for this patent until November 6, 2021. The Company has not received final approval of the patent extension beyond the interim patent term extension already granted. The maximum extension requested would be through May 2022; however, the length of the patent term extension will be determined by the United States Patent and Trademark Office <span style="color:#000000;">(“USPTO”) based on input from the FDA.  </span>On February 8, 2021, the FDA provided to the USPTO a determined regulatory review period for the OCS Lung. Under the FDA’s analysis, the patent term extension of the ’082 patent would be until November 6, 2021<span style="color:#000000;">.</span> The Company has not yet received communication from the USPTO but expects that the USPTO’s determination of patent term extension for the ’082 patent will maintain the November 6, 2021 expiration date. The final determination of the length of the patent extension is not expected to have a material impact on the Company’s financial results.<span style="font-style:italic;"> </span>The license includes the right to grant sublicenses, subject to approval by the VA and other restrictions, and is subject to the U.S. government’s right to practice the licensed patents on its own behalf without payment of a royalty and obligation to grant certain sublicenses as necessary to fulfill public health, welfare and safety needs. The license agreement also requires the Company to make its products covered by the licensed patents available to the public on reasonable terms and to provide the U.S. government such products at the lowest price. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licenses granted by the VA, the Company is obligated to pay tiered royalties ranging from a low single-digit to a mid single-digit percentage on net sales of each product covered by a licensed patent (subject to a minimum aggregate royalty payment of less than $0.1 million per year during each of the first five years after the first commercial sale, after which no minimum is required). Royalties will be paid by the Company on a licensed product-by-licensed product and country-by-country basis, beginning on the first commercial sale of such licensed product in such country until expiration of the last valid patent claim covering such licensed product in such country. The Company is also responsible for all costs related to the amendment, prosecution and maintenance of the licensed patent rights. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The VA license agreement can be terminated by the Company or the VA only if the other party fails to cure its material breach within a specified period after receiving notice of such breach. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">401(k) Savings Plan </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the plan may be made at the discretion of the board of directors. As of March 31, 2022 and December 31, 2021, the Company had not made any contributions to the plan. </p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indemnification Agreements </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company has agreed to defend and indemnify its customers against third-party claims asserting infringement of certain intellectual property rights, which may include patents, copyrights, trademarks, or trade secrets. The Company’s exposure under these indemnification provisions is generally limited to the total amount paid </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the end-customer under the agreement. However, certain agreements include indemnification provisions that could potentially expose the Company to losses </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in excess of</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the amount received under the agreement. In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or services as directors or officers. </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and had not accrued any liabilities related to such obligations in its consolidated financial statements as of March 31, 2022 and December 31, 2021. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-weight:bold;;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-weight:bold;;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unconditional Purchase Commitment</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company entered into an unconditional $9.5 million purchase commitment, in the ordinary course of business, for goods with specified annual minimum quantities to be purchased through December 2029. The contract is not cancellable without penalty. The remaining purchase commitment as of March 31, 2022 was $8.0 million.</p> <p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Legal Proceedings </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.<span style="font-weight:bold;font-style:italic;"> </span></p> 100000 0 0 9500000 2029-12 8000000.0 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Segment Reporting and Geographic Data </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that it operates in one segment (see Note 2). </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 11 for revenue by country. Long-lived assets by geography are summarized as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:1pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.54%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets by country(1):</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,317</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,085</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other countries</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">727</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">756</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-lived assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,044</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,841</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.57%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.63%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Company’s only long-lived assets consist of property and equipment, net of depreciation, which are categorized based on their location of domicile.</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2%;text-indent:-3.63%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> 1 See Note 11 for revenue by country. Long-lived assets by geography are summarized as follows (in thousands): <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:1pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.54%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets by country(1):</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,317</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,085</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other countries</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">727</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">756</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total long-lived assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,044</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,841</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.57%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.63%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Company’s only long-lived assets consist of property and equipment, net of depreciation, which are categorized based on their location of domicile.</p></td></tr></table></div> 11317000 9085000 727000 756000 12044000 9841000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Revenue </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the payments made to the customer for reimbursement of clinical trial materials and customer’s costs incurred to execute specific clinical trial protocols related to the Company’s OCS products do not provide the Company with a distinct good or service transferred by the customer, and therefore such payments are recorded as a reduction of revenue from the customer in the Company’s consolidated statements of operations. Reductions of revenue related to such payments made to customers for reimbursements are recognized when the Company recognizes the revenue for the sale of its OCS disposable sets.</p> <p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of gross revenue to net revenue for these certain payments is shown below (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue from sales to customers</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,880</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: clinical trial payments reducing</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">584</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,880</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,053</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that payments made to customers to obtain information related to post-approval studies or existing standard-of-care protocols (i.e., unrelated to the Company’s OCS products) meet the criteria to be classified as a cost because the Company receives a distinct good or service transferred by the customer separate from the customer’s purchase of the Company’s OCS products and the consideration paid to the customer represents the fair value of the distinct good or service received. As a result, such payments made to the customers are recorded as operating expenses. The Company recorded payments made to customers related to post-approval studies and for documentation related to existing standard-of-care protocols of $0.5 million for each of the three months ended March 31, 2022 and 2021, as operating expenses. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disaggregated Revenue</p> <p style="margin-bottom:6pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company disaggregates revenue from contracts with customers by product type and geographical area as it believes this presentation best depicts how the nature, amount, timing and uncertainty of the Company’s revenue and cash flows are affected by economic factors, as shown below (in thousands): </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenue by OCS product:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OCS Lung net revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,298</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,430</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OCS Heart net revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,713</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,181</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OCS Liver net revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,869</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,880</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,053</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.29%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenue by country(1):</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,561</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,757</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other countries</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,319</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,296</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,880</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,053</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.29%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:2.72%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:3.57%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Net revenue by country is categorized based on the location of the end customer.</span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contract Assets and Liabilities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes a receivable at the point in time at which it has an unconditional right to payment. Such receivables are not contract assets. Contract assets arise from unbilled amounts in customer arrangements when revenue recognized exceeds the amount billed to the customer and the Company’s right to payment is not just subject to the passage of time. The Company had no contract assets as of March 31, 2022 and December 31, 2021.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities represent the Company’s obligation to transfer goods or services to a customer for which it has received consideration (or the amount is due) from the customer. The Company has determined that its only contract liabilities are deferred revenue, which consists of amounts that have been invoiced but that have not been recognized as revenue.</p> <p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally satisfies performance obligations within one year of the contract inception date. As of March 31, 2022, the Company’s wholly- or partially unsatisfied performance obligations totaled $2.1 million and are expected to be completed within the next year.</p> <p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of gross revenue to net revenue for these certain payments is shown below (in thousands):</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross revenue from sales to customers</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,880</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: clinical trial payments reducing</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">584</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,880</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,053</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 15880000 7637000 584000 15880000 7053000 500000 500000 <p style="margin-bottom:6pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company disaggregates revenue from contracts with customers by product type and geographical area as it believes this presentation best depicts how the nature, amount, timing and uncertainty of the Company’s revenue and cash flows are affected by economic factors, as shown below (in thousands): </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenue by OCS product:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OCS Lung net revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,298</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,430</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OCS Heart net revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,713</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,181</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OCS Liver net revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,869</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,880</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,053</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.29%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenue by country(1):</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,561</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,757</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other countries</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,319</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,296</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,880</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,053</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.29%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:2.72%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:3.57%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Net revenue by country is categorized based on the location of the end customer.</span></p></td></tr></table></div> 2298000 2430000 5713000 4181000 7869000 442000 15880000 7053000 13561000 5757000 2319000 1296000 15880000 7053000 0 0 The Company generally satisfies performance obligations within one year of the contract inception date. 2100000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Related Party Transactions </p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employment of Dr. Amira Hassanein </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Amira Hassanein, who serves as Product Director for the Company’s OCS Lung program, is the sister of Dr. Waleed Hassanein, the Company’s President and Chief Executive Officer and a member of the Company’s board of directors. <span style="color:#000000;"> The Company paid Dr. Amira Hassanein approximately $0.1 million in total compensation for each of the three months ended March 31, 2022 and 2021 for her services as an employee.</span></p> 100000 100000 The Company’s only long-lived assets consist of property and equipment, net of depreciation, which are categorized based on their location of domicile Net revenue by country is categorized based on the location of the end customer. EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 105 201 1 true 40 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 100040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 100050 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) Sheet http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 7 false false R8.htm 100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 100080 - Disclosure - Nature of the Business and Basis of Presentation Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation Nature of the Business and Basis of Presentation Notes 9 false false R10.htm 100090 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 100100 - Disclosure - Marketable Securities Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecurities Marketable Securities Notes 11 false false R12.htm 100110 - Disclosure - Fair Value of Financial Assets and Liabilities Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities Fair Value of Financial Assets and Liabilities Notes 12 false false R13.htm 100120 - Disclosure - Inventory Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventory Inventory Notes 13 false false R14.htm 100130 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 14 false false R15.htm 100140 - Disclosure - Long-Term Debt Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebt Long-Term Debt Notes 15 false false R16.htm 100150 - Disclosure - Stock-Based Compensation Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 100160 - Disclosure - Commitments and Contingencies Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 100170 - Disclosure - Segment Reporting and Geographic Data Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicData Segment Reporting and Geographic Data Notes 18 false false R19.htm 100180 - Disclosure - Revenue Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenue Revenue Notes 19 false false R20.htm 100190 - Disclosure - Related Party Transactions Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 100200 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 100210 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 100220 - Disclosure - Marketable Securities (Tables) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecurities 23 false false R24.htm 100230 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables Fair Value of Financial Assets and Liabilities (Tables) Tables http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities 24 false false R25.htm 100240 - Disclosure - Inventory (Tables) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryTables Inventory (Tables) Tables http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventory 25 false false R26.htm 100250 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 26 false false R27.htm 100260 - Disclosure - Long-term Debt (Tables) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtTables Long-term Debt (Tables) Tables 27 false false R28.htm 100270 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensation 28 false false R29.htm 100280 - Disclosure - Segment Reporting and Geographic Data (Tables) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataTables Segment Reporting and Geographic Data (Tables) Tables http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicData 29 false false R30.htm 100290 - Disclosure - Revenue (Tables) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueTables Revenue (Tables) Tables http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenue 30 false false R31.htm 100300 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail Nature of the Business and Basis of Presentation - Additional Information (Detail) Details 31 false false R32.htm 100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 32 false false R33.htm 100320 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) Details 33 false false R34.htm 100330 - Disclosure - Marketable Securities - Components of Marketable Securities by Security Type (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail Marketable Securities - Components of Marketable Securities by Security Type (Detail) Details 34 false false R35.htm 100340 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail Fair Value of Financial Assets and Liabilities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail) Details 35 false false R36.htm 100350 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryScheduleOfInventoryCurrentDetail Inventory - Schedule of Inventory, Current (Detail) Details 36 false false R37.htm 100360 - Disclosure - Inventory - Additional Information (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryAdditionalInformationDetail Inventory - Additional Information (Detail) Details 37 false false R38.htm 100370 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Details 38 false false R39.htm 100380 - Disclosure - Long-term Debt - Additional Information (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail Long-term Debt - Additional Information (Detail) Details 39 false false R40.htm 100390 - Disclosure - Long-term Debt - Schedule of Long-term Debt Instruments (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail Long-term Debt - Schedule of Long-term Debt Instruments (Detail) Details 40 false false R41.htm 100400 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 41 false false R42.htm 100410 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) Details 42 false false R43.htm 100420 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 43 false false R44.htm 100430 - Disclosure - Segment Reporting and Geographic Data - Additional Information (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataAdditionalInformationDetail Segment Reporting and Geographic Data - Additional Information (Detail) Details 44 false false R45.htm 100440 - Disclosure - Segment Reporting and Geographic Data - Geographic Areas Long Lived Assets (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataGeographicAreasLongLivedAssetsDetail Segment Reporting and Geographic Data - Geographic Areas Long Lived Assets (Detail) Details 45 false false R46.htm 100450 - Disclosure - Revenue - Schedule of Recognized Revenue Net of Payments (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfRecognizedRevenueNetOfPaymentsDetail Revenue - Schedule of Recognized Revenue Net of Payments (Detail) Details 46 false false R47.htm 100460 - Disclosure - Revenue - Additional Information (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueAdditionalInformationDetail Revenue - Additional Information (Detail) Details 47 false false R48.htm 100470 - Disclosure - Revenue - Schedule of Net Revenue by OCS Product and Country (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail Revenue - Schedule of Net Revenue by OCS Product and Country (Detail) Details 48 false false R49.htm 100480 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.transmedics.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 49 false false All Reports Book All Reports tmdx-10q_20220331.htm tmdx-20220331.xsd tmdx-20220331_cal.xml tmdx-20220331_def.xml tmdx-20220331_lab.xml tmdx-20220331_pre.xml tmdx-ex311_9.htm tmdx-ex312_6.htm tmdx-ex321_8.htm tmdx-ex322_7.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tmdx-10q_20220331.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 105, "dts": { "calculationLink": { "local": [ "tmdx-20220331_cal.xml" ] }, "definitionLink": { "local": [ "tmdx-20220331_def.xml" ] }, "inline": { "local": [ "tmdx-10q_20220331.htm" ] }, "labelLink": { "local": [ "tmdx-20220331_lab.xml" ] }, "presentationLink": { "local": [ "tmdx-20220331_pre.xml" ] }, "schema": { "local": [ "tmdx-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 331, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 9, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 13 }, "keyCustom": 16, "keyStandard": 185, "memberCustom": 19, "memberStandard": 21, "nsprefix": "tmdx", "nsuri": "http://www.transmedics.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Marketable Securities", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Fair Value of Financial Assets and Liabilities", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Inventory", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Accrued Expenses and Other Current Liabilities", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Long-Term Debt", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Stock-Based Compensation", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Commitments and Contingencies", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Segment Reporting and Geographic Data", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicData", "shortName": "Segment Reporting and Geographic Data", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Revenue", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Related Party Transactions", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Marketable Securities (Tables)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Inventory (Tables)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Long-term Debt (Tables)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtTables", "shortName": "Long-term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Segment Reporting and Geographic Data (Tables)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataTables", "shortName": "Segment Reporting and Geographic Data (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "tmdx:ScheduleOfSourcesHealthCareOrganizationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Revenue (Tables)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "tmdx:ScheduleOfSourcesHealthCareOrganizationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-5", "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Marketable Securities - Components of Marketable Securities by Security Type (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail", "shortName": "Marketable Securities - Components of Marketable Securities by Security Type (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Inventory - Schedule of Inventory, Current (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryScheduleOfInventoryCurrentDetail", "shortName": "Inventory - Schedule of Inventory, Current (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "tmdx:InventoryTransferToPropertyPlantAndEquipment", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Inventory - Additional Information (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryAdditionalInformationDetail", "shortName": "Inventory - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "tmdx:AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "tmdx:AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Long-term Debt - Additional Information (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail", "shortName": "Long-term Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_us-gaapLineOfCreditFacilityAxis_tmdxOrbiMedMember_20180629", "decimals": "-5", "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Long-term Debt - Schedule of Long-term Debt Instruments (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail", "shortName": "Long-term Debt - Schedule of Long-term Debt Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "lang": null, "name": "tmdx:LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail", "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Segment Reporting and Geographic Data - Additional Information (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataAdditionalInformationDetail", "shortName": "Segment Reporting and Geographic Data - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Segment Reporting and Geographic Data - Geographic Areas Long Lived Assets (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataGeographicAreasLongLivedAssetsDetail", "shortName": "Segment Reporting and Geographic Data - Geographic Areas Long Lived Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "tmdx:ScheduleOfSourcesHealthCareOrganizationTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Revenue - Schedule of Recognized Revenue Net of Payments (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfRecognizedRevenueNetOfPaymentsDetail", "shortName": "Revenue - Schedule of Recognized Revenue Net of Payments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "tmdx:ScheduleOfSourcesHealthCareOrganizationTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-5", "first": true, "lang": null, "name": "tmdx:CustomerPaymentsRecordedAsOperatingExpenses", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Revenue - Additional Information (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueAdditionalInformationDetail", "shortName": "Revenue - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-5", "first": true, "lang": null, "name": "tmdx:CustomerPaymentsRecordedAsOperatingExpenses", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Revenue - Schedule of Net Revenue by OCS Product and Country (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail", "shortName": "Revenue - Schedule of Net Revenue by OCS Product and Country (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_srtStatementGeographicalAxis_countryUS_20220101_20220331", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20220101_20220331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Related Party Transactions - Additional Information (Detail)", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtDirectorMember_20220101_20220331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "role": "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)", "role": "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20210101_20210331", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Nature of the Business and Basis of Presentation", "role": "http://www.transmedics.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation", "shortName": "Nature of the Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tmdx-10q_20220331.htm", "contextRef": "C_0001756262_20220101_20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 40, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataGeographicAreasLongLivedAssetsDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_DirectorMember": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r175", "r280", "r285", "r466" ], "lang": { "en-us": { "role": { "label": "Major Customers [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r235", "r258", "r301", "r303", "r387", "r388", "r389", "r390", "r391", "r392", "r411", "r463", "r467", "r489", "r490" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r235", "r258", "r301", "r303", "r387", "r388", "r389", "r390", "r391", "r392", "r411", "r463", "r467", "r489", "r490" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r175", "r280", "r285", "r466" ], "lang": { "en-us": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r170", "r280", "r283", "r414", "r462", "r464" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r170", "r280", "r283", "r414", "r462", "r464" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r235", "r258", "r291", "r301", "r303", "r387", "r388", "r389", "r390", "r391", "r392", "r411", "r463", "r467", "r489", "r490" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r235", "r258", "r291", "r301", "r303", "r387", "r388", "r389", "r390", "r391", "r392", "r411", "r463", "r467", "r489", "r490" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r112", "r117", "r302" ], "lang": { "en-us": { "role": { "label": "Scenario Unspecified [Domain]", "terseLabel": "Scenario" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r171", "r172", "r280", "r284", "r465", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataGeographicAreasLongLivedAssetsDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r171", "r172", "r280", "r284", "r465", "r476", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataGeographicAreasLongLivedAssetsDetail" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r112", "r117", "r219", "r302", "r380" ], "lang": { "en-us": { "role": { "label": "Statement Scenario [Axis]", "terseLabel": "Scenario" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r177", "r373" ], "lang": { "en-us": { "role": { "label": "Title Of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_AccruedExpensesAndOtherCurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Expenses and Other Current Liabilities [Abstract]", "label": "Accrued Expenses And Other Current Liabilities [Abstract]" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilitiesAbstract", "nsuri": "http://www.transmedics.com/20220331", "xbrltype": "stringItemType" }, "tmdx_AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research, development and clinical trials expenses.", "label": "Accrued Research Development And Clinical Trials Expenses Current", "terseLabel": "Accrued research, development and clinical trials expenses" } } }, "localname": "AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "tmdx_AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to common stock for recognition of cost for option under share-based payment arrangement.", "label": "Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "tmdx_BalloonPaymentToBePaidPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt, as a percentage of the principal amount of any prepayment or repayment.", "label": "Balloon Payment To Be Paid Percentage", "terseLabel": "Final payment" } } }, "localname": "BalloonPaymentToBePaidPercentage", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "tmdx_ClinicalTrialExpense": { "auth_ref": [], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfRecognizedRevenueNetOfPaymentsDetail": { "order": 10020.0, "parentTag": "us-gaap_Revenues", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reimbursable clinical costs recorded as a reduction to revenue.", "label": "Clinical Trial Expense", "verboseLabel": "Less: clinical trial payments reducing revenue" } } }, "localname": "ClinicalTrialExpense", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfRecognizedRevenueNetOfPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "tmdx_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit agreement.", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer four.", "label": "Customer Four [Member]", "terseLabel": "Customer Four [Member]" } } }, "localname": "CustomerFourMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One", "label": "Customer One [Member]", "terseLabel": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_CustomerPaymentsRecordedAsOperatingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of payments made to customers related to post-approval studies or existing standard-of-care protocols that are recorded as operating expenses..", "label": "Customer Payments Recorded As Operating Expenses", "terseLabel": "Research development and clinical trials expenses" } } }, "localname": "CustomerPaymentsRecordedAsOperatingExpenses", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tmdx_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer three.", "label": "Customer Three [Member]", "terseLabel": "Customer Three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Two", "label": "Customer Two [Member]", "terseLabel": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_DebtInstrumentMaturityMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, maturity month and year.", "label": "Debt Instrument Maturity Month And Year", "terseLabel": "Debt instrument, maturity month and year" } } }, "localname": "DebtInstrumentMaturityMonthAndYear", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "tmdx_EmployeesAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees and director.", "label": "Employees And Director [Member]", "terseLabel": "Employees and Directors [Member]" } } }, "localname": "EmployeesAndDirectorMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_FromTwoThousandFourteenPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "From 2014 Plan.", "label": "From Two Thousand Fourteen Plan [Member]", "terseLabel": "From 2014 Plan [Member]" } } }, "localname": "FromTwoThousandFourteenPlanMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_GuaranteedMinimumAnnualRoyaltyPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum annual aggregate royalty payment due for the first five years after the first commercial sale.", "label": "Guaranteed Minimum Annual Royalty Payment", "terseLabel": "Guaranteed minimum annual royalty payment" } } }, "localname": "GuaranteedMinimumAnnualRoyaltyPayment", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tmdx_InEventOfDefaultMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "In Event Of Default [Member]", "terseLabel": "In Event Of Default [Member]" } } }, "localname": "InEventOfDefaultMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_InventoryTransferToPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of inventory transferred to the entity's property plant and equipment in noncash transactions.", "label": "Inventory Transfer To Property Plant And Equipment", "terseLabel": "Transfers of inventory to property and equipment", "verboseLabel": "Inventory transfer to property plant and equipment" } } }, "localname": "InventoryTransferToPropertyPlantAndEquipment", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "tmdx_LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments": { "auth_ref": [], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail": { "order": 10010.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, excluding current portion. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long Term Debt Noncurrent Before Debt Discount And Accrued Payments", "totalLabel": "Long-term debt, net of current portion" } } }, "localname": "LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "tmdx_MinimumLiquidityCovenantAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum liquidity covenant amount.", "label": "Minimum Liquidity Covenant Amount", "terseLabel": "Minimum liquidity covenant amount" } } }, "localname": "MinimumLiquidityCovenantAmount", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "tmdx_NetRevenueProductAndCountryAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net revenue product and country [Abstract].", "label": "Net Revenue Product And Country [Abstract]", "terseLabel": "Net revenue by OCS product and country" } } }, "localname": "NetRevenueProductAndCountryAbstract", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail" ], "xbrltype": "stringItemType" }, "tmdx_NonCashInterestAndEndOfTermAccretionExpense": { "auth_ref": [], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for interest and accretion on long-term debt.", "label": "Non Cash Interest And End Of Term Accretion Expense", "terseLabel": "Non-cash interest expense and end of term accretion expense" } } }, "localname": "NonCashInterestAndEndOfTermAccretionExpense", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "tmdx_NonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense related to leasing arrangements.", "label": "Non Cash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "NonCashLeaseExpense", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "tmdx_NonUsAndUkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non US and UK member.", "label": "Non Us And Uk [Member]", "terseLabel": "All Other Countries [Member]" } } }, "localname": "NonUsAndUkMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail" ], "xbrltype": "domainItemType" }, "tmdx_OcsHeartProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ocs Heart Product [Member]", "terseLabel": "OCS Heart net revenue [Member]" } } }, "localname": "OcsHeartProductMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail" ], "xbrltype": "domainItemType" }, "tmdx_OcsLiverProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ocs Liver Product [Member]", "terseLabel": "OCS Liver net revenue [Member]" } } }, "localname": "OcsLiverProductMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail" ], "xbrltype": "domainItemType" }, "tmdx_OcsLungProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ocs Lung Product [Member]", "terseLabel": "OCS Lung net revenue [Member]" } } }, "localname": "OcsLungProductMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail" ], "xbrltype": "domainItemType" }, "tmdx_OrbiMedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Orbi Med [Member]", "label": "Orbi Med [Member]", "terseLabel": "Orbi Med [Member]" } } }, "localname": "OrbiMedMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_OtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Countries [Member]", "terseLabel": "All Other Countries [Member]" } } }, "localname": "OtherCountriesMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataGeographicAreasLongLivedAssetsDetail" ], "xbrltype": "domainItemType" }, "tmdx_PaidInKindInterestRateThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The threshold interest rate over/under which paid-in-kind interest is due.", "label": "Paid In Kind Interest Rate Threshold", "terseLabel": "Paid in kind interest threshold" } } }, "localname": "PaidInKindInterestRateThreshold", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "tmdx_RecordedUnconditionalPurchaseCommitmentMaturityYearAndMonth": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity year and month of recorded unconditional purchase commitment.", "label": "Recorded Unconditional Purchase Commitment Maturity Year And Month", "terseLabel": "Recorded unconditional purchase commitment, maturity year and month" } } }, "localname": "RecordedUnconditionalPurchaseCommitmentMaturityYearAndMonth", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "tmdx_ResearchDevelopmentAndClinicalTrialsExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research, development and clinical trials expenses [Member]", "label": "Research Development And Clinical Trials Expenses [Member]", "terseLabel": "Research, development and clinical trials expenses [Member]" } } }, "localname": "ResearchDevelopmentAndClinicalTrialsExpensesMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "tmdx_ReversalOfEstimatedOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The change in value for stock issued as a result of a change in estimated offering costs during the period.", "label": "Reversal Of Estimated Offering Costs", "terseLabel": "Reversal of estimated offering costs" } } }, "localname": "ReversalOfEstimatedOfferingCosts", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "tmdx_ScheduleOfSourcesHealthCareOrganizationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from sales to customers, including detail for clinical trial payments that are not distinct which are removed from revenue recognized.", "label": "Schedule Of Sources Health Care Organization Table [Text Block]", "terseLabel": "Schedule of Recognized Revenue Net of Payments" } } }, "localname": "ScheduleOfSourcesHealthCareOrganizationTableTextBlock", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "tmdx_SignificantCustomersBenchmarkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant Customers Benchmark.", "label": "Significant Customers Benchmark [Member]", "terseLabel": "Significant Customer Benchmark [Member]" } } }, "localname": "SignificantCustomersBenchmarkMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_TwoThousandNineteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Employee Stock Purchase Plan [Member]", "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]", "terseLabel": "2019 Employee Stock Purchase Plan [Member]" } } }, "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_TwoThousandNineteenStockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Stock Plan [Member]", "label": "Two Thousand Nineteen Stock Plan [Member]", "terseLabel": "2019 Stock Plan [Member]" } } }, "localname": "TwoThousandNineteenStockPlanMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_TwoThousandTwentyOneInducementPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one inducement plan.", "label": "Two Thousand Twenty One Inducement Plan [Member]", "terseLabel": "2021 Inducement Plan [Member]" } } }, "localname": "TwoThousandTwentyOneInducementPlanMember", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "tmdx_UnconditionalPurchaseObligationRemainingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount remaining on an unconditional purchase commitment.", "label": "Unconditional Purchase Obligation Remaining Amount", "terseLabel": "Remaining purchase commitment" } } }, "localname": "UnconditionalPurchaseObligationRemainingAmount", "nsuri": "http://www.transmedics.com/20220331", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r38", "r379" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10110.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r23", "r178", "r179" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10210.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities And Other Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other liabilities current" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r10", "r11", "r44" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r25", "r56", "r58", "r59", "r452", "r472", "r473" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r55", "r59", "r66", "r67", "r68", "r104", "r105", "r106", "r334", "r468", "r469", "r506" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r305", "r313", "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Allocated Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r180", "r196", "r198", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Allowance For Doubtful Accounts Receivable", "terseLabel": "Allowance for credit losses" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r82", "r90", "r248", "r360" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization Of Debt Discount Premium", "terseLabel": "Net amortization of premiums on marketable securities" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r99", "r150", "r160", "r166", "r194", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r330", "r335", "r348", "r377", "r379", "r430", "r450" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r8", "r51", "r99", "r194", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r330", "r335", "r348", "r377", "r379" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10150.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r343" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "totalLabel": "Cash equivalents and marketable securities" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r186" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Marketable Securities, Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r187" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Marketable Securities, Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r184", "r204" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Marketable Securities, Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Available For Sale Securities [Abstract]", "terseLabel": "Marketable securities:" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r182", "r185", "r204", "r434" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": { "order": 10020.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Marketable Securities, Fair Value", "verboseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r306", "r315" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Unaudited Interim Financial Information" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r103", "r141" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description And Basis Of Presentation [Text Block]", "terseLabel": "Nature of the Business and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r93", "r94", "r95" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r37", "r92" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10190.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash And Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": { "order": 10010.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash Cash Equivalents And Short Term Investments", "terseLabel": "Cash equivalents and marketable securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r87", "r92", "r96" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r87", "r351" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Equivalents At Carrying Value [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r48", "r218", "r435", "r456" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r214", "r215", "r217", "r220", "r479" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r104", "r105", "r340" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock No Par Value", "terseLabel": "Common Stock, No Par Value" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22", "r379" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, no par value; 150,000,000 shares authorized; 27,968,583 shares and 27,791,615 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold.", "label": "Compensation Expense Excluding Cost Of Good And Service Sold", "terseLabel": "Compensation expense" } } }, "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r62", "r64", "r65", "r75", "r439", "r459" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r136", "r137", "r175", "r346", "r347", "r478" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r136", "r137", "r175", "r346", "r347", "r474", "r478" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r136", "r137", "r175", "r346", "r347", "r474", "r478" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r132", "r448" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Risk of Concentrations of Credit, Significant Customers and Significant Suppliers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r136", "r137", "r175", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r136", "r137", "r175", "r346", "r347", "r478" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r267", "r269", "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract With Customer Asset Net", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r267", "r268", "r281" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r79", "r99", "r194", "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r348" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10120.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost Of Revenue", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of revenue [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r100", "r324", "r327", "r328" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense Benefit", "negatedLabel": "Provision for income taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r135", "r175" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r18", "r19", "r20", "r98", "r102", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r252", "r253", "r254", "r255", "r363", "r431", "r432", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r20", "r250", "r432", "r449" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail": { "order": 10040.0, "parentTag": "tmdx_LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument Carrying Amount", "terseLabel": "Long-term Debt, Gross", "verboseLabel": "Principal amount of long-term debt" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentCovenantDescription": { "auth_ref": [ "r20", "r446" ], "lang": { "en-us": { "role": { "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.", "label": "Debt Instrument Covenant Description", "terseLabel": "Description of covenants" } } }, "localname": "DebtInstrumentCovenantDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of reference rate used for variable rate of debt instrument.", "label": "Debt Instrument Description Of Variable Rate Basis", "terseLabel": "Description of variable rate basis" } } }, "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r46", "r251", "r361", "r363" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument Interest Rate Effective Percentage", "terseLabel": "Interest rate effective percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Debt Instrument Interest Rate Increase Decrease", "terseLabel": "Increasing applicable margin" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r46", "r233" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "LIBOR rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r47", "r98", "r102", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r252", "r253", "r254", "r255", "r363" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "auth_ref": [], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail": { "order": 10030.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.", "label": "Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid", "terseLabel": "Accrued end-of-term payment" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r239", "r360", "r364" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail": { "order": 10020.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument Unamortized Discount", "negatedLabel": "Debt discount, net of accretion" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt Weighted Average Interest Rate", "terseLabel": "Average effective interest rate" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan Employer Discretionary Contribution Amount", "terseLabel": "Defined contribution plan, contribution amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r90", "r149" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r280", "r283", "r284", "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue Table [Text Block]", "terseLabel": "Schedule of Net Revenue by OCS Product and Country" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r76", "r109", "r110", "r111", "r112", "r113", "r118", "r120", "r122", "r123", "r124", "r127", "r128", "r341", "r342", "r440", "r460" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r76", "r109", "r110", "r111", "r112", "r113", "r120", "r122", "r123", "r124", "r127", "r128", "r341", "r342", "r440", "r460" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Diluted", "terseLabel": "Net loss per share attributable to common stockholders, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r351" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10060.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued payroll and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Unrecognized compensation cost related to unvested employee and director stock-based awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Weighted average period for unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee stock purchase plan [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "verboseLabel": "Options to purchase common stock [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r66", "r67", "r68", "r104", "r105", "r106", "r108", "r114", "r116", "r129", "r195", "r260", "r265", "r317", "r318", "r319", "r325", "r326", "r340", "r352", "r353", "r354", "r355", "r356", "r358", "r468", "r469", "r470", "r506" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r241", "r252", "r253", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r344", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r241", "r292", "r293", "r298", "r300", "r344", "r384" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r241", "r252", "r253", "r292", "r293", "r298", "r300", "r344", "r385" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r241", "r252", "r253", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r344", "r386" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement Policy Policy [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r241", "r252", "r253", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r188", "r189", "r191", "r192", "r193", "r197", "r200", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r249", "r259", "r339", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r91", "r349", "r350" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain Loss Unrealized", "negatedLabel": "Unrealized foreign currency transaction losses" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicAreasLongLivedAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographic Areas Long Lived Assets [Abstract]", "terseLabel": "Geographic Areas, Long-Lived Assets [Abstract]" } } }, "localname": "GeographicAreasLongLivedAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataGeographicAreasLongLivedAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r78", "r99", "r150", "r159", "r162", "r165", "r168", "r194", "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r348" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10070.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r72", "r150", "r159", "r162", "r165", "r168", "r427", "r436", "r442", "r461" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r89" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r89" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r89", "r412" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Contract With Customer Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCharges": { "auth_ref": [ "r89" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.", "label": "Increase Decrease In Deferred Charges", "negatedLabel": "Deferred rent" } } }, "localname": "IncreaseDecreaseInDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r89" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase Decrease In Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r89", "r367" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase Decrease In Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r89" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r70", "r148", "r359", "r362", "r441" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10050.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r29", "r209" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryScheduleOfInventoryCurrentDetail": { "order": 10030.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory Finished Goods Net Of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryScheduleOfInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r50", "r379" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryScheduleOfInventoryCurrentDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10220.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Net", "terseLabel": "Inventory", "totalLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryScheduleOfInventoryCurrentDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r31", "r209" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryScheduleOfInventoryCurrentDetail": { "order": 10010.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory Raw Materials Net Of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryScheduleOfInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r30", "r209" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryScheduleOfInventoryCurrentDetail": { "order": 10020.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory Work In Process Net Of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryScheduleOfInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r190", "r428", "r444", "r475", "r504" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r42", "r99", "r161", "r194", "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r331", "r335", "r336", "r348", "r377", "r378" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r99", "r194", "r348", "r379", "r433", "r454" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r99", "r194", "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r331", "r335", "r336", "r348", "r377", "r378", "r379" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10080.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r40", "r98" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Line Of Credit Facility [Axis]", "terseLabel": "Lender Name" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r40", "r98" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line Of Credit Facility Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate L I B O R [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long Lived Assets By Geographic Areas Table [Text Block]", "terseLabel": "Long-lived assets by geographical area" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail": { "order": 10050.0, "parentTag": "tmdx_LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Current", "negatedLabel": "Less: Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Noncurrent", "terseLabel": "Long-term debt, net of discount and current portion", "totalLabel": "Long-term debt, net of discount and current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtScheduleOfLongTermDebtInstrumentsDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long Term Debt [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r6", "r43" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10200.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Text Block]", "terseLabel": "Components of Marketable Securities by Security Type" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r87" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10050.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r87" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10040.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r87", "r88", "r91" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r60", "r63", "r68", "r73", "r91", "r99", "r107", "r109", "r110", "r111", "r112", "r115", "r116", "r121", "r150", "r159", "r162", "r165", "r168", "r194", "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r342", "r348", "r437", "r457" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "negatedLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r172" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Noncurrent Assets", "terseLabel": "Long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataGeographicAreasLongLivedAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r81" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10040.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10080.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r150", "r159", "r162", "r165", "r168" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10030.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r366" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r366" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r365" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r12", "r44" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 10040.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r52" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 10030.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r61", "r64", "r66", "r67", "r69", "r74", "r260", "r352", "r357", "r358", "r438", "r458" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income Loss Net Of Tax", "totalLabel": "Total other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r53", "r56" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 10040.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized gains (losses) on marketable securities, net of tax of $0", "verboseLabel": "Unrealized gains (losses) on marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r54", "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax", "terseLabel": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r83" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10060.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income Expense [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r183" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments To Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r84" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r306", "r315" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockNoParValue": { "auth_ref": [ "r21", "r257" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock No Par Value", "terseLabel": "Preferred Stock, No Par Value" } } }, "localname": "PreferredStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21", "r257" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21", "r379" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock, no par value; 25,000,000 shares authorized; no shares issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r7", "r35", "r36" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10230.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds From Sale And Maturity Of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r85", "r316" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r85" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds From Stock Plans", "terseLabel": "Proceeds from issuance of common stock in connection with employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r60", "r63", "r68", "r86", "r99", "r107", "r115", "r116", "r150", "r159", "r162", "r165", "r168", "r194", "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r329", "r332", "r333", "r337", "r338", "r342", "r348", "r442" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r211", "r379", "r445", "r455" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligation": { "auth_ref": [ "r216" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Recorded Unconditional Purchase Obligation", "terseLabel": "Recorded unconditional purchase commitment, minimum quantity required" } } }, "localname": "RecordedUnconditionalPurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r299", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r299", "r370", "r374", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r368", "r369", "r371", "r375", "r376" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r323", "r413", "r491" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10090.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research, development and clinical trials" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r14", "r92", "r96", "r429", "r451" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r9", "r17", "r96", "r477" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r265", "r320", "r379", "r453", "r471", "r473" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r104", "r105", "r106", "r108", "r114", "r116", "r195", "r317", "r318", "r319", "r325", "r326", "r340", "r468", "r470" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r146", "r147", "r158", "r163", "r164", "r170", "r171", "r175", "r279", "r280", "r414" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfRecognizedRevenueNetOfPaymentsDetail": { "order": 10010.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Gross revenue from sales to customers" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfRecognizedRevenueNetOfPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r277", "r278", "r282", "r290" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue From Contract With Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.", "label": "Revenue Performance Obligation Description Of Timing", "terseLabel": "Revenue performance obligation description of timing" } } }, "localname": "RevenuePerformanceObligationDescriptionOfTiming", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue Remaining Performance Obligation", "terseLabel": "Performance obligations totaled" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r71", "r99", "r146", "r147", "r158", "r163", "r164", "r170", "r171", "r175", "r194", "r221", "r222", "r223", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r348", "r442" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfRecognizedRevenueNetOfPaymentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10110.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Net revenue", "totalLabel": "Total net revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfNetRevenueByOCSProductAndCountryDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRevenueScheduleOfRecognizedRevenueNetOfPaymentsDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r136", "r175" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue Net [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule Of Available For Sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r47", "r102", "r252", "r254", "r261", "r262", "r263", "r264", "r360", "r361", "r364", "r447" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule Of Debt Instruments [Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r13", "r32", "r33", "r34" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule Of Inventory Current Table [Text Block]", "terseLabel": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureInventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r372", "r374" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r142", "r144", "r145", "r150", "r151", "r162", "r166", "r167", "r168", "r169", "r170", "r174", "r175", "r176" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting and Geographic Data" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicData" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r152", "r153", "r154", "r155", "r156", "r157", "r171" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 10100.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling General And Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling General And Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized", "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Share based compensation arrangement by share based payment award number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period", "terseLabel": "Number of shares issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r304", "r308" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Purchase price of common stock, percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r266", "r322" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders Equity And Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r97", "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r49", "r66", "r67", "r68", "r104", "r105", "r106", "r108", "r114", "r116", "r129", "r195", "r260", "r265", "r317", "r318", "r319", "r325", "r326", "r340", "r352", "r353", "r354", "r355", "r356", "r358", "r468", "r469", "r470", "r506" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataGeographicAreasLongLivedAssetsDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r104", "r105", "r106", "r129", "r414" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSegmentReportingAndGeographicDataGeographicAreasLongLivedAssetsDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r21", "r22", "r260", "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock in connection with employee stock purchase plan , Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r21", "r22", "r260", "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock in public offering,net of discounts and issuance costs, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r260", "r265", "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "terseLabel": "Issuance of common stock upon the exercise of common stock options, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r21", "r22", "r260", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock in connection with employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r21", "r22", "r260", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock in public offering,net of discounts and issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r49", "r260", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock upon the exercise of common stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r26", "r27", "r99", "r181", "r194", "r348", "r379" ], "calculation": { "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS", "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r188", "r189", "r191", "r192", "r193", "r249", "r259", "r339", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r101", "r292", "r443" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government Agency Bonds (due within one year) [Member]", "verboseLabel": "U.S. Government Agency Bonds [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r101", "r292", "r300", "r443" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U S Treasury Securities [Member]", "terseLabel": "U.S. Treasury Securities (due within one year) [Member]", "verboseLabel": "U.S. Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.transmedics.com/20220331/taxonomy/role/DisclosureMarketableSecuritiesComponentsOfMarketableSecuritiesBySecurityTypeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r130", "r131", "r133", "r134", "r138", "r139", "r140" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "verboseLabel": "Warrants to purchase common stock [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r119", "r124" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Weighted average common shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r118", "r124" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Weighted average common shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.transmedics.com/20220331/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25383-109308" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r376": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r428": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r444": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(g)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r475": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r492": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r493": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r494": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r495": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r496": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r497": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r498": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r499": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r501": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r502": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r503": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r504": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r505": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 68 0001564590-22-018257-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-018257-xbrl.zip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Ǘ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